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PET imaging, using the bone tracer Na18F, allows the non-invasive location of atherosclerotic 
plaques that are at risk of rupture. However, the spatial resolution of PET is only 4-5 mm, 
limiting the mechanistic information this technique can provide. In this thesis, the use of 
fluorescence and Raman imaging to elucidate the mechanism of micro-calcification within 
atherosclerotic plaques has been investigated. 
A number of fluorescent probes to detect fluoride and calcium have been synthesised. One of 
the fluoride probes has been shown to be selective for fluoride however, the concentration of 
fluoride required to activate the probe is order of magnitudes higher than the amount of Na18F 
used for PET imaging making it problematic to use for future studies. On the other hand, a 
calcium probe has been shown to: selectively bind to hydroxyapatite (HAP); permit 
visualisation and quantification of HAP in both vascular and bone cell models; and effectively 
stain cultured aortic sections and whole mouse aorta for OPT imaging. Building on these 
preliminary data, fluorescence imaging and immunohistochemistry (IHC) imaging of both 
healthy and atherosclerotic tissue that were previously subjected to PET imaging, were 
successfully carried out showing the ability of the probe to detect HAP in human vascular 
tissue. IHC staining for Osteoprotegerin (OPG) and Osteopontin (OPN), two bone proteins 
recently detected in vascular tissue, showed the co-localization of OPG with the probe. 
Conversely,   the OPN was shown to localize in areas surrounding high OPG and probe signal. 
To determine the exact composition of vascular calcification, Raman spectroscopy was also 
used. It is believed that the biosynthetic pathway to HAP passes through a series of transitional 
states; each of these has different structural characteristics which can be studied using Raman 
spectroscopy. In particular, HAP has a strong characteristic Raman peak at 960 cm-1. An 
increase in HAP concentration has been detected by Raman in both calcified cell models and 
aortic sections. When human vascular tissue was analysed, an additional peak at 973 cm-1 was 








Cardiovascular related deaths (CVD) are the second most common cause of death worldwide. 
It was estimated that around 17 million people died in 2015 due to a complication of heart 
disease. Atherosclerosis is one of the main causes of CVD and it consists of the build-up of 
plaques in the arteries. The arteries are highly inflamed and could rupture leading to infarcts 
and strokes. It is thought that the way the body tries to deal with the plaque formation is by 
creating a barrier between the plaque and the artery, this barrier, known as calcification, is 
formed of hydroxyapatite, a calcium mineral which is also present in bone. At the start, when 
the calcification is weak, it increases the chances of plaque rupture however, once the 
calcification is bigger it stabilizes the plaque. 
Unfortunately, even though the field of cardiovascular diagnostic has advanced, there are only 
a limited way of detecting the smaller calcification deposits which could cause sudden acute 
death. Those that are currently available do not provide enough information into why 
calcification forms. In this project, two imaging techniques are used to study the formation of 
calcification in cells, rodent and human models. These imaging techniques have provided new 
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Chapter 1 - Atherosclerosis 
1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is a global concern which was responsible for taking more than 
17 million lives in 2015.1–8 In 2012, CVD was classed as the second main cause of death in 
the UK (28%), behind cancer (29%) (Table 1).6,9 CVDs are a group of disorders of the heart 
and blood vessels which are caused by the formation of atherosclerotic plaques within the 
arteries.  Atherosclerotic plaques containing calcific lesions are reported in more than 65% of 
the population over the age of 45.6 
Table 1: Cause of death in the UK in 2014. All values obtained from the British Heart 
Foundation (BHF) 2014 statistics. 
Cause Number of people affected 
CVDs 161,252 
Cancer 165,818 
Respiratory disease 79,899 




Atherosclerosis is a progressive disease characterized by macrophage infiltration within the 
vessel and by the accumulation of lipids and fibrous elements in the large arteries. This is 
frequently accompanied by inflammation and vascular remodelling of the vessel wall.3,8,10–13 
Plaques are made up of various substances such as; fat, cholesterol, calcium and a wide range 
of other entities commonly found in the blood.14  They are characterized histologically as an 
atheroma with a fibrous cap, consisting of smooth muscle cells (VSMCs), extracellular 
matrix,10,11 and a lower lipid-rich necrotic core.8,10 Over time, with the progression of the 
disease, the accumulation of lipids and fibrous elements will harden making the arteries 
narrower (Figure 1.1) which result in myocardial ischaemia and angina.8,10,11,15  




Figure 1.1: H&E of a normal (A) and atherosclerotic (B) coronary artery. H&E showing 
the adventitia (Ad), media (M) and intimal layers (I) of the coronary artery with the positive 
remodelling of the artery wall. Reproduced with permission.16 
The most important clinical complication is caused by sudden plaque rupture or erosion of the 
lesions, resulting in thrombosis or myocardial infarction.8,10,11,13,15,17–20 The chance of rupture 
is determined by the plaque composition and vulnerability.7,11 Vulnerable plaques generally 
have  a thin fibrous caps and an increased number of inflammatory cells.2,10,11,21,22  
The plaques can become progressively more complex, with calcification, ulceration and 
neovascularisation affecting their stability (Figure 1.2).10,23  
 
Figure 1.2:  Schematic representation of an atherosclerotic plaque which has caused 
positive remodelling of the vessel. Neovascularisation and spotty calcification start appearing 
around the necrotic core. 
Vascular calcification, a hallmark of atherosclerosis,  is a complex biological process that 
involves the deposition of calcium and phosphate.21,24–26 Calcification was only realised to be 
important in vascular disease in 1990s.20,27 Research discovered osteogenic morphogens 
present in calcifying blood vessels as well as the presence of bone matrix proteins (BMP) in 
cardiovascular tissue. These findings established the ‘osteogenic hypothesis’ which suggested 
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that vascular and valvular calcification is an active process regulated by a process similar to 
the one in bone mineralization.6,23,25–33 This hypothesis has been strengthened by the 
observation of events such as the production of matrix vesicles, apoptotic bodies and 
hydroxyapatite (HAP).10,25,34,35 Small calcified HAP micronodules (Figure 1.3 A) appear first 
in the vessel and subsequently grow into much larger macroscopic deposits (Figure 1.3 B).24  
 
Figure 1.3 Micro-calcification (A) and Macro-calcification (B). HAP crystal (blue) deposits 
on the fibrous cap of the plaque. At the start, HAP is only small but with time it will grow and 
stabilize the plaque. Reproduced with permission.22  
The size of the deposits is very important in assessing the vulnerability of the plaque. The 
presence of large deposits, >50 µm,24 known as macro-calcification (Figure 1.3 B),22 stabilize 
the plaque while the occurrence of smaller deposits, <50 µm,24 known as micro-calcification 
(Figure 1.3 A), the beginning of the mineralization of the vessel wall, is known to be involved 
in plaque rupture.10,22,24–26 Micro-calcification is therefore associated with high risk lesions,13,17 
and directly weakens the fibrous cap.13 
Currently there are little to no methods for assessing the degree of vulnerability of the plaques. 
As a consequence, developing techniques to identify micro-calcification is a major research 
goal with the potential of improving patient outcome.  
1.2 The pathology of calcification 
An artery consists of three distinct layers: the intima, the media and the adventitia (Figure 1.1 
and Figure 1.4).36 The intima is the inner layer which consists of extracellular matrix and is 
surrounded by a layer of endothelial cells on the luminal side and a layer of elastic fibres on 
the peripheral side. The adventitia is the outer layer which consists mainly of connective tissue 
with fibroblasts and VSMCs. Between the two, the media is located, which mainly consists of 
VSMCs.11,36–38 




Figure 1.4: Schematic cross-sections showing the difference between a normal artery (A), 
an atherosclerotic one where plaque deposits between the media and the endothelium of the 
vessel wall (C) and a ruptured one (D). Over time the plaque will harden and cause 
obstruction to the blood flow causing patients to have cardiac events. Reproduced with 
permission.39 
Vascular calcification can occur at different locations within the vessel wall, either in the 
intima or in the media (Figure 1.4). Intimal calcification is mainly associated with 
atherosclerosis while medial calcification is largely associated with chronic kidney disease 
(CKD) and was also recently shown to be the main type of mineralisation in valve 
calcification.20,22,23,29,32,34,40–42 
Vascular calcification, as mentioned previously, is very similar to the physiological bone 
formation process.23,26,28–30,43 Under stress, VSMCs can differentiate into different 
mesenchymal-derived cell types such as osteoblasts, adipocytes and chondrocytes. This in turn 
leads to calcification, altering lipid accumulation and matrix production.6,11,20,23,25,28,29,37,44,45  
There are at least three key aspects to be considered regarding the role of VSMCs in the 
pathogenesis of vascular calcification; 25,45  
- endocytosis and toxicity of HAP crystals,  
- transformation into osteochondrogenic phenotype,  
- generation of nucleating structures for HAP deposition. 
Endocytosis and cell death phase: 
In order to activate osteogenic gene expression, HAP crystals need to be endocytosed and 
accumulated in the lysosomes, where the calcium and phosphate crystals are then dissolved 
(Figure 1.5).   The release of calcium causes either apoptosis or osteogene expression which 
causes the release of HAP-filled matrix vesicles.46 




Figure 1.5 The role of calcium and phosphate crystals in HAP deposition. Crystals of 
calcium and phosphate in VSMC’s can be nucleated and either deposited on extracellular 
elastin or endocytosed and directed to lysosomes where they are then dissolved, and free 
calcium ions are released in the cytosol. Here, cell death or cell differentiation takes place. 
Transformation phase: 
At the sites where HAP nanocrystals are depositing, VSMCs undergo an osteochondrogenic 
phenotypic change and increase the expression of mineralization-regulating proteins that 
would otherwise only be found in bones and cartilage. Runx, Osterix, Osteopontin (OPN) and 
Osteoprotegerin (OPG) are just a few.20,23,26,33,34,47 The upregulation of osteochondrogenic 
genes concurrently downregulates smooth muscle cell genes. The transcription factor that is 
responsible for this process is Runx2.26 It is the Bone Morphogenic Protein (BMP) that 
activates the transcription activity of Runx2. Upon vascular injury, the differentiated VSMCs 
increase osteogenic signalling though BMP and upregulate HAP deposition.26,29,48 The 
deposition of HAP on the matrix has also been shown to upregulate not only BMP but also 
OPN which in turn accelerates the calcification process (Figure 1.5).  
 
 
Chapter 1 - Atherosclerosis 
6 
 
Nucleation site formation phase: 
In order to create an environment that tolerates calcification, matrix vesicles are used as 
nucleation sites for HAP.6,26,46 Normally, VSMCs do not calcify as they are loaded with 
mineralization inhibitors such as Matrix Gla Protein (MGP), Fetuin-A and 
Pyrophosphate.23,31,33,37,43,45 However, when the cells undergo a phenotypic change and there 
are high levels of calcium and calcification inhibitors are low, VSMCs produce mineralization-
competent vesicles that contain already synthesised HAP.6,25,31,46 To permit the growth of the 
crystals, the vesicles contain alkaline phosphate (ALK) which creates a phosphate source by 
degrading pyrophosphate. 
Over time the HAP sediments grow and eventually stabilize the plaque, however, at the 
beginning when smaller deposits are being laid down, the plaque is very fragile and the HAP 
deposits will weaken the plaque and cause its rupture.10,22,24–26 A new understanding is required 
to appreciate the mechanism behind HAP deposition and to distinguish weakened plaques 
before they rupture. 
1.3 The inflammatory response and its link to calcification 
Although significant progress has been achieved over recent years, the exact role and process 
of calcification in atherosclerosis remains to be defined.22,26 Emerging evidence suggests that 
intimal calcification occurs as a healing response to intense inflammation and cell death within 
the atherosclerotic plaque.22,23,31,49 Aiwaka et al. were able to demonstrate the association of 
inflammation and calcification in mouse atherosclerotic models, showing that macrophage 
infiltration takes place before the osteogenic conversion of VSMCs and subsequently followed 
by the release of matrix vesicles.30 This is one of the first studies that provides evidence that 
inflammation is a powerful initiator of calcification. Recently, vesicles have been shown to 
not only be released by VSMCs but also by inflammatory macrophages, suggesting that 
macrophages are also a potential source of calcification.22  Pro-inflammatory cytokines, 
produced as an immune response to inflammation, are also shown to promote the 
differentiation of VSMCs to osteoblastic and/or chondrocytic cells which will then provide 
HAP and lead to a more stabilized plaque with macro-calcification (Figure 1.6).22,36,50,51 




Figure 1.6 Relationship between inflammation, calcification and infarction. A large 
necrotic core, thin fibrous cap and intense inflammation are key players in plaque rupture. 
Calcification occurs as a healing process, however, at the early stages the calcification is 
microscopic (blue) and causes increased stress on the cap, increasing the chance of plaque 
rupture. However, once a large amount of calcification is deposited, the plaque is considered 
clinically stable and therefore not at risk of rupture. Reproduced with permission.22  
The continuous process of atherosclerosis and atheroma formation can be divided in six stages. 
These are classified into pre-lesional stages (stages I, II, III) and progressive plaque formation 
stages (stages IV, V, VI) (Figure 1.7).36 
Stage I start of plaque formation: 
In arterial lesion-prone areas, the initial event that takes place in response to a change in body 
homeostasis is the alteration of endothelial cells (ECs). There are two main functions that are 
affected: modification of EC permeability to allow for Low Density Lipoprotein (LDL) 
deposition and change in EC phenotype.8,15,26,36,52–54 The LDLs that enter the vessel via the 
modification of the EC permeability are then confined in the intima. Here, they interact with 
the proteoglycans and matrix proteins converting them into modified lipoproteins (MLp), rich 
in cholesterol (Figure 1.7). When the ECs allow the accumulation of MLp within the intima, 
major changes to the biosynthetic capacity of ECs takes place. This change causes the 
proliferation of the basal lamina (BL) and the disruption of the myo-endothelial junctions and 
in turn leads to gaps between the neighbouring VSMCs.36 




Figure 1.7: Atheroma formation and its phases. Phase I, start of plaque formation; phase II, 
disruption of the EC; phase III, inflammatory reaction; phase IV, formation of fibrous plaque; 
phase V, formation of calcified atherosclerotic plaque; phase VI thrombus formation. LDL: 
low density lipoproteins, EC: endothelial cells, MLp: modified lipoproteins, (V)SMC: smooth 
muscle cells, BL: basal lamina, Mon: monocytes, Mac: macrophages, FC: foam cells, ECM: 
extracellular matrix, Ca: hydroxyapatite crystals, cc: cholesterol crystals. Reproduced with 
permission.36 
Phase II disruption of the EC: 
The alteration of the plasma lipid and the sub-endothelial build-up of MLp initiate a defence 
mechanism which causes an inflammatory response by recruiting blood inflammatory cells 
(Figure 1.7).8,36,53,54 
Phase III inflammatory reaction: 
There are eight main immune cells that are responsible for the inflammatory process.36 
Monocytes, being one of them, undergo a coordinated process which causes their adhesion to 
the endothelium lining and they then progress through the EC junctions to the sub-
endothelium.36  Platelets, T-cells, dendritic cells, neutrophils, mast cells and B-cells also play 
an important role in the inflammatory process. Platelets specifically aid in the recruitment of 
blood monocytes (Mon), therefore playing an important role in plaque formation.36,55 Dendritic 
cells instead activate the T-cells which are important for the expression and secretion of 
cytokines; these are in turn responsible for the differentation of macrophages (Mac) from 
monocytes.20,26,36,50,55,56 The activated macrophages, also known as macrophage-derived foam 
cells (FC), take up MLp and loads the latter with cholesterol (Figure 1.7). Accumulation of 
foam cells is what characterises fatty-streak type lesions, which may then evolve into advanced 
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plaques.8,26,36,55 The cytokines also convert the VSMCs to the osteoblastic phenotype which 
initiates the start of the calcification pathway  allowing the VSMCs to produce HAP.26,32,52 
Stage IV formation of fibrous plaque: 
The inflammatory cells send molecular messages which direct the plaque development, 
specifically the build-up of VSMCs within the intima (Figure 1.7). This is known as intimal 
thickening.36,51 
Stage V and VI Calcified atherosclerotic plaque and thrombus formation: 
The progression of the plaques is characterized by accumulation of extracellular lipid droplets, 
macrophage foam cells, VSMC-derived foam cells and calcification mini clusters which will 
then develop into macro-calcification.36,54 The accumulation of cholesterol in the plaque 
causes apoptosis of both the macrophage-derived foam cells and the VSMCs. Upon cell death, 
the cells release their content forming the necrotic core (Figure 1.7).8,23,26,36,51,54 Plaque 
inflammation triggers VSMC loss and the production of Matrix Metalloproteinases (MMP) 
that weaken the fibrous cap and lead to thrombus formation (stage VI).8,36 Calcification is 
thought to be the healing response to intense necrotic plaque inflammation and when macro-
calcification is deposited it results in the separation of inflammatory regions from the lumen, 
making the plaque less likely to rupture.  
1.4 Current imaging techniques 
Imaging inflammatory and calcific processes that take place in the arteries has the potential to 
improve the understanding of the pathways that lead to CVD, and consequently to improve 
patient outcomes.7 Advances have occurred in a variety of both invasive and non-invasive 
imaging modalities.3,7,8,57 Invasive imaging relies on accessing the arteries with specifically 
designed catheters via the coronary vessels and then administering contrast media. Novel 
advances in the design and technology of such catheters allow for a selection of different 
invasive approaches which can be coupled to the standard angiographic assessment. Examples 
of these additional imaging technologies are intravascular ultrasonography (IVUS), optical 
coherence tomography (OCT), near-infrared spectroscopy (NIRS) as well as near-infrared 
fluorescence (NIRF). In the field of non-invasive modalities, developments in computed 
tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography 
(PET) have taken place. Each approach provides complementary information and allows for a 
comprehensive, multidimensional evaluation of coronary atherosclerosis.7,8,22 
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The main assessment focus of coronary artery disease using imaging has been the detection of 
luminal stenosis or obstruction to blood flow. However, the capacity of the angiography results 
to prevent myocardial infarction leaves somewhat to be desired.3,58 Studies have shown that 
the majority of lesions that go on to rupture and cause myocardial infarction are in fact non-
obstructive on previous angiographies.7,22,59,60 
Plaque burden however can provide a powerful prognostic on the basis that the more plaques 
a patient has, the greater the likelihood that one will rupture and cause myocardial infarction. 
The wide range of invasive and non-invasive imaging techniques that are available are 
described below.  
1.4.1 Invasive techniques 
1.4.1.1 Angiography 
Angiography is the most commonly used and reproducible technique to accurately assess the 
lesion severity and is therefore used to diagnose coronary artery disease (Figure 1.8). An 
angiogram is an X-ray of the blood vessels after they are filled with a contrast material, such 
as gadolinium or iodine, which will reveal the extent and severity of a blockage. The technique 
involves the selective intubation of the patient with a catheter, allowing for high spatial 
resolution (0.1-0.2 mm)7,59 of the vessel wall. However, detailed analysis of the plaque cannot 
be obtained.7 Angiography has been combined with IVUS, OCT and NIRS to provide more 
information on the coronary plaque composition.7 
 
Figure 1.8: Coronary angiography of the left coronary artery. (A) Total occlusion (white 
arrow) of the mid left anterior descending artery. (B) After balloon angioplasty distal flow 
was obtained. Reproduced with permission.61 




IVUS involves using a small ultrasound transducer to record the reflection of high frequency 
sound waves and therefore generating greyscale cross-sectional images of the arterial wall 
(Figure 1.9).3 The transducer itself has limited ability to differentiate the individual plaque 
components but virtual histology on the backscattered radiofrequency allows features such as 
the necrotic core, the calcium fibrous density and the fatty plaques to be detected at an 
exceptionally high spatial resolution (150-200 µm).7 IVUS can be used to accurately assess 
the luminal dimensions and the volume of the plaque. By doing so it allows for an accurate 
quantification of plaque burden and therefore acts as a powerful predictor of disease 
progression.3,8  However, a major limitation of this technology is the low signal-to-noise ratio 
and the increased number of artefacts making which render interpretation difficult. In addition, 
the spatial resolution is too low to accurately and reliably detect the fibrous cap.7  
 
Figure 1.9: Normal IVUS (A) and virtual histology IVUS (B). (A) shows three layers; intima 
(white arrow), external elastic membrane that represents interface between media and 
adventitia (yellow arrow). IVUS catheter shown with the red arrow. (B) virtual reconstruction 
of the artery. Image shows necrotic core shown in red (white arrow) and fibrous plaque shown 
in green (yellow arrow).  Reproduced with permission.21 
1.4.1.3 OCT 
OCT uses a near-infrared (NIR) fibre-optic wire within the catheter which, by emitting light 
in the NIR area is able to measure the backscatter signal from tissues while still inside the 
artery.3,7 The fibre-optic wire is set with a rotating lens and thus allows high spatial resolution, 
up to 10-15 µm, permitting accurate measurements of the thickness of the fibrous cap.3,7,21 In 
contrast to IVUS, OCT is able to image the thrombus, plaque rupture and superficial plaque 
erosion with improved sensitivity and definition.3,62 Measurement of the fibrous cap thickness 
not only allows the assessment of the plaque vulnerability, but also disease progression and 
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plaque stabilization in response to therapy.3,63 The major limitation of OCT is the lack of 
penetration, 1-3 mm, which makes assessment of the entire plaque volume impossible.3,7,64 
1.4.1.4 NIRS 
NIRS works on the phenomenon that organic molecules absorb and reflect light differently at 
specific wavelengths. When light is emitted onto the vessel wall, a chemogram based on the 
absorption and emission pattern of the vessel wall components is created. This technique is 
extremely useful in the detection of lipids within the plaque, thus allowing the identification 
of areas of lipid-rich lesions and quantification of the lipid core.3,7,65,66 Apart from the ability 
to provide information on lipid content, NIRS is not able to offer any structural information 
on the plaque. This can be overcome by the development of NIRS-IVUS hybrids which have 
been shown, in preclinical studies, to discriminate between vulnerable and non-vulnerable 
plaques.67  
In the research environment, NIR-OCT catheters have been used with an indocyanine green 
(ICG) fluorophore to enhance the signal of in vivo lipid-rich inflamed plaques in rabbits and 
of ex-vivo human atheroma specimens.68 This technology could not only be used to provide 
read-outs of high risk plaques, but also to examine the mechanism and efficacy of 
atherosclerosis therapeutics.7,68–70 Other NIRS tracers are undergoing preclinical evaluation 
and include agents activated by proteases that localize inflamed plaques,3,71,72 tracers that target 
fibrin,73 and expensive HAP specific tracers such as Osteosense.17,30,74–76 Unfortunately, the 
cost of the HAP specific tracer has limited its use in a research environment resulting in the 
synthesis of novel probes. Nonetheless, due to the higher spatial resolution, NIRS and 
molecular imaging are already well positioned to further elucidate the first steps of 
calcification and the role of inflammation in myocardial infarction.68–70  
1.4.2 Non-Invasive techniques 
1.4.2.1 Coronary artery calcium scoring (CAC) using CT 
CAC scoring uses electrocardiogram-gated CT, providing an accurate and simple measure of 
the overall atherosclerotic burden, plaque morphology and composition (Figure 1.10). 
Without the need for contrast agents, CAC scoring quantifies the macroscopic calcium within 
the vessels.3,7,22,24,26,35 It can also provide some information on the less stable adjacent plaques. 
However, as for IVUS, the spatial resolution is low and overall this technique underestimates 
the size of non-calcified plaques and overestimates the size of calcified plaques due to 
‘booming artefacts’.7,12,13,22  




Figure 1.10: Imaging of coronary calcification by CT.  Coronary macro-calcification 
deposits (white arrow) have high attenuation and are therefore clearly visible by CT. 
Reproduced with permission.77 
This makes the technique unsuitable for detecting micro-calcification as it is not able to 
identify calcium deposits smaller than 200 µm in diameter.7,13 When compared to IVUS, CAC 
is better for the detection of fibrous plaques and to a lesser extent the necrotic core and fibro-
fatty tissues.7 However, unstable lesions tend to be very sparsely calcified and therefore tend 
to be unnoticed on CAC images.8  
1.4.2.2 PET 
PET in contrast to CAC can detect molecular signals at picomolar concentrations. 
Unfortunately, the spatial resolution of this technology is low, 4-5 mm, which only allows it 
to be used together with either CT or MRI for precise anatomical localization of the PET signal 
(Figure 1.11).  
 
Figure 1.11: PET and Fused PET/CT of the aortic valve. Image downloaded.78 
PET relies on using tracers which will localize in specific areas, allowing biological processes 
to be measured in vivo.3,8,22,79,80 To date, the most commonly used tracer is fluorodeoxyglucose  
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(18F-FDG) which has been routinely used to image inflammation.22,35,54,57 18F-FDG localizes 
in areas with high metabolic rate and within the vascular tissue it will accumulate in the 
macrophages.7,8,13,35 18F-FDG has been used to characterize atherosclerotic burden and 
inflammation in vessels as well as being used to monitor therapy.12,22,74,79 However, high levels 
of inflammation within the plaques are not always associated with vulnerable plaques (Figure 
1.12). 
 
Figure 1.12: Focal 18F-sodium fluoride and 18F-fluorodeoxyglucose uptake in patients with 
myocardial infarction and stable angina. (A) invasive coronary angiography of a proximal 
occlusion (red arrow) of the left anterior descending artery (B) Fused PET/CT image using 
18F-NaF showing intense fluoride uptake at the site of the vulnerable plaque (red arrow). (C) 
Fused PET/CT using 18F-FDG showing no uptake at the site of the plaque (red arrow). Blue 
and yellow arrows indicative of other areas where 18F-FDG has been taken up (yellow- 
coronary artery, blue- oesophagus). Reproduced with permission.13 
On the other hand, another recently repurposed tracer, which had previously been used in 
bones, is 18F-NaF. In contrast to 18F-FDG, 18F-NaF binds to HAP via an exchange process 
between the hydroxyl groups in HAP with the fluoride ions on 18F-NaF.8,13,24,35,54,80 This 
exchange process had been reported by Volker et al. in 1972. In the first instance, the fluoride, 
associates rapidly with the HAP surface and within hours the exchange process occurs before 
converting HAP into fluorinated apatite (f-HAP).81–85 It appears that the tracer binds 
preferentially to regions of newly developing vascular micro-calcification, with calcium 
deposits which are beyond the resolution of CT (Figure 1.13). The binding appears to be 
dependent upon the surface area of the calcification.3,13,24,26,35,84  




Figure 1.13 Transaxial images of a patient with chronic stable angina. (A) CAC showing 
high volume calcium in the left anterior artery (white arrow). (B) Intense 18F-NaF uptake on 
fused PET–CT image (white arrows). Larger arrows show area where only 18F-NaF is picked 
up with no CAC signal being observed. Reproduced with permission.86 
A recent study by Irkle et al. shows that in patients with stable coronary artery disease 18F-
NaF uptake correlates with CAC, although nearly half the patients with a high CAC score do 
not present any 18F-NaF signal and high 18F-NaF signal can be seen in areas with a low CAC 
score.13,24 This is indicative that 18F-NaF can be used to identify high-risk coronary lesions and 
hence plaques that are at high risk of rupture.24 18F-NaF has proven promising in the 
identification of high risk plaques but lacks the resolution required to determine the specific 
calcification that may contribute to plaque rupture. One strategy to access this is to use 
molecular imaging techniques to study plaque and calcification morphology with higher  
resolution than PET.68,70 
1.5 Conclusion 
Vulnerable atherosclerotic plaques are an important topic in cardiology as CVD is the second 
highest cause of death and currently there is little understanding of the mechanism behind the 
disease. Another major issue is the lack of imaging techniques that are able to assess the 
vulnerability of the plaque.  As a consequence, the development of techniques that can identify 
micro-calcification and therefore plaque vulnerability is a major research goal with the 
potential to improve the understanding of the disease pathology and also to reduce morbidity 
and mortality rates. The emerging technique that has proven the most promising required for 
the identification of plaques at high risk of rupture is 18F-NaF. However, it lacks the resolution 
required to provide anatomical information on the vulnerability of the plaque. One strategy to 
access this additional information is to use molecular imaging techniques such as fluorescence 
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and Raman which have a much higher resolution and can provide us with additional molecular 
and anatomical information about the plaque.  
1.6 Approach 
The focus of this thesis is on the development of optical probes to better understand the 
mechanism behind plaque formation, looking specifically at calcification with the hope to 
develop an improved and more suitable approach to detect micro-calcification at an early stage 
before plaque rupture. 
Two types of fluorescent probes were synthesized; a fluoride-specific probe to detect the 
fluoride PET tracer, upon localization of the fluoride anions around the surface of the HAP, 
and a calcium-specific probe to bind directly to HAP. It was anticipated that both probes would 
provide a better understanding of the binding of NaF to calcified deposits and additional 
information on the mechanism behind calcification and plaque formation.  
Fluorescent fluoride and calcium probes were synthesized and their selectivity was tested 
against different types of anions (fluoride probe) and calcium minerals (calcium probe) 
(Chapter 2). For the fluoride probe to be valuable, its limit of detection (LOD) needed to be in 
the pM concertation range for it to be able to detect Na18F, unfortunately, this did not appear 
to be the case and therefore the fluoride probe was set aside. Upon examining the specificity 
of the calcium probes for HAP, only one was shown to be selective for HAP and this was taken 
forward into cell and ex vivo mouse studies (Chapter 3). At this point, the focus was on proving 
that the probe was nontoxic at the concentration used and it was compared to the current gold 
standard laboratory techniques used for the detection of calcification (Alizarin S, calcium 
leaching assay and von Kossa).  
Once cell and ex vivo models proved satisfactory, the probe was tested on calcified vascular 
tissue (Chapter 4). Again, similarly to the previous chapter, the probe was compared to 
Alizarin S and von Kossa stains.  
In the final results chapter (Chapter 5) of this thesis, the focus was shifted on analyzing 
calcified tissue (cells, ex vivo rat aortic tissue and human vascular tissue) by Raman 
spectroscopy in order to understand the crystal form of the calcified deposits.  
Together, fluorescence and Raman spectroscopy have provided us with additional scientific 
knowledge that will hopefully shape the future of cardiovascular research. 
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Chapter 2- Synthesis of Fluorescent Dyes 
for the In Vitro Detection of 
Calcification  
 Fluorophores 
Fluorescence has long been used to visualize biological processes at many levels, from single 
molecules to complete organisms.1,2 In the past, fluorescence imaging was achieved by the 
attachment of small organic dyes attached to antibodies or proteins of interest (Figure 2.1).  
 
Figure 2.1: A fluorophore, can be: (A) small molecules; (B) genetically encoded material 
(e.g. GFP) and (C) genetically encoded hybrid system (e.g. aequorin). 
The use of fluorescent proteins has enabled non-invasive imaging in living cells and 
organisms, protein trafficking and numerous dynamic biochemical signals.3,4 Hybrid systems 
in which fluorescent proteins are genetically encoded are filling other useful niches in 
identifying cancer, cardiovascular and neurodegenerative diseases.5,6  
Fluorophores (Figure 2.2), for covalently labelling macromolecules, have undergone intensive 
optimization in wavelength range, brightness, photostability and reduction in self-
quenching.1,7 Molecular strategies have included extension of double-bond conjugation, 
rigidification through addition of extra ring systems and decoration with electron-withdrawing 
or charged substituents such as fluorine and/or sulfonates.8 Fluorophores can be compared by 
assessing the brightness, a product of the extinction coefficient and the quantum yield (ε × Φ) 
which accounts for both the amount of light absorbed and the quantum efficiency of the 




fluorophore.9 Hundreds of such dyes are commercially available and further progress is likely 
to be incremental.1 
 
Figure 2.2: Commonly used fluorophores. Fluorophores are reported in a graph plotting 
brightness against emission wavelength.  
Over the last several decades there has been a remarkable growth in the use of small-molecule 
fluorescent probes in the field of biological sciences (Figure 2.3). Non-fluorescent molecules 
of interest can be tagged with a fluorescent moiety using well established protocols, thus 
allowing the visualisation of specific biological pathways. In addition to aiding imaging, 
functional fluorescent probes have become indispensable tools in modern biology because 
they provide dynamic information concerning the localization and a number of molecules of 
interest.10  





Figure 2.3: Small molecule probes. Illustrated are a zinc finger-small molecule probe (top 
left), pH probe (top middle), protease probe for in vivo imaging (top right), β-galactosidase 
probe (middle), Ca2+ probe (bottom left) and a hypochlorite specific reactive-oxygen species 
probe (bottom right). Image reproduced with permission.10 
Fluorescent dyes, in comparison to absorbance-based probes often used by researchers in the 
nineteenth century, provide nearly infinite contrast, this arises from the release of light on a 
dark background when illuminated with shorter-wavelength light.10 Fluorescent dyes can 
provide single-molecule sensitivity, real time quantification and molecule localization.11 The 
great potential utility for fluorescence visualisation of biomolecules, has led to the 
development of a wide range of fluorophores for labelling biological molecules.10  
 Approach for the detection of HAP 
As mentioned in Chapter 1, two different approaches have been identified to study vascular 
calcification; one involving fluoride probes (section 2.3) and the other involving calcium 
probes (section 2.4). 
The fluoride probes, will allow the presence of Na18F localized around the HAP crystals to be 
detected and will be correlated with PET while the calcium probes will bind directly to HAP 
and will therefore allow for a more direct study of the calcification process. 




 Fluoride probes 
 Probe selection 
The design and synthesis of fluorescent probes that allow for a selective and sensitive detection 
of anions has gained a large amount of attention the past few years.12–14 Anions are known to 
play an important role in a wide range of chemical and biological processes and have been the 
target of investigations into these processes for the past decade.15 Effort has been put into the 
development of rapid, selective and sensitive chemical sensors for the detection and imaging 
of the location of fluoride ions by exploiting the unique reactivity of fluoride.13 These are based 
on cleavage reactions, nucleophilic additions and molecular interactions. Most of them have 
been proven to work only in anhydrous organic media, with slow response times and low 
sensitivity. Very few have been reported to be tolerated in biological systems for cell imaging 
applications.15,16  
To investigate the Na18F PET tracer, a number of published fluoride sensors were analysed for 
their potential application to this target. The selected fluorophore should: be cell permeable; 
have high sensitivity for fluoride; and have excellent properties for fluorescent 
microscopy.13,17–19 Five probes with the above characteristics were inspected further (Table 
2.1), one of which is based on a tetrahydroquinoxaline motif (1) which had previously been 
investigated by the Song group.15 The probe (1) was described to have excellent water 
solubility, photostability properties and emission in the NIR region. However, the synthetic 
approach to obtain the tetrahydroquinoxaline (1) involved several laborious synthesis and 












Table 2.1: Potential fluoride probes and their advantages. 




λex = 511 nm λem = 616 nm 
Multi-step Reported to present excellent 
water solubility and photostability 
properties.  
 
λex = 465 nm λem = 535 nm 
2 step Reported to show high sensitivity 
for fluoride. 
 
λex = 388 nm λem = 490 nm 




4 step  
 
Parent compound 3 reported to 
demonstrate excellent cell 
permeability. 
 
λex = 500 nm λem = 557 nm 
1 step  Reported to be highly sensitive and 
selective for fluoride. 
 
Another probe explored was (E)-2-(benzo[d]thiazol-2-yl)-3-(2-tert-butyl-(diphenylsilyloxy-4-
diethylaminophenyl)acrylonitrile) (2). In the presence of fluoride this probe is reported to 
cyclize and form a highly fluorescent cyclic coumarin.19 In contrast to the 
tetrahydroquinoxaline (1), to acquire 2, only a two-step synthesis was required making the 




probe of interest in investigating the role of the Na18F PET tracer. However, upon close 
inspection of the fluorescent characteristics of probe (2), a very strong background 
fluorescence signal was observed even before the addition of NaF and therefore this probe was 
also set aside.   
Two other fluorophores, based on the naphthalene cyanoacrylate motif, were considered 
excellent candidates for detecting fluoride. The naphthalene cyanoacrylate motif (3 and 4) has 
been previously shown to have excellent cell permeability properties,13 in addition, the 
synthesis appeared straightforward with only 3-4 steps required. 
Rhodamine-based probe (5) was yet another probe with interesting properties and was recently 
reported to detect fluoride in biological systems with high sensitivity and selectivity.20 Another 
advantage of this probe was the rapid one-step reaction required to synthesise the probe, 
making it very appealing for our application. 
These three most biologically relevant fluoride sensors (3-5) were explored in more detail for 
their potential to be used to analyse the mechanism underlying the uptake of the tracer.  
 Naphthalene 2-cyanoacrylate 
One of the two probes that were selected was reported by Qu’s group whose focus was on 
synthesizing new water soluble fluorescent dyes containing a phenol group based on 
naphthalene 2-cyanoacrylate.13 Cyanoacrylate dyes have previously been used for amyloid 
fluorescent detection due to their excellent cell permeability. Cyanoacrylate probe (3) was 
prepared by reacting 6-hydroxy-2-naphthaldehyde (6) with 2-(2-(2-methoxyethoxy)ethoxy)-
ethyl 2-cyanoacetate (7) (Scheme 2.1). These two starting materials had to be synthesised as 
they were not commercially available.  
 
Scheme 2.1: Synthesis of cyanoacrylate probe (3). Reagents and conditions: i) 7, DMAP, 
THF, 60 °C, 24 h. 
Thus 6-hydroxy-2-naphthaldehyde (6) was synthesised by the cleavage of the methyl ether 
moiety of 6-methoxy-2-naphthaldehyde (8) using AlCl3 in chlorobenzene at 130 °C for 4 hours 
with 20% yield (Scheme 2.2 (a)). 2-(2-(2-Methoxyethoxy)ethoxy)-ethyl 2-cyanoacetate (7) 




was also synthesised as it is not commercially available by coupling 2-cyanoacetic acid (9) 
triethylene glycol monomethyl ether (10) using DCC and DMAP at 0 °C for 6 hours. The 
product was obtained in 86% yield (Scheme 2.2 (b)).  
 
Scheme 2.2 Synthesis of the two precursors for the assembly of the cyanoacrylate probe (3). 
(a) Synthesis of 6-hydroxy-2-naphthaldehyde (6). Reagents and conditions: i) AlCl3, 
chlorobenzene, 130 °C, 4 h. (b) Synthesis of 2-(2-(2-methoxyethoxy)ethoxy)-ethyl 2-
cyanoacetate (7). Reagents and conditions: ii) DMAP, DCC, DCM, 0 °C, 6 h.  
The reaction of the two fragments was then carried out using catalytic amounts of DMAP to 
give naphthalene 2-cyanoacrylate (3) in 72% yield (Scheme 2.1). 
A TBDMS protected naphthalene 2-cyanoacrylate probe (4) was also synthesised as it was 
proposed that a silyl protecting group would be more selective towards fluoride than to any 
other anions. Having a free hydroxyl group, it was suspected that naphthalene 2-cyanoacrylate 
could also be deprotonated by other anions, and thus its selectivity solely for fluoride had to 
be proven. TBDMS protected naphthalene 2-cyanoacrylate (4) was synthesised by reacting 
naphthalene 2-cyanoacrylate (3) with tert-butyldimemethylsilyl chloride (TBDMS-Cl) using 
DMAP and imidazole to obtain the TBDMS product in 44% yield (Scheme 2.3). 
 
Scheme 2.3: Synthesis of TBDMS protected cyanoacrylate (4). Reagents and conditions: i) 
TDBMS-Cl, DMAP, imidazole, DMF, rt, 1 h. 
 Imidazole bearing rhodamine 6G 
Another fluoride probe (5) which was synthesised by the Chellappa group was also considered. 
Here, the development of a rhodamine based sensor for the detection of fluoride ions in live 
cell imaging was investigated.20 The imidazole bearing rhodamine 6G (5) was readily 




synthesised using a one-step reaction involving two commercially available starting materials. 
The synthesis involved the reaction between rhodamine 6G with 2-formyl imidazole to obtain 
a colourless solid in a 78% yield (Scheme 2.4) which was then used for selectivity studies. 
 
Scheme 2.4: Synthesis of imidazole bearing Rhodamine 6 G. Reagents and conditions: i) 2-
formyl imidazole, EtOH, 90 °C, 24 h.  
 Selectivity of fluoride probes 
The 2,2-cyanoacrylate probes (3, 4) and the imidazole bearing rhodamine 6G (5) were studied 
to determine their reactivity and selectivity toward fluoride ions.  
For the 2,2-cyanoacrylate probes, UV/VIS was used as a first line of assessment to determine 
both the absorption of the probes and the reproducibility of the data presented in the literature. 
Upon addition of NaF to both probe 3 and 4, deprotonation of the hydroxyl group was expected 
(Scheme 2.5).  
 
Scheme 2.5: Deprotonation or deprotection of the hydroxyl group on the cyanoacrylate 
probes (3 and 4) upon addition of fluoride. 
It had been reported in the literature that the addition of NaF to naphthalene 2-cyanoacrylate 
(3) would lead to a change in the absorption spectra (Figure 2.4 A); with a decrease in peaks 
at 290 and 382 nm and the rapid appearance of a peak at 548 nm. However, when UV/VIS 
tests were carried out on both naphthalene 2-cyanoacrylate probes (3 and 4) the change in 
spectra did not take place as established (Figure 2.4 B, C). Peaks at 290 nm and 382 nm did 
indeed decrease with increased addition of NaF however, no additional peak appeared at 548 
nm, even when a large excess of the fluoride source was added. This test was carried out using 
phosphazene base (P2-Et). Upon addition of the basic solution to the probe there was an 
immediate change in colour; from light yellow to bright red however, the UV spectra did not 




provide the same data reported in the literature. These results suggest that fluoride ions are not 
able to deprotonate or deprotect the hydroxyl group therefore making this probe ineffective 
for the study of Na18F PET tracer. 
 
Figure 2.4: UV/VIS spectra of cyanoacrylate probes. (A) Reported absorption spectrum of 
2-cyanoacrylate probe (3) reproduced with permission.13 UV/VIS spectra of (B) 2-
cyanoacrylate (3) and (C) TBDMS protected 2-cyanoacrylate (4) (30 µM) upon addition of 
excess NaF (5 mM) in PBS buffer (10 mM, pH 7.4, with 1% DMSO). 
Chellappa et al. reported that when the imidazole bearing Rhodamine 6G (5) was incubated 
with different concentrations of NaF an increase in fluorescence intensity was recorded. The 
increase in fluorescence is associated with the conversion of the rhodamine spiro form (5) to 
the amide form (14) stimulated by the fluoride (Scheme 2.6).  
 
Scheme 2.6: Proposed mechanism of fluoride incorporation in imidazole bearing 
rhodamine 6G (5). 
Similar data to those presented by the Chellappa lab were achieved: on titrating the imidazole-
bearing Rhodamine 6G (5) with increasing equivalents of fluoride ions, the probe showed a 
gradual increase in the intensity of the peak at 557 nm (Figure 2.5). However, it was noticeable 
that there was a weak fluorescent signal which was present prior to the addition of the NaF 
(Figure 2.5), suggesting that the starting material 5 is weakly fluorescent. 





Figure 2.5: Fluorescence response of imidazole bearing rhodamine 6G (5 µM) toward 
different concentrations of NaF (0-300 µM) in HEPES buffer (20 mM, pH 7.4) solution in 
acetonitrile:water (3:7). (A) Literature reported data, reproduced with permission.20 (B) Data 
from the synthesised imidazole bearing rhodamine 6G. λex = 500 nm. Data points for 30, 120 
and 150 µM removed for clarity. Data shown is from 3 repeats and is shown as the mean.  
The fluorescence response was shown to increase linearly upon increasing of concentration of 
NaF (15-150 µM) indicating that the probe could be used accurately to determine fluoride ion 
concentration up to 150 µM (Figure 2.6).  
 
Figure 2.6: Change of fluorescence intensity of imidazole bearing rhodamine 6G upon 
addition of fluoride at λem =556 nm. Graph plotting response at 556 nm against 
concentration of fluoride ions in HEPES buffer (20 mM, pH 7.4) solution in 
acetonitrile:water (3:7) when 5 µM of probe was used. 300 µM data point reported in red as 
it does not fit with the linear fit. Data shown is from 3 repeats and shown as the mean ± S.E.M. 




The limit of detection (LOD) of the probe was calculated using the formula mean blank + 3* 
SD of blank. This suggests that 2.9 µM of NaF is required in order to detect any fluorescence 
signal when 5 µM of rhodamine probe (5) is used. The LOD would have been lower if the 
rhodamine probe (5) did not show any fluorescent signal prior to incubation with NaF. 
Additional studies on the selectivity of the probe to NaF were carried out. The imidazole-
bearing rhodamine 6G (5) was incubated with a range of anions including F-, AcO-, Cl-, I-, Br- 
and HPO4-. The other anions did not produce any colour change nor an increase in fluorescence 
which was only visible upon addition of NaF (Figure 2.7).  
 
Figure 2.7: Fluorescence response of imidazole bearing rhodamine 6G (5 µM) in the 
presence of various anions (5 equivalents) in HEPES buffer (20 mM, pH 7.4) solution in 
acetonitrile:water (3:7). λex = 500 nm.  
  Conclusion 
A number of fluoride probes were considered for their potential utility to detect the Na18F PET 










Table 2.2: Pros and cons of selected fluoride sensors 
Probe Pros Cons 
1 Reported to present excellent water solubility 
and photostability properties. 
Numerous reaction steps 
2 Reported to show high sensitivity for fluoride. Highly fluorescent starting 
material 
3 Reported to demonstrate excellent cell 
permeability. 
Product synthesised with a two-step reaction 
Fluoride ions do not 
deprotonate the hydroxyl group 
4 Product synthesised with a four-step reaction Fluoride ions do not deprotect 
the silyl group 
5 Reported to be highly sensitive and selective for 
fluoride. 
Product synthesised with a one-step reaction 
LOD is in the µM range rather 
than pM required for PET 
imaging 
 
Probe 1 and 2 were discarded due to the labour intensive synthetic approach and the high 
fluorescence signal of the starting material, respectively. Unfortunately, the cyanoacrylate 
probes (3 and 4) were also not taken forward as upon addition of NaF no peak at 548 nm 
appeared, while the imidazole bearing Rhodamine 6G (5) showed great sensitivity and 
selectivity towards fluoride ions.  
However, for the fluorescence signal for 5 µM of probe 5 to be intense enough to be detected 
over the background signal, concentrations of NaF of 2.9 µM or above are required. This 
suggests that the ratio between the probe and the NaF is of 1: 0.6 approximately. For the probe 
to be used in a PET imaging setting, pM concentration of Na18F are required,21 suggesting that 
the probe should also be in the pM range. However, the fluorescence signal of the probe is not 
intense enough to be visualised at those concentrations, therefore even this probe was rejected. 
 




 Calcium probes 
A range of calcium probes precursors were examined and, two fluorophores and calcium 
binding molecules were selected for coupling. For the fluorophore entity, cyanine dyes and 
fluorescein were selected and these are discussed in more detail below, while as a binding 
motif, bisphosphonates and a calcium binding peptide were carefully chosen due to their 
ability to bind to HAP. 
 Cyanine dyes  
The cyanine (Cy) dyes are a class of highly fluorescent compounds that possess the key 
requirements necessary for highly sensitive multicolour detection, with wavelengths which are 
tuneable upon the addition of specific functional groups, across the visible spectrum.22 They 
also display excellent photophysical properties that include high extinction coefficients and 
moderate quantum yields, while possessing fluorescent wavelengths removed from the natural 
autofluorescence of biomolecules.22–24 
Cy dyes are photosensitive structures composed of two heterocycles, one of which is a 
quaternary ammonium salt, that are linked together through a polymethine bridge (15) which 
allows for delocalization of the positive charge (Scheme 2.7).24,25 The absorbance and 
fluorescence wavelengths can be controlled by a choice of the polymethine bridge length: Cy 
dyes with a longer bridge posses higher absorbance and emission wavelengths up to the near 
infrared region.  
 
Scheme 2.7: Cy dye polymethine bridge structure. Polymethine bridge and delocalization of 
the double bonds within the system. 
There are a variety of Cy dyes which have been reported in the literature (Figure 2.8): non-
sulfonated (16-21) or sulfonated (sulfo; 22) being two key classes. For many applications they 
are interchangeable, this is due to their spectral properties being nearly identical. Both can be 
used for labelling biomolecules however, critically, sulfo-dyes are water soluble and do not 
require organic co-solvent for the labelling of molecules in aqueous environments. 




Inopportunely, the synthesis and purification of sulfo-Cy dyes is more challenging. Common 
Cy dye core structures include Cy3 (16), Cy3.5 (19), Cy5 (17), Cy5.5 (20), Cy7 (18) and Cy7.5 
(21) (Figure 2.8), where the number identifies the number of carbons between the two 
indolenine groups. The suffix .5 is added for cyanine dyes which contain a benzo-fused indole 
motif as part of the cyanine dyes. 
 
Figure 2.8: Library of Cy dyes. Cy3 (16), Cy5 (17), Cy7 (18) all possess two indole groups 
while Cy3.5 (19), Cy5.5 (20), Cy7.5 (21) contain two benzo-fused indoles. Sulfo-Cy7 (22) 
contains sulfo groups. 
In recent years cyanine dyes have been used as fluorescent probes in biomedical screening 
techniques,22,23,26 as luminescent materials for labelling27 and as analyte-responsive fluorescent 
probes in optoelectronic applications.14,28 
 Fluorescein  
Fluorescein (23) is a common fluorophore used in microscopy with an absorption maximum 
at 494 nm and emission maximum of 515 nm. Fluorescein (23) was first synthesised by Adolph 
Von Baeyer in 1871 who reacted resorcinol (24) with phthalic anhydride (25).29,30 Scheme 2.8 
shows a modern adaptation of this reaction.  
 





Scheme 2.8: Synthesis of fluorescein via a modified Friedel-Craft acylation. Reagents and 
conditions: i) ZnCl2, H2O, MW, 200 °C, 1 h. 
To demonstrate the sensitivity of fluorescein (23), 10 kg of sodium fluorescein were placed in 
the Danube and 60 hours later green fluorescence was detected in the river Rhine, 200 km 
from where it was first introduced. In 1942, Albert Coons labelled antibodies with fluorescein 
(23) thus giving birth to the field of immunofluorescence.31,32 Since then, c has been widely 
used as a fluorophore bound to antibodies but also to other molecules of interest, allowing 
scientists to utilise fluorescence immunocytochemical techniques to visualise cellular 
mechanisms. Fluorescein (23) has many uses in the fields of biochemical and medical 
research. In cellular biology, it is used to label and track cells in fluorescence microscopy, 
specifically in flow cytometry.  
Ten years later, in 1953, the use of sodium fluorescein (9) to assess in vivo circulation was 
reported by Paul Ehrlich, who detected fluorescein in a rabbit eye following parenteral 
administration.30,33 Once the nontoxic properties of fluorescein (23) were demonstrated it 
started being used in human subjects mainly in the field of ophthalmology and especially in 
the analysis of corneal abrasion and surface irregularities (Figure 2.9).30,34,35 This work was 
pioneered by MacLean and Maumenee in the late 1950s where they injected fluorescein in a 









Figure 2.9 Fluorescein angiography. (A) Early and (B) late phase of angiography of a 
patient with multifocal choroiditis. Arrows indicate an area of fluorescein localization. 
Image reproduced with permission.37 
Another medical application is seen in the field of angiography, where it is used intravenously, 
or orally, to diagnose and categorize vascular disorders including: retinal disease; macular 
degeneration; diabetic retinopathy; and intraocular tumours. Most recently, it has discovered 
an application in surgery for brain tumours,38 as well as in open heart surgery.39 
 Examples of HAP binding molecules 
Bisphosphonates (BPs) are a class of drugs that are used to treat adult disease of high bone 
turnover such as Paget’s, osteoporosis myeloma and metastatic bone disease.40–42 Alendronate 
(26) is part of the bisphosphonate family together with pamidronate (27) and risedronate (28), 
as well an numerous others (Figure 2.10).40,43,44 
 
Figure 2.10: Bisphosphonates. Alendronate (26) pamidronate (27), risedronate (28) and 
pyrophosphate (29). 
BPs are structurally similar to pyrophosphate (29) which is a normal product of human 
metabolism. BPs inhibit the farnesyl pyrophosphate synthase enzyme (Figure 2.11) and 
eventually induce osteoclast apoptosis.45,46  





Figure 2.11: Systematic diagram of the mevalonate pathway for cholesterol synthesis. BPs 
inhibit farnesyl pyrophosphate synthase, preventing the synthesis of Farnesyl-PP from 
Geranyl-PP which is required for the prenylation of a number of key proteins essential for cell 
survival. Cross indicates where BPs inhibit the synthase enzyme. 
The bisphosphonate moieties bind directly to mineralized bone surfaces where they are then 
taken up by osteoclasts and therefore inhibit osteoclast activity, this in turn leads to the 
reduction of bone resorption and a net positive bone balance.47–51 Recently BPs have been used 
in both animal and human studies and have been shown to accumulate in the arterial wall and 
to suppress macrophage activity in atheromatous lesions as well as suppressing arterial 
calcification.49,50 Previous data has shown that alendronate (26) is readily able to bind to bulk 
calcium mineral, in the micromolar range (Ki = 61 µM),52 even in the presence of free calcium 
ions.41,53,54 The ready availability of the FDA-approved drug makes it a particularly attractive 
candidate for the development of probes for the detection of calcification. 
Other molecules that have shown selectivity towards HAP are short 12-16mer peptides.55–57 
The Becker lab discovered a variety of short peptide sequences with strong affinity, 55 in the 
micromolar range, and specificity for binding to HAP. The sequence SVSVGMKPSPRP (30) 
was reported to have the greatest affinity for HAP, therefore was analysed further. Studies on 
the selectivity of peptide 30 towards other solids, specifically calcium carbonate (CaCO3) and 
calcium phosphate (CaPi) were conducted and the group concluded that there was little 
adhesion of the peptide to CaCO3 or to CaPi, demonstrating that the peptide was only binding 
to calcium phosphate. It was shown to be selective towards the more crystalline HAP (Figure 
2.12).55 





Figure 2.12 Binding specificity of peptide 30 to CaCO3 (A), CaPi (B) and HAP (C). Image 
reproduced with permission.55 
Due to the selectivity of both alendronate (26) and the SVSVGMKPSPRP-peptide (30) to 
HAP; these were considered excellent candidates to conjugate to selected fluorophores to 
study cardiovascular calcification. 
 Synthesis of Cy dyes 
A range of Cy dyes were synthesised in order to create a range of fluorophores that could be 
linked to the different calcification markers. Cy dyes, as discussed in 2.4.1, are compounds 
that are made up of two heterocyclic rings such as those found in the indolium ions (31-35) 
and a polymethine chain.24 Their synthesis can be divided into two main parts: synthesis of the 
quaternary heterocyclic ammonium salt precursors (Section 2.4.5) and cyanine dye assembly 
(Section 2.4.6).  
 Synthesis of quaternary heterocyclic ammonium salt precursors 
 
Figure 2.13: Selection of heterocyclic ammonium salts. 
The heterocyclic ammonium salts (31-35) (Figure 2.13) were synthesized by quaternization 
of the corresponding heteroaromatic base, 2,3,3-trimethylindolenine (36), with suitable alkyl 
halides. This can be performed in the presence or absence of solvent.22,58 




For example, N-methyl-2,3,3-trimethylindoleninium iodide (31) was prepared by the 
alkylation reaction between 2,3,3-trimethylindolenine (36) with 2 equivalents of methyl iodide 
at 100 °C in MeCN for 2 hours (Scheme 2.9). The resulting benzindolium salt was readily 
separated from the crude reaction mixture, in high purity, by precipitation upon the addition 
of Et2O and was isolated in 99% yield. 
 
Scheme 2.9: Synthesis of N-methyl-2,3,3-trimethylindoleninium. Reagents and conditions: 
i) MeI, MeCN, 100 °C, 2 h. 
The other quaternary heterocyclic ammonium salt precursors (32-35) were synthesised in a 
similar manner to the example above as reported in Table 2.3. 
Table 2.3: Conditions for benzindolium salt synthesis. 
 
Entry # R1-X Time (h) Temp. (°C) Product % Yield 
1 MeI 24 110(a) 31 68 
2 MeI 10 50(b) 31 75 
3 (CH2)3CH2SO3- a 24 120(a) 32 98 
4 Br(CH2)4CO2H 5 145(a) 33 0 
5 Br(CH2)4CO2H 24 145(a) 33 0 
6 Br(CH2)4CO2Me, KI 1 120 (b) 34 0 
7 Br(CH2)4CO2Me, KI 4 days 80 (b) 34 82 
8 Cl(CH2)3C≡CH, KI 24 Reflux(b) 35 72 
* Reactions were carried out in either DCB (a) or MeCN (b). All reactions were purified by trituration 
with Et2O. a Butane sultone was used. 
Most quaternary heterocyclic ammonium salt precursors (Table 2.3 entry 1-3 and 8; 31, 32, 
35) were synthesised following a one-step reaction and obtained in good yield. Only 3-(4-
carboxybutyl)-1,1,2-trimethyl-1H-Benzo[e]indolium (33) required a two-step reaction (Table 
2.3 entry 7) involving the alkylation of 2,3,3-trimethylindolenine (34) with ethyl 




bromovalerate, which was achieved in a 82% yield, followed by hydrolysis to the acid (33) 
using HCl (5 N aq.) in a quantitative yield. 
 Cyanine dye assembly 
A synthetic route to symmetrical and unsymmetrical Cy dyes involves the alkylation of 
quaternary heterocyclic ammonium salt precursors containing an activated methyl group (31-
35) with derivatives of N-[5-(phenylamino)-2,4-pentadienylidene]aniline monohydrochloride 
(37). This reaction can be carried out both in solution and using a solid support resin, with 
both routes described below.  
2.4.6.1 Off resin approach 
Unsymmetrical cyanine dyes are synthesized in two steps from benzindolium salt (31-35) 
through activated hemicyanine intermediates, such as 2-[6-(acetylphenylamino)-1,3,5-
hexatrien-1-yl]-1,1-dimethyl-3-(methyl)-1H-Benz[e]indolium 38 as shown in Scheme 2.10.  
 
Scheme 2.10: Synthesis of the acetylated hemicyanine dye activated intermediate (38). 
Reagents and conditions: i) N-(5-Anilino-2,4-pentadienylidene)aniline hydrochloride (37), 
acetic acid, acetic anhydride, 120 °C, 3 h. 
The acetylated precursors were prepared by the reaction of equimolar amounts of the 
corresponding benzindolium salt (31) and N-[5-(phenylamino)-2,4-pentadienylidene]aniline 
monohydrochloride (37) under reflux in Ac2O over 3 hours. The clean product was obtained 
by trituration of the reaction mixture with Et2O and water in a 1:1 mixture in 40% yield. 
Scheme 2.10 describes the synthesis of one of the four activated hemicyanine intermediates 
38, while Table 2.4 reports the yield for the synthesised compounds. The two benzindolium 
salts selected were 1,1,2,3-tetramethyl-1H-benzo[e]indolium (31) and 1,1,2-trimethyl-3-(4-
sulfobutyl)-1H-Benzo[e]indolium (32) as their synthesis was more straightforward and took 
less time in comparison to the carbonyl (33) and the alkyne (35) benzindolium salts. From the 
two benzindolium salts, only four intermediates were synthesised, two using N-[5-
(phenylamino)-2,4-pentadienylidene]aniline monohydrochloride and two using 




malondialdehyde bis(phenylimine)monohydrochloride to produce hemicyanine intermediates 
for Cy7.5 and Cy5.5, respectively.   
Table 2.4: Activated hemicyanine intermediates synthesis. 
 
Entry # R1 Polymethine bridge Intermediate Yield % 
1 Me n=3 38 40% 
2 (CH2)3CH2SO3- n=3 39 38% 
3 Me n=2 40 (a) 
4 (CH2)3CH2SO3- n=2 41 (a) 
*for n=3 N-[5-(phenylamino)-2,4-pentadienylidene]aniline monohydrochloride is used while for n=2 
malondialdehyde bis(phenylimine) monohydrochloride is used. (a) Intermediates taken directly to the 
next reaction without purification. 
The hemicyanine intermediates were obtained by the reaction of the benzindolium salts with 
malondialdehydes in the presence of acetic acid and acetic anhydride for 2 hours to afford the 
activated intermediates in around 40% yield, this reaction provided as side products unwanted 
symmetrical cy dyes and unreacted benzindolium salts. The completed Cy dye (an example 
reported in  Scheme 2.11) was obtained by reaction of the purified activated intermediate, such 
as 38-41, and 1 equivalent of another benzindolium salt (31-33 and 35), in the presence of 
pyridine and under reflux for 24 hours. This afforded the unsymmetrical Cy dyes, such as 42, 









Scheme 2.11: Synthesis of 4-(2-(1E,3E,5E,7Z)-7-(3-(4-carboxybutyl)-1,1-dimethyl-1H-
benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1H-benzo[e]indolinium-3-yl 
(39). Reagents and conditions: i) Pyridine, 50 °C, 24 h. 
The standard reaction conditions as described above were used for the attempted synthesis of 
Cy7.5 (Table 2.5 entries 1-4; 42, 43, 44, 45) and Cy5.5 (Table 2.5 entries 5-7; 46, 47, 48) dyes 
and the yields are reported in Table 2.5.  
Table 2.5: Building blocks and yields for the solution phase synthesis of Cy7.5 and Cy5.5 
library. 
 
Entry # R1 Polymethine 
bridge 
R2 Cy dye Yield 
1 Me n=3 (CH2)4CO2H 42 75% 
2 Me n=3 (CH2)3C≡CH 43 69% 
3 (CH2)3CH2SO3- n=3 Me 44 n.d. 
4 (CH2)3CH2SO3- n=3 (CH2)4CO2H 45 n.d. 
5 Me n=2 (CH2)4CO2H 46 70% 
6 Me n=2 (CH2)3C≡CH 47 71% 
7 (CH2)3CH2SO3- n=2 (CH2)4CO2H 48 n.d. 
*for n=3 N-(5-Anilino-2,4-pentadienylidene)aniline hydrochloride is used, while for n=2 
malondialdehyde bis(phenylimine)monohydrochloride is used. 
When 1,1,2-trimethyl-3-(4-sulfobutyl)-1H-Benz[e]indolium (32) was used as the starting 
benzindolium salt and was coupled to either N-[5-(phenylamino)-2,4-pentadienylidene]aniline 
monohydrochloride or malondialdehyde bis(phenylimine) monohydrochloride to produce 
hemicyanine intermediates, the latter were not able to couple to the additional benzindolium 
salt. To overcome this, on resin approach was attempted as it had previously reported in the 




literature of being a suitable method of overcoming the problem of unreacted hemicyanine 
production. 
2.4.6.2 On resin approach   
Conventional synthetic methods for the preparation of unsymmetrical Cy dyes are based on 
the condensation of benzindolium salts with malondialdehydes and typically afford mixtures 
of the desired compounds along with unreacted hemicyanine and undesired symmetrical 
analogues. To avoid time consuming purifications and allow enhanced access to a broad range 
of Cy dyes, solid-phase synthesis methods have been reported.22,24 The synthesis of 
benzindolium salts was carried out as described for the solution phase reactions previously 
discussed. The solid support is functionalised (Scheme 2.12) by reacting a N-Boc-4-
hydroxyaniline handle (49) with 1% DVB cross-linked chloromethyl polystyrene (PS) to 
afford (4-hydroxyphenyl)carbamic acid tert-butyl ester PS (50) from which the Boc group 
could be removed to reveal the free amine (51).  
 
Scheme 2.12: Solid support synthesis. Reagents and conditions (i) 1% DVB crossed-linked 
chloromethyl polystyrene, C2CO3, KI, acetone, 70 °C, 16 h; (ii) 20% TFA in DCM, rt, 2 h. 
To synthesise the Cy dyes the hemicyanine intermediate, such as 38-41, was synthesised in 
solution, as described in section 2.4.6.1, and loaded onto the aniline-functionalised solid 
support 52 using DCM as a solvent for 1 hour to give intermediates of the type (51) (Scheme 
2.13). The reactions were monitored by IR. Cleavage from the solid support was then 
accomplished using a benzindolium salt (31-33 and 35) in a mixture of pyridine and Ac2O 
(10:1) to afford the unsymmetrical cyanine dye (Table 2.5; 42) in good yield. 
 
Scheme 2.13: On resin approach for the synthesis of 4-(2-(1E,3E,5E,7Z)-7-(3-(4-
carboxybutyl)-1,1-dimethyl-1H-benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trienyl)-1,1-
dimethyl-1H-benzo[e]indolinium-3-yl (42). Reagents and conditions: (i) 4-aminophenol PS, 




DCM (51), rt, 1 h; (ii) 3-(4-carboxybutyl)-1,1,2-trimethyl- 1H-Benz[e]indolium (33), pyridine, 
rt, 3 h. 
A number of compounds (Table 2.6 entries 1-7; 42-48) were synthesised using the on resin 
approach and obtained in the yields reported in Table 2.6, differently from the in solution 
approach cy dyes synthesised on resin did not require any purification after the second 
benzindolium salt was added. 
Table 2.6: Building blocks and yields for the on resin synthesis of Cy7.5 and Cy5.5 
compounds. 
 
Entry # R1 Polymethine 
bridge 
R2 Cy dye Yield 
1 Me n=3 (CH2)4CO2H 42 64% 
2 Me n=3 (CH2)3C≡CH 43 60% 
3 (CH2)3CH2SO3- n=3 Me 44 n.d. 
4 (CH2)3CH2SO3- n=3 (CH2)4CO2H 45 n.d. 
5 Me n=2 (CH2)4CO2H 46 73% 
6 Me n=2 (CH2)3C≡CH 47 81% 
7 (CH2)3CH2SO3- n=2 (CH2)4CO2H 48 n.d. 
*for n=3 N-(5-Anilino-2,4-pentadienylidene)aniline hydrochloride is used, while for n=2 
malondialdehyde bis(phenylimine)monohydrochloride is used. 
In conclusion, both methods were able to provide some of the Cy dyes required. The solution 
phase approach (Table 2.5) was able to provide Cy7.5 and Cy5.5 (Table 2.5 entries 1, 4, 6, 7; 
42, 43, 46, 47) with reasonable yield (69-75%) while the solid phase method (Table 2.6) was 
able to provide the Cy dyes (Table 2.6 entries 1, 4, 6, 7; 42, 43, 46, 47) with similar yields 
(60-83%), however, an additional step was required in order to functionalise the resin support. 
Nevertheless, for both solution and solid approach, when indoles with sulfonated side chains 
were used, no cyanine dye product was observed.  




 Coupling and synthesis of bisphosphonate protected alendronate 
Two fluorophore-alendronate complexes, Scheme 2.14, were required; one that had high 
brightness and a relatively moderate emission wavelength as well as one that would emit at a 
region closer to the near infrared (NIR) region, as this would allow for potential in vivo 
experiments.  
 
Scheme 2.14: Fluorophore coupling to alendronate. 
Because of these requirements, 5/6-carboxy-fluorescein NHS ester (54) was selected as the 
fluorophore with high brightness and the Cy7.5 (42) and Cy5.5 (46) dyes were chosen as 
possible NIR fluorophores.  
The coupling of 5/6-carboxy-fluorescein NHS ester (54) to alendronate (26) was facile 
(Scheme 2.15). Different conditions were examined including PBS buffer (pH 7.4) and TRIS 
buffer (pH 7.6) however, NaHCO3 (sat.) gave the best conversion to fluorescein-alendronate 
(Fluorescein-BP, 55) in a 50% yield. 
 
Scheme 2.15: Fluorescein coupling to alendronate. Reagents and conditions: i) HNaCO3 
(sat.), rt, 2 days. 
However, when the coupling of alendronate (26) to the mixed Cy7.5 (42) or the mixed Cy5.5 
(46) was attempted and conditions such as NaHCO3 (sat.), PBS buffer (pH 7.4), NHS with 
EDCI and DCC with Oxyma were used, none of the conjugated dye-alendronate systems were 
observed.   
To define where the problem lies in the fluorophore-conjugation, a number of reactions with 
either the Cy dyes (46, 42) or alendronate (26) were carried out. To do this, small organic 
molecules that had either amine groups or a carboxylic acid motif were chosen to act as 




models. The data using the cyanine dyes are reported below in Table 2.7 while those using the 
alendronate are reported in Table 2.8.  
Table 2.7: Different conditions for the coupling of Cy 5.5 (47) and Cy 7 (42) dyes with n-
butylamine. 
 
Table # Reagent Coupling Conditions Yield 
1 Cy5.5 (46) NHS, EDCI n.r. 
2 Cy5.5 (46) DCC, Oxyma n.r. 
3 Cy7.5 (42) NHS, EDCI n.r. 
4 Cy7.5 (42) DCC, Oxyma n.r. 
5 H (33) NHS, EDCI 56% 
*All reactions were performed at room temperature for 24 hours. 
When either Cy5.5 (46) or Cy7.5 (42) were reacted with n-butylamine (Table 2.7 entry 1-4), 
under different reaction conditions, neither cyanine dye afforded the coupled product. 
Conversely, coupling of 3-(4-carboxybutyl)-1,1,2-trimethyl-1H-Benz[e]indolium (33) with n-
butylamine (Table 2.7, entry 5) yielded the coupled product in a 56% yield. This suggests that 
the problem with the coupling reaction might be related to the strong ion pairing between the 
iminium and the carboxybutyl chain of Cy5.5 (46) or Cy7.5 (42), and therefore might make 
the carboxybutyl chain unreactive. 
 
 








Coupling Conditions R1 Time (h) Yield 
1 NHS (1.5 eq), EDCI (1 eq) H  24 n.r. 
2 PBS buffer (pH 7.4) Benzo-fused indole (33)  8 n.r. 
3 NHS (1.5 eq), EDCI (1eq) Benzo-fused indole (33) 24 n.r. 
4 HNaCO3 (sat) Benzo-fused indole (33) 24 n.r. 
*All reactions were performed at room temperature. 
The reaction of alendronate (26) with pentynoic acid or 3-(4-carboxybutyl)-1,1,2-trimethyl- 
1H-Benz[e]indolium salt (33) was trialed under a range of conditions (Table 2.8 entry 1-4), 
however, no coupled product was obtained. It can therefore be supposed that the phosphate 
group is directly interfering with the coupling reaction. 
With the lack of success in amide coupling reactions, it was decided that the phosphonate 
groups on the alendronate would be protected in order to remove any potential interaction 
between them and the cyanine dye itself. It was decided to attempt the synthesis of an azido-
alendronate substrate with protected phosphate groups (56) and to then: either (a) convert the 
azide to the amine functionality required for amide bond formation; or (b) to attempt a copper 
mediated 1,3-dipolar cycloaddition reaction (click) with the alkyne substituted Cy5.5 dye (47) 
(Scheme 2.16). Triazoles have recently attracted a lot of attention as a bioisostere of the amide 
bond moiety due to their similarity in size, dipole moment and H bond acceptor capacity. In 
contrast to amide bonds, triazoles, offer the advantage of being extremely stable to hydrolysis 
which therefore make them potential surrogates of the amide bonds.59  
The azido-alendronate substrate with protected phosphate groups (56) could be used for both 
click coupling to the Cy5.5 dye (47) to obtain the triazole linked protected product (59) 




(Scheme 2.16) as well as reduction of the azide to a amine (57) to allow for amide bond 
formation between the protected phosphate alendronate and the Cy7.5 dye (42) or Cy5.5 dye 
(46) giving product 58 (Scheme 2.16). 
 
Scheme 2.16: Proposed pathways to obtain click coupled Cy-alendronate and amide coupled 
Cy-alendronate from the intermediate azide (56). 
The synthesis of the azide protected bisphosphonate alendronate (56) was carried out using a 
two-step reaction involving a two stage Michaelis-Arbuzov reaction from 4-chlorobutyryl 
chloride (60) with triethylphosphite and diethylphosphite followed by a hydroxyl group 
protection step with tert-butyl silyl chloride to obtain 61 followed by the substitution of the 
chloride by an azide to obtain 56 in a 55% yield (Scheme 2.17).  
 
Scheme 2.17: Synthesis of phosphate-protected azido alendronate. Reagents and conditions: 
(i) triethyl phosphite, DCM, rt, 15 minutes; (ii) diethylphosphite, DMAP, DCM, rt, 2 h; (iii) 
tert-butyldimethylsilyl chloride, rt, 24 h; (iv) NaN3, DMF, 75 °C, 3 h. * Yield over 3 steps. 
After purification of 56, click chemistry was attempted with the alkyne substituted Cy5.5 dye 
(47) (Scheme 2.18) using conditions previously reported in the Hulme group to give the 
protected triazoles (62).60 
 
Scheme 2.18: Click and deprotection. Reagents and Conditions i) 0.2 mol % CuSO4, 4 mol% 
sodium ascorbate, rt, 24 h. 




After successful triazole formation, the protected phosphate group were submitted to 
deprotection conditions to provide the free phosphate groups (63) (Scheme 2.18). The 
deprotection was attempted using a number of conditions; Me3BrSi,61,62 TMS-I,61 and 
NH4OH,63 however, under these conditions the ether groups did not cleave and only starting 
material was observed when the reaction mixtures were analysed. 
Unfortunately, since the deprotection of the triazoles intermediate could not be carried out, 
Fluorescein-BP (55) was the only alendronate probe that was taken forward into selectivity 
and animal studies. 
  HAP binding peptide 
As mentioned in section 2.4.3, a range of short peptides were also considered as calcium 
probes due to their ability to selectively bind to specific minerals. Becker et al. showed that 
the peptide SVSVGMKPSPRP (30) binds with both high specificity and high affinity to HAP. 
In order to obtain a more stable peptide, the click chemistry approach between the peptide and 
the Cy5.5 dye (47) was selected. To do so, a small 4 amino acid long linker, the same as the 
one used by the Becker lab was included in the peptide sequence. The linker was composed of 
AAAK and in our instance, instead of lysine, a modified azido-lysine (Az-Lys) was 
incorporated in the linker. Az-Lys (64) was synthesised from Fmoc-Lys(OtBu)-OH (65) by a 
deprotection step to afford the free amine (66) and then a diazo transfer to afford Az-Lys (64) 
(Scheme 2.19). The unnatural amino acid Az-Lys (64) was then incorporated into the linker in 
place of the natural lysine.  
 
Scheme 2.19: Synthesis of Az-Lysine. Reagents and conditions: i) TFA, DCM, rt, 1 h ii) 
CuSO4.5H2O, imidazole-1-sulfonyl azide HCl, NaHCO3, MeOH/H2O, rt, 16 h. 
Peptide synthesis can occur both in solution and on solid support with both techniques 
affording peptides with excellent coupling efficiencies and facile scalability. However, the 
large number of couplings required when synthesising larger peptides in solution leads to 




prolonged processes where isolating and recoupling the synthesised peptides offsets the 
benefits of solution phase synthesis.64–66 On the other hand, solid phase synthesis (SPPS),67 
involving a solid support resin to restrain and grow the peptide can fast-track the process and 
it is for this reason that peptide 30 with Az-lysine (67) was synthesised on resin. An Fmoc/tBu 
protection strategy was used as the Fmoc protecting group is orthogonal to an array of 
protecting groups. Rink amide resin was selected firstly for its compatibility with the Fmoc 
strategy and secondly because the resin releases a neutral C-terminal amide. SPPS synthesis 
also allows facile peptide capping at the N-terminus with an N-acetyl cap at the end of the 
synthesis. Capping at both the C and N termini ensures that charges on the peptide originate 
from the residue side chains only. These charges are responsible for the interaction with HAP, 
and removing any potential additional charges on the peptide will decrease the chances of 
unselective interactions between the peptide and the HAP. The SPPS synthesis of peptide 67 
was carried as shown below in Scheme 2.20. 
 
Scheme 2.20: Synthesis of peptide 16 via SPPS. Reagents and conditions: i) 20% piperidine, 
DMF, rt, 20 minutes; ii) Az-Lys, DIC, Oxyma, DMF, rt, 45 minutes; iii & deprotection) 20% 
piperidine, DMF, rt, 20 minutes; coupling) a.a., DIC, Oxyma, DMF, rt, 45 minutes.   
A number of conditions were tested for the coupling of the peptide to the Cy5.5 (47) with 5% 
TBTA, 5% Cu(MeCN)4BF4 proving optimal coupling conditions to obtained Cy-Pep (71) 
(Scheme 2.21). 





Scheme 2.21: Coupling of Cy5.5 and HAP selective peptide by click chemistry approach. 
Reagents and conditions: i) 5% TBTA, 5% Cu(MeCN)4BF4, rt, 24 h. 
  Characterization of the calcium probes 
In H2O:DMF mix, Fluorescein-BP (55) and Cy-Pep (71) showed absorption maxima at 490 
nm and 660 nm respectively. Upon excitation, Fluorescein-BP (55) showed maximum 
fluorescence intensity at 515 nm with Cy-Pep (71) at 695 nm. 
Upon increasing concentration of Fluorescein-BP (55) (Figure 2.14 A) there was an increase 
in fluorescence signal when the fluorophore was excited at 488 nm. The signal response at 515 
nm (Figure 2.14 B) also shows linear growth with increasing concentration (0.5-5 µM) 
suggesting that, under these specific conditions,  Fluorescein-BP (55) could be detected at a 
concentration of 0.0065 µM. However, above 3 µM the response is not linear suggesting that 
there might be some quenching taking place. 





Figure 2.14: Fluorescent signal of Fluorescein-BP. (A) Fluorescence spectrum of increasing 
fluorescence signal upon increasing concentration (0-5 µM) (λex = 488 nm). (B) Change of 
fluorescence intensity at λem =515 nm vs concentration of Fluorescein-BP probe (0-4 µM). 3 
and 4 µM data points reported in red as they do not fit with the linear fit. Data shown is from 
3 repeats (A) and 6 repeats (B) and shown as the mean ± S.E.M. 
For Cy-Pep (71) upon increasing concentration, there was an increase of fluorescence at 660 
nm, signal from 1 µM to 10 µM after which, at 20 µM the fluorescence intensity still increased 
but a small shift in wavelength was noticeable (λem = 708 nm) (Figure 2.15 A). When a 50 µM 
solution is used, a similar wavelength shift was apparent (λem = 717 nm) and there was a large 
decrease in fluorescence intensity to a value closer to that seen for probe concentrations of 10 
µM. The high concentration of Cy-Pep (71) in solution leads to clustering, which in turn leads 
to significant quenching of the fluorescence signal, a phenomenon that has already been shown 
to take place with cyanine dyes.68 However, between 1 µM to 10 µM of Cy-Pep, a linear 
response at 695 nm was visible (Figure 2.15 B) suggesting the lowest concentration for 
detection is 0.025 µM. 





Figure 2.15: Fluorescence signal of Cy-Pep. (A) Fluorescence spectrum of increasing 
fluorescence signal upon increasing concentration (0-50 µM) (λem = 660 nm). (B) Change of 
fluorescence intensity at λem =695 nm vs concentration of Cy-Pep probe. 50 µM removed for 
clarity as, together with 20 µM, it does not give a linear response. Data shown in (A) and (B) 
is from 3 repeats and shown as the mean ± S.E.M. 
Φ by ε (Table 2.9) are also easily calculated and show that Fluorescein-BP (55) is brighter 
than Cy-Pep (71). This can also be deduced from the fluorescence intensity of the probe at 5 
µM (Figure 2.14 A and Figure 2.15 A) showing that the signal for Fluorescein-BP (55) and 
Cy-Pep (71) are 10,000,000 and 300,000 AU respectively. 
Table 2.9: Absorbance and fluorescence maximum wavelength, quantum yield and 
extinction coefficient of Fluorescein-BP (55) and Cy-Pep (71). 
Compound λabs (nm) λem (nm) Φ ε (M-1cm-)1 
Fluorescein-BP (55) 491 515 0.83 41,100 
Cy-Pep (71) 660 695 0.73 110,000 
*quantum yields were measured in H2O:DMF mix using: 5/6-carboxy-fluorescein NHS ester (54) as a 
standard (Φ 0.79) for Fluorescein-BP (55) and Cy5.5 NHS ester (Φ 0.2) for Cy-Pep (71). 
 Binding affinity of probes to calcium compounds 
As many calcium compounds are present in animal and human models, the ability of 
Fluorescein-BP (55) and Cy-Pep (71) to bind specifically to HAP needed to be assessed. To 
study the affinity of the probes to HAP, a range of other calcium based compounds were 
selected; calcium oxalate (CaOx) present in benign cancer,69–72 calcium pyrophosphate 
(CaPyr) present in Pseudogout,73–77 and calcium phosphate (CaPi) which is a precursor to the 
more crystalline HAP. 




Two methods were explored to determine the selectivity of the probe towards calcium 
compounds. The first method used an aqueous suspension of these minerals, while the second 
method used calcium minerals embedded into an agarose phantom. 
Method 1 involved an aqueous suspension of the calcium minerals, at fixed w/v, which were 
incubated with Fluorescein-BP (55) or Cy-Pep (71) for 2 hours, before removing any un-bound 
probe from the solids through a series of centrifugation and washing steps. Fluorescence 
analysis of the combined aqueous extracts (Figure 2.16) allowed the levels of un-bound probe 
to be quantified and hence a direct comparison could be made between the levels of 
Fluorescein-BP (55) or Cy-Pep (71) binding to each of the different calcium-containing 
minerals. These data showed that Fluorescein-BP (55) exhibited almost an order of magnitude 
higher selectivity towards HAP than any other calcium species tested. In contrast, when Cy-
Pep (71), was incubated with the calcium minerals it showed a very similar fluorescent 
intensity for all of them indicating non-specific binding. There was also a sharp difference in 
fluorescence intensity obtained from both probes where Fluorescein-BP (55) displays a 
fluorescence intensity of around 32,500 AU upon binding to HAP while Cy-Pep (71) only 
displays an intensity of 7,625 AU upon the same binding, proving that Fluorescein-BP is more 










Figure 2.16: Selectivity of Fluorescein-BP (55) (A), Cy-Pep (71) (B) towards Calcium 
minerals in comparison to Alizarin S stain (C). Calcium minerals were incubated with 
Fluorescein-BP (5 μM) λem/ex =491/515 nm (A) or Cy-Pep (5 μM) λem/ex =660/695 nm (B) or 
1% w/w Alizarin S λem/ex =530/560 nm (C) in water for 2 hours and the un-bound probe was 
removed and quantified. The histograms show the relative amounts of bound probe for each 
of the calcium minerals. (A-C) show data that is representative of at least 3 independent 
experiments yielding comparable results. * P < 0.05, ** P < 0.01, *** P < 0.001. 
Non-specific binding was also observed when Alizarin S was incubated with the same 
minerals. Alizarin S is one of the most common staining methods for calcification together 
with von Kossa,77,78 but comes with its own limitations. The colourimetric stain Alizarin S 
detects calcium, and not phosphate, thus it can also interact with calcium binding proteins and 
proteoglycans without discriminating for the presence of HAP.79  
In order to achieve effective visualisation of the Alizarin S stain by fluorescence, millimolar 
concentrations of the stain were required which is in sharp contrast to the low micromolar 
concentrations required of Fluorescein-BP (55) and Cy-Pep (71). This reflects the relative 
brightness of the signal for each fluorophore which is proportional to its quantum yield (Φ = 
0.79 for fluorescein,80–82 Φ = 0.30 for Cy5.5,83–85 and Φ = 0.001 for Alizarin S82,86). Not only 
Φ is low for Alizarin S, it is also known that its binding affinity to HAP is 10-fold lower than 
the bisphosphonates which have a µM affinity.52,87 




Method 2, the ‘phantom method’ involves creating a phantom substrate by mixing calcium 
compounds in an agarose hydrogel. The phantoms were then incubated with Fluorescein-BP 
(55), Cy-Pep (71) and Alizarin S (Figure 2.17). After 2 hours, the supernatant was removed 
and the phantoms were washed twice with water to remove excess un-bound probe and then 
imaged.  
 
Figure 2.17: Phantom models showing binding of Fluorescein-BP (55), Cy-Pep (71) and 
Alizarin S to different calcium species. Calcium minerals were embedded in agarose and then 
incubated with Fluorescein-BP (5 μM) or Cy-Pep (5 μM) or 1% w/w Alizarin S in water for 2 
hours. The agarose phantoms were then washed with water and imaged. All data are 
representative of at least 3 independent experiments yielding comparable results.  
The phantom method initially appeared advantageous as it measured directly bound 
Fluorescein-BP (55) and Cy-Pep (71); however when combining the agarose and the calcium 
crystals, it became apparent that specific minerals disperse in different manners when in 
contact with the agarose. HAP and CaOx, being very crystalline in structure, form clusters 
while CaPi and CaPyr being powder-like dispersed evenly. Furthermore, when staining with 
Alizarin S, using powder-like materials was not easily differentiated from the unselective 
staining of the agarose gel itself. The addition of HAP caused the agarose to become basic, 
and when interacting with Alizarin S there was a colour change from bright red to a purple 
which this does not allow direct comparison with the other calcium compounds. 
It was for the above reasons that the aqueous suspension method was selected as the most 
appropriate method to determine selectivity of the probes towards the different calcium 




minerals. Due to the high selectivity of the Fluorescein-BP (55) probe towards HAP, it was 
selected for the next step involving in vitro and ex vivo studies.  
 Conclusion  
Several fluorescent probes with different optical properties were synthesised. Three fluoride 
probes, two based on the cyanoacrylate motif; one with a free hydroxyl group (3) and one with 
a TBDS protected group (4), as well as a rhodamine-based probe (5) were synthesised and 
their selectivity towards NaF was tested. Upon addition of fluoride ions, a decrease in 
absorption was visible for both the cyanoacrylate probes, however no novel peak appeared as 
expected from the literature. On the other hand, when the imidazole bearing rhodamine 6G 
probe (5) was incubated with NaF an increase in the fluorescence peak was observed and when 
incubated with a range of anions the probe showed selectivity towards fluoride ions only, 
suggesting that it could be a respectable probe to examine the mechanism of NaF uptake in 
calcified models. However, for the florescence signal of probe 5 at 5 µM concentration to be 
intense enough to be detected over the background signal, concentrations of NaF of 2.9 µM or 
above are required; as previously mentioned, this suggests that the required ratio between the 
probe and NaF is 1:0.6. For PET imaging, pM concentrations of NaF are used suggesting that 
the probe will also need to be in the same concentration range. Unfortunately, the fluorescence 
signal of the probe is not intense enough to be visualised at those concentrations, therefore 
even this probe was rejected.  
A number fluorophores were synthesised and their coupling to calcium targeting molecules 
was investigated. Once synthesised, the Cy7.5 (42) and Cy5.5 (47) were reacted with 
alendronate (26), however, the conjugated cyanine-alendronate system was never observed. 
Cy5.5 bearing an alkyne group (48) was also synthesised and its coupling to the phosphate-
protected azido alendronate (56) was successful, however, the deprotection of the phosphate 
protecting groups was never obtained. Cy5.5 (48) was nonetheless, coupled to a HAP selective 
peptide (30) which was then studied further to characterise the fluorophore and assess the 
selectivity of the probe. In contrast, Fluorescein-BP (55) was successfully synthesised without 
any complication. Fluorophore characterisation showed that although the Cy5.5-pep (71) 
emits in the NIR region, it is lacking in characteristics that the Fluorescein-BP (55) can 
provide; high quantum yields and extinction coefficient. When selectivity studies were carried 
out on different calcium minerals, Fluorescein-BP (55) provided a stronger fluorescence 
response when bound to HAP in comparison to the other minerals. When the same experiment 
was performed with Cy-Pep (71), although not using the same fluorophore, it was shown that 




the peptide motif lacked the same selectivity and provided the roughly the same fluorescence 
signal for all the calcium minerals. For this reason, Fluorescein-BP (55) was selected as a 
robust selective calcium probe for application in biological systems. 
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Chapter 3- Characterization of 
Fluorescein-BP in an in vitro model of 
osteoblast matrix calcification 
 Importance of calcium 
Calcium is a crucial intracellular element that is responsible for regulating many cellular 
processes across every cell type in biological organisms.1–5 Calcium is found in either the free 
ion form or as a mineral phase. An example of this is hydroxyapatite (HAP) which makes up 
bone and teeth. Numerous physiological processes, including: muscle contraction; cell 
adhesion; hormone/neurotransmitter release; glycogen metabolism; cell 
proliferation/differentiation; blood clotting and nerve or sympathetic impulse transmission are 
regulated by calcium signalling. 6–10 Defects in the integrity of cell-specific calcium signalling 
systems are associated with a number of human diseases including neurodegenerative and 
kidney diseases.1,11,12  
 
Figure 3.1: Role of calcium ions. Calcium plays an important role in bone structure, nerve 
impulse transmission, wound healing, muscle contraction and in cell metabolism. Images 
downloaded. 
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Moreover, pathological calcification is also a critical component of a wide range of diseases 
such cancer, arthritis and CVD.13 One example of this is the presence of two types of calcium 
species in breast cancer: calcium oxalate (CaOx) which is associated with benign breast 
disease; and HAP which is associated with malignant breast cancer.14–18 As described in 
Chapter 1, HAP is also present in a range of CVD disorders.19,20 Microscopic deposits of HAP, 
present in atherosclerotic lesions, can weaken the fibrous cap of an atherosclerotic plaque, 
leading to rupture of the plaque and vessel occlusion.21–25 Thus, the development of a calcium 
assay which is able to selectively detect HAP with high sensitivity and specificity could both 
improve our pathophysiological understanding and the diagnosis of a range of clinical 
disorders including vascular calcification.  
 Gold standard methods of detecting calcification 
The most common assays for calcium phosphate calcification are calcium leaching by 
hydrochloric acid (HCl); and staining with Alizarin S and von Kossa (Figure 3.2).26,27 Each 
comes with their own advantages and limitations and will be briefly discussed below. 
 
Figure 3.2: Alizarin S and von Kossa stain of murine mammary adenocarcinoma 4T1 cell 
calcification under a range of different conditions which induce (β-glycerolphosphate (β-
GP) & ascorbic acid (AA), β-GP& AA & dextran, β-GP) or inhibit calcification (AA). Image 
reproduced with permission.18 
3.2.1 Alizarin S 
Alizarin S staining has been used for decades as a staining tool to evaluate calcium rich 
deposits in cell culture (Figure 3.2) as well as a bone marker by staining calcification in red 
.28–30 After staining with Alizarin S, the dye can be extracted from the cell monolayer or tissue 
sample and can be quantified by carrying out a colourimetric assay.31 Alizarin S functions by 
forming a chelate ring around calcium, specifically the hydroxyl groups on the alizarin which 
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are adjacent to each other are capable of forming a ring structure (Figure 3.3) with metals such 
as aluminium, iron and other metal cations as well as calcium.28,30,32 
 
Figure 3.3: Mechanism of binding of Alizarin S to calcium present in bones. 
However, even though it binds to calcific lesions, Alizarin S cannot discriminate between 
different calcium forms thus making it hard to confirm specifically the presence of HAP.33  
3.2.2 Von Kossa 
In contrast to Alizarin S, the colourimetric von Kossa stain reacts with phosphates but only in 
acidic environments (Figure 3.4). In von Kossa staining, sections are placed in a silver nitrate 
solution and exposed to light. Once exposed, the sections are then treated with sodium 
thiosulfate which removes unreacted silver. Silver nitrate reacts with phosphate, upon 
exposure to light the silver phosphate is then reduced to its metallic form.34 
 
Figure 3.4: Von Kossa staining of atherosclerotic plaques. (A) Unobserved calcification in 
early lesion and (B) prominent calcification in advanced plaque. Image reproduced with 
permission.35  
However, the presence of phosphate does not necessarily imply the presence of calcification 
or even specifically HAP as CaPi can also provide a positive stain.26,3336 Moreover, high 
phosphate levels are also associated with other components in the cell and the high level of 
free phosphate in the cytosol which could also display positive von Kossa staining.31,34  
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Both Alizarin S and von Kossa stains are used to indicate calcium depositions but at best give 
only semi-quantitative calcium readings and often stain in different areas due to the different 
binding abilities (Figure 3.2).37  
3.2.3 HCl/DC assay 
The calcium leaching assay is a further method used to determine calcium concentrations and 
has been used in laboratory settings to determine the presence of calcification in vascular and 
bone cell models.38–41 The assay involves treating cell monolayers with HCl which allows the 
extraction of free calcium ions from the cells. The calcium content is then detected using a 
colorimetric assay, typically using o-cresolphthalein complexone, and normalised against the 
total number of cells per sample.42 However, the assay presents major disadvantages when a 
large volume of cells are used as the HCl is not able to dissolve all the cell content and therefore 
an accurate reading of the total protein concentration is not obtained which makes the 
normalisation step hard. Furthermore, the calcium leaching assay is time intensive as it takes 
around 24-48 hours, making it unsuitable for high-throughput applications. 
3.2.4 Calcein and other fluorescence methods 
The discrepancies between the amounts of calcium visualized by Alizarin S and von Kossa 
has led scientists to develop novel calcium imaging probes that are more selective and more 
sensitive. 
An example of this is calcein, this probe has routinely been used as a tool for imaging calcium, 
with higher sensitivity to Alizarin S and von Kossa. However, similarly to Alizarin S, calcein 
interacts with calcium (Figure 3.5) as well as a range of other metals including aluminium and   
zinc.43,44 Nonetheless, even though it is able to bind to a range of cations, it has mainly been 
used for cell viability studies due to its ability to penetrate the cells and if alive fluoresce. 
 
Figure 3.5: Calcein staining of zebrafish embryos. Calcein localization in the vertebrate 
column which is mainly composed of calcium. Image reproduced with permission.45    
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Another recently reported probe used in animal bone and vascular disease models is 
Osteosense (680 and 750), an expensive commercially available, near infrared (NIR) probe 
conjugated to a bisphosphonate.35,46–48 This probe has been shown to be specifically selective 
for HAP and more sensitive than the current gold standard imaging techniques such as Alizarin 
S and von Kossa. However, the benefits offered by a NIR probe for in vivo studies, are negated 
by the need for non-standard filters for plate readers and microscopes in laboratory-based 
experiments which is why the development of new and more accessible imaging tools are 
necessary. 
 
Figure 3.6: Von Kossa and OsteoSense staining of atherosclerotic plaques. (A) Early stage 
plaque formation showing no von Kossa staining but OsteoSense staining is visible in areas 
of micro-calcification. (B) Calcified plaque showing both von Kossa and OsteoSense staining 
of macro-calcification. Image reproduced with permission.35 
 Models for calcification 
In vitro and in vivo models are important for underpinning the pathogenesis of human disease 
with the drive of developing novel therapies and imaging tools.49 A number of models to 
address cardiovascular complications such as atherosclerosis have been recreated in different 
animal species and have been crucial in advancing the understanding of the disease 
mechanisms. 
3.3.1 Cells 
Cells cultures are the first line of study. Specifically, primary vascular smooth muscle cells 
(VSMCs) which are the principal cell type involved in vascular calcification. They have been 
reported to provide respectable models to study calcification as they can undergo a phenotypic 
transition to calcifying osteoblastic cells.50 Cell lines can also be used and, in contrast to 
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primary cells, offer a reliable, convenient and economical system in which to investigate 
vascular calcification in vitro.50 The mouse VSMC cell line MOVAS-1 exhibits a smooth 
muscle cell phenotype and has also been previously employed to investigate the VSMC cell 
cycle and vascular calcification.50,51  
3.3.2 Ex vivo rings 
Cell monolayers only offer limited information of CVD due to their 2D structure which 
therefore does not provide the correct architecture and matrix structure which you would 
expect from normal vessels. They reach confluence over a short timeframe; they rapidly 
convert to a proliferative, secretory phenotype.52 Morphological and phenotypic changes also 
occur at high passage numbers which lead to false results. In contrast, cultured aortae which 
have a 3D structure, are able to bridge the gap between 2D cultures and animal models using 
in vivo conditions.52,53 Previous studies have cultured sectioned thoracic aortas dissected from 
mice and estimated the status of calcification under Pi stimulation at 2.6-3 mM Pi (Figure 
3.7);53 these phosphate concentrations correlate with myocardial infarction in human studies.53  
 
Figure 3.7: Thoracic aortic sections cultured under different phosphate concentrations (1.4, 
1.8, 2.2, 2.6, 3.0 mM Pi) for 7 days and stained with Alizarin S and von Kossa. Both Alizarin 
S and von Kossa show an increase in calcification present with increasing phosphate 
concentrations. Image reproduced with permission.52 
3.3.3 Genetically modified mouse models  
Another method for studying disease progression is by using animal models. Currently the use 
of small rodents, explicitly mice, as the main model of human disease is extensive. Their 
popularity is due to cost effectiveness and the ease with which a litter can be maintained. Other 
advantages include the large number of litters that provides a larger n value for studies as well 
as the ease in genetically modifying mice in order to either ablate, or overexpress, genes of 
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interest which can then provide useful information underpinning the mechanisms of CVD.49,54–
56 
In atherosclerosis murine models offer an additional advantage which is the development of 
the plaque in a very short time frame.56 The two most commonly used mouse models are: 
apolipoprotein E knockout mouse (ApoE-/-) and low density lipoprotein receptor deficient 
mouse (LDLR-/-).49,54,55,57,58 ApoE-/- is the most widely used as it develops atherosclerosis 
spontaneously (Figure 3.8),59 and this development can be accelerated if the mice are placed 
on a high fat western type diet. These mice provide excellent models to study atherosclerosis 
as similarly to humans, they exhibit various phases of the disease including; early stage fatty 
streaks, accumulation of foam cells and the development of a fibrous cap and calcification 
nodules.56 However, in contrast to humans where atherosclerotic plaques manifest in carotid 
and coronary arteries, mice predominantly develop plaques in the aortic arch.54,55  
 
Figure 3.8: Wild type and ApoE-/- mice on a normal diet. ApoE-/- mice spontaneously develop 
atherosclerotic plaque over time. Image reproduced with permission.60 
Several other murine knockout models have been created, where genes that regulate bone 
formation have been ablated, and these have led to new insight in the pathogenesis of arterial 
calcification. MGP knockout mice have shown extensive calcification in the aorta while OPG 
knockout mice developed medial and subintimal calcification in sites where endogenous OPG 
expression would be found suggesting that OPG may have a specific role in protecting the 
arteries from calcification.61 
Another model that provides vascular calcification is the ENPP1 knockout mouse. ENPP1 is 
a key regulator of biomineralization and vascular calcification, however these knockout mice 
are mainly used in the study of generalised arterial calcification in infancy (GACI).39,40 Due to 
the inhibition of pyrophosphate in constraining calcium deposition in ENPP1 mice, they could 
provide a potential therapeutic understanding on calcification deposition.62 
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 Probe toxicity studies 
Before any cell and ex vivo experiments could be carried out with the new probe, toxicity study 
to determine the optimum concentration of the probe that would not kill the cells had to be 
determined. To do this, MOVAS-1 cells were treated with a range of different concentrations 
of Fluorescein-BP (55) together with Alamar blue (Figure 3.9). Alamar blue is an accurate 
and rapid indicator of cellular health which has been used for the past 50 years in studies on 
cell viability and cytotoxicity.63 Cells were incubated with both probes for 4 hours. Two 
controls were required, one which included cells with only Alamar Blue (positive control) and 
the other containing cells, Alamar Blue and DTT (identified in Figure 3.9 as lysis buffer) 
which in turn causes cell lysis. It was found that, high concentrations of the Fluorescein-BP 
probe (5 and 10 µM) would cause the cells to die, while lower concentrations (0.5, 1, 2 µM) 
caused reduced levels of cell death. It was decided to use 1 μM in subsequent studies as this 
provides a higher fluorescence signal when incubated with a cell monolayer in comparison to 
0.5 μM. 
 
Figure 3.9: MOVAS-1 cell viability assay using Alamar Blue for different concentrations 
of Fluorescein-BP (55). Cells were seeded and grown until confluent. Cells were either: left 
untreated, treated with DTT to cause cell lysis, or treated with different concentrations of the 
probe to determine the optimum concentration of probe. Alamar blue was added to the cells 
for 4 hours before measuring the absorbance (λex= 570 nm). Data shown is from at least 6 
repeats and shown as the mean ± S.E.M. * p< 0.05, ** p< 0.01, *** p < 0.001 
Another cytotoxicity study with Alamar Blue assay was performed to determine whether the 
Ca2+ concentrations used to induce calcification were too high and were leading to cell 
apoptosis. 2.4 mM Ca2+ and 1.4 mM Pi and 2.7 mM Ca2+ and 2.5 mM Pi calcification 
conditions were selected as they are reported to induce calcification in VSMCs and resonance 
on real hypercalcemia and hyperphosphatemia conditions in patients.64 Control and calcified 
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cell samples were incubated with, or without, Fluorescein-BP (55). Cells were also incubated 
with Fluorescein-BP (55) to determine whether incubation with the probe and the calcification 
conditions could have a negative synergistic effect on the cell monolayer and then lead to cell 
death. Both calcifying conditions ((i) 2.4 mM Ca and 1.4 mM Pi, and (ii) 2.7 mM Ca and 2.5 
mM Pi) and control cell monolayers were grown for 7 days after which Fluorescein-BP (55) 
and Alamar Blue were added (Figure 3.10). Upon fluorescence examination, it was visible 
that neither calcification conditions, with or without Fluorescein-BP (55), had any negative 
effect on the cell monolayer as the optical density reading was equivalent within experimental 
error. 
 
Figure 3.10 MOVAS-1 cell viability assay using Alamar Blue for different calcification 
conditions. Cells were seeded and treated with calcification media ((i) 2.4 mM Ca and 1.4 
mM Pi, or (ii) 2.7 mM Ca and 2.5 mM Pi) for 7 days. Cells were then incubated with 
Fluorescein-BP (1 µM, 2 hours) followed by Alamar blue (10 µL, 4 hours) reported in black 
or Alamar blue (10 µL, 4 hours) alone reported in grey. After incubation, the absorbance (λex= 
570 nm) was measured. Data shown is from at least 6 repeats and shown as the mean ± S.E.M. 
Together these data show that conditions such as 2.4 mM Ca and 1.4 mM Pi, or 2.7 mM Ca 
and 2.5 mM Pi, were appropriate for further studies. 
 Probe localization studies 
Localisation studies were also carried out on MOVAS-1 cell monolayers. A monolayer of 
MOVAS-1 cells was incubated with 2.4 mM Ca and 1.4 mM Pi for 7 days, then treated with 
Fluorescein-BP (55) for 2 hours. Once treated, the monolayer was imaged using confocal 
microscopy (Figure 3.11) which showed extracellular localisation of probe (55). This is 
indicative of the presence of HAP in the extracellular matrix which is in agreement with 
previous reports.65–68 




Figure 3.11: Confocal imaging of calcified MOVAS-1 monolayers. Monolayers of MOVAS-
1 cells were grown to confluence (day 0) and then switched to calcification media (2.4 mM Ca 
and 1.4 mM Pi) for 7 days, changing media on alternate days. The cell monolayers were 
treated sequentially with Fluorescein-BP (1 μM, 2 hours; green); CellMask Orange (500 nM, 
10 minutes, pink); NBF (10%, 15 minutes); Triton X (0.05%, 3 x 5 minutes); DAPI (300 nM, 
5 minutes, blue); then imaged on an Zeiss Confocal LSM710 microscope (ex = 488 nm, 554 
nm and 350 nm). Images are representative of at least 3 repeats. Scale bars = 100 µm. (A) 
Incubation with Fluorescein-BP and DAPI. (B, C) Incubation with Fluorescein-BP, CellMask 
Orange and DAPI. 
In contrast to Fluorescein-BP (55) when the cells were incubated with Fluorescein-amino-1-
pentol (Fluorescein-OH, 73), a control fluorescein-based probe which lacks the 
bisphosphonate motif, no signal was observed (Figure 3.12). This demonstrated that the 
bisphosphonate motif was responsible for the Fluorescein-BP (55) binding to HAP in a cellular 
environment. 
 
Figure 3.12: Structure of Fluorescein-OH (73) (A) and fluorescence image of Calcified 
MOVAS-1 cells incubated with Fluorescein-OH (B). A monolayer of MOVAS-1 cells was 
grown to confluence (day 0) and then switched to calcification media (2.4 mM Ca and 1.4 mM 
Pi) for 7 days, changing media on alternate days. The cell monolayer was incubated with 
Fluorescein-OH (1 μM, 2 hours), fixed with NBF (10%, 15 minutes) and mounted using 
ProLong Gold Antifade with DAPI. Scale bar = 100 µm. 
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 Comparison of probe with Alizarin S and calcium leaching assay 
To investigate the range of conditions under which the Fluorescein-BP (55) probe can be used 
and to compare its efficacy with the calcium leaching assay and Alizarin S stain a 
supplementary series of calcification assays were conducted with both the MOVAS-1 cell line 
and primary VSMC cells. 
3.6.1 MOVAS 
Monolayers of the MOVAS-1 cell line were incubated in both phosphate-enriched (3 mM and 
5 mM Pi) and both phosphate and calcium-enriched (2.4 mM Ca and 1.4 mM Pi and 2.7 mM 
Ca and 2.5 mM Pi) growth media. Both, the calcium leaching assay (4-fold, p < 0.001) (Figure 
3.13 A) and the fluorescence assay (4-fold, p < 0.001)   (Figure 3.13 B) demonstrated 
significant levels of calcium deposition when incubated in calcium enriched media. A 
comparison of the fluorescence images obtained for well plates with images of Alizarin S 
staining of equivalent plates (Figure 3.13 C), suggest that both fail to distinguish calcification 
in media only enriched with phosphate. Nevertheless, when cells are incubated in the presence 
of both calcium and phosphate enriched media, the fluorescent probe can detect the deposition 
of microcrystalline HAP with greater sensitivity than the Alizarin S stain. This is most notable 
when using commonly applied in vitro vascular calcification conditions, where the growth 
media have been enriched with 2.4 mM Ca and 1.4 mM Pi.38  
 
 




Figure 3.13: Determination of calcification in the MOVAS cell line at various 
concentrations (3.0 mM Pi, 5.0 mM Pi, 2.4 mM Ca and 1.4 mM Pi, 2.7 mM Ca and 2.5 mM 
Pi). Monolayers of MOVAS-1 cells were grown to confluence (day 0) and then switched to 
calcification media. The monolayers were incubated in calcification media (3.0 mM Pi, 5.0 
mM Pi, 2.4 mM Ca and 1.4 mM Pi, 2.7 mM Ca and 2.5 mM Pi) for 7 days, changing media on 
alternate days. (A) Calcium leaching assay: o-cresolphthalein complexone. (B) Fluorescence 
assay: cell monolayers were incubated with Fluorescein-BP (1 μM, 2 hours); NBF (10%, 15 
minutes). (C) Fluorescence images and Alizarin S stain images: cell monolayers were either: 
incubated with Fluorescein-BP (1 µM, 2 hours) and then fixed with NBF (10%, 15 minutes), 
or fixed with NBF (10%, 15 minutes) and then incubated with Alizarin S (2%, 500 μL, 10 
minutes). Data shown in (A) and (B) are from at least 6 repeats and shown as the mean 
± S.E.M., * P < 0.05, ** P < 0.01, *** P < 0.001 compared to control. Images shown in (C) 
are representative of at least 3 independent experiments yielding comparable results. Arrows 
indicate the location of calcium deposits within the well. Scale bars = 250 μm. 
In further experiments, MOVAS-1 cells (Figure 3.14) were incubated under the standard 
vascular calcification conditions (2.4 mM Ca and 1.4 mM Pi) and the calcification on days 3, 
5 and 7 was detected using Fluorescein-BP probe (55) (2.5-fold, p < 0.001). These results were 
then compared with calcium leaching assay (5-fold, p < 0.001) and staining by Alizarin S. 
Again in this instance, the fluorescent probe was shown to be more sensitive than both the 
other assays. 




Figure 3.14: Determination of calcification in the MOVAS-1 cell line at various days 
incubation (3, 5 and 7). A monolayer of MOVAS-1 cells was grown to confluence (day 0) and 
then switched to calcification media (2.4 mM Ca and 1.4 mM Pi) for 3, 5, or 7 days, changing 
media on alternate days. (A) Calcium leaching: o-cresolphthalein complexone. (B) 
Fluorescence assay; the cell monolayer was incubated with Fluorescein-BP (1 μM, 2 hours); 
NBF (10%, 15 minutes). (C) Fluorescence images and Alizarin S stain images: cell 
monolayers were either: incubated with Fluorescein-BP (1 µM, 2 hours) and then fixed with 
NBF (10%, 15 minutes), or fixed with NBF (10%, 15 minutes) and then incubated with Alizarin 
S (2%, 500 μL, 10 minutes). Data shown in (A) and (B) are from at least 6 repeats and shown 
as the mean ± S.E.M., * P < 0.05, ** P < 0.01, *** P < 0.001 compared to day 0 (control). 
Images shown in (C) are representative of at least 3 independent experiments yielding 
comparable results. Scale bars = 250 μm. 
 
3.6.2 VSMCs 
When equivalent studies were completed using primary mouse VSMCs (Figure 3.15) where 
the monolayers were incubated with increasing levels of phosphate to induce calcification (1.8 
mM Pi, 2.6 mM Pi and 3 mM Pi), the fluorescent probe (5-fold, p < 0.001) was once more 
shown to be more sensitive than both the Alizarin S or calcium leaching assays (1.2-fold, p < 
0.001). 
 




Figure 3.15: Determination of calcification in primary mouse VSMCs at various 
concentrations (1.8 mM Pi, 2.6 mM Pi, 3.0 mM Pi). Monolayers of primary mouse VSMCs 
were grown to confluence (day 0) and then switched to calcification media. The monolayers 
were incubated in calcification media (1.8 mM Pi, 2.6 mM Pi, 3.0 mM Pi) for 7 days, changing 
media on alternate days. (A) Calcium leaching assay: o-cresolphthalein complexone. (B) 
Fluorescence assay: cell monolayers were incubated with Fluorescein-BP (1 μM, 2 hours); 
NBF (10%, 15 minutes). (C) Fluorescence images and Alizarin S stain images: cell 
monolayers were either incubated with Fluorescein-BP (1 µM, 2 hours) and then fixed with 
NBF (10%, 15 minutes) or fixed with NBF (10%, 15 minutes) and then incubated with Alizarin 
S (2%, 500 μL, 10 minutes). Data shown in (A) and (B) are from at least 6 repeats and shown 
as the mean ± S.E.M., * P < 0.05, ** P < 0.01, *** P < 0.001 compared to control. Images 
shown in (C) are representative of at least 3 independent experiments yielding comparable 
results. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to control, n = 6. Scale bars = 250 
μm. 
Additional experiments were carried out where VSMCs were calcified for different times 
(Figure 3.16). VSMCs were incubated under standard calcification conditions (3.0 mM Pi)69 
and the calcification was detected on days 3, 5 and 7 using Fluorescein-BP (55) (2.5-fold, p < 
0.001) and compared with calcium leaching assay (2.5-fold, p < 0.001) and staining by 
Alizarin S. As for the MOVAS-1 cell line, the fluorescent probe was revealed to be more 
sensitive than both other assays.  




Figure 3.16: Determination of calcification in VSMCS at various days incubation (3, 5 and 
7). A monolayer of VSMCS cells was grown to confluence (day 0) and then switched to 
calcification media (3.0 mM Pi) for 3, 5, or 7 days, changing media on alternate days. (A) 
Calcium leaching assay: o-cresolphthalein complexone. (B) Fluorescence assay; the cell 
monolayer was incubated with Fluorescein-BP (1 μM, 2 hours); NBF (10%, 15 minutes). (C) 
Fluorescence images and Alizarin S stain images: cell monolayers were either incubated with 
Fluorescein-BP (1 µM, 2 hours) and then fixed with NBF (10%, 15 minutes) or   fixed with 
NBF (10%, 15 minutes) and then incubated with Alizarin S (2%, 500 μL, 10 minutes).   Data 
shown in (A) and (B) are from at least 6 repeats and shown as the mean ± S.E.M., * P < 0.05, 
** P < 0.01, *** P < 0.001 compared to day 0 (control). Images shown in (C) are 
representative of at least 3 independent experiments yielding comparable results. Scale bars 
= 250 μm. 
3.6.3 MC3T3 
Parallel experiments using MC3T3 cells (Figure 3.17) were performed. MC3T3 are an 
osteoblast derived cell line which is commonly used for studies in the field of bone and skeletal 
calcification.70,71 Since both vascular, bone and skeletal calcification compromises of HAP 
deposits a comparative study between the different cell lines would allow the versatility of the 
probe to be determined. MC3T3 cells were incubated with Fluorescein-BP (55), and calcium 
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mineralisation was readily detected (2-fold, p < 0.001). Differently from vascular calcification 
which occurs within 7 days, bone mineralization can take up to 21 days. 
 
Figure 3.17: Determination of calcification in MC3T3 at various days incubation (7, 14 and 
21). MC3T3 cells were grown to confluence (day 0) and switched to calcification media (2.5 
mM β-GP and 50 μg/ml AA). Cells were incubated for 7, 14, or 21 days, changing media on 
alternate days. (A) Calcium leaching assay: o-cresolphthalein complexone.   (B) Fluorescence 
assay: cell monolayers were incubated with Fluorescein-BP (1 μM, 2 hours); NBF (10%, 15 
minutes). (C) Fluorescence images and Alizarin S stain images: cell monolayers were either 
incubated with Fluorescein-BP (1 µM, 2 hours) and then fixed with NBF (10%, 15 minutes), 
or fixed with NBF (10%, 15 minutes) and then incubated with Alizarin S (2%, 500 μL, 10 
minutes). Data shown in (A) and (B) are from at least 6 repeats and shown as the mean 
± S.E.M., * P < 0.05, ** P < 0.01, *** P < 0.001 compared to day 0 (control). Images shown 
in (C) are representative of at least 3 independent experiments yielding comparable results. 
Scale bars = 250 μm. 
 Aortic rings 
To have a better understanding of the 3D structure of the mineral deposits in vascular tissue, 
ex vivo aortic rings from wild type (WT) rats were used. These were incubated under different 
calcification conditions (1.8 mM Pi, 2.6 mM Pi and 3.0 mM Pi) for 7 days and subsequently 
incubated with Fluorescein-BP (55) followed by Alizarin S (Figure 3.18). From both staining 
methods, it is apparent that with increasing calcification conditions there is an increase in 
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signal in both the Alizarin S and Fluorescein channel. When the two channels are merged, it 
is clear that the Alizarin S and Fluorescein-BP (55) stains co-localize in most areas. However, 
the Alizarin S stain appears more intense at the edges of the sections in comparison to the 
Fluorescein-BP (55) probe suggesting a different calcium mineral content at the edges. This is 
perhaps not surprising as in vitro experiments show that a supersaturated solution of calcium 
phosphate initially forms a precipitate of amorphous calcium phosphate (ACP) which is then 
converted into the thermodynamically more stable crystalline form, HAP; a process which is 
also known to take place in biological calcification.72 These different staining patterns might 
thus reflect the relative stages of mineralisation in the sections, with the most recently 
deposited calcium phosphate appearing at the edges in contact with the phosphate-enriched 
calcification media. 
 
Figure 3.18: Determination of calcification in rat aorta incubated under different 
calcification conditions (1.8 mM Pi, 2.6 mM Pi and 3.0 mM Pi). Rat aortic rings were 
incubated for 2 days in fresh control media followed by calcification media (1.8 mM Pi, 2.6 
mM Pi and 3.0 mM Pi) for 7 days. The rings were subsequently incubated with Fluorescein-
BP (1 µM, 2 hours), fixed with NBF (10%, 15 minutes), permeabilised in KOH (1%, 1 hour) 
and then incubated with Alizarin S (0.00005% Alizarin S in 1% KOH, 24 hours). Brightfield 
(A, B, C, D,), Fluorescence (I, J, K, L), Alizarin S (E, F, G, H). Merged images (M, N, O, P) 
recorded using both Alizarin S and Fluorescein-BP channels. Images shown are 
representative of at least 3 independent experiments yielding comparable results. Scale bars 
= 250 µm. Fluorescein-BP λex/em = 491/515 nm; Alizarin S λex/em = 530/560 nm. 
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A series of control experiments (Figure 3.19) to confirm that: no autofluorescence was present 
on the tissue samples that were not incubated with either Fluorescein-BP (55) (Figure 3.19; B, 
F, J, N) or Alizarin S stain (Figure 3.19; C, G, K, O) and that no Fluorescein-BP (55) or 
Alizarin S staining was bleeding into the other channel (Figure 3.19). Imaging aortic rings 
which were not stained didn’t show any background autofluorescence in either channel 
suggesting that the fluorescence signal we obtain when the aortic rings are stained are due to 
the dye and only to the dye which emits in that specific channel. 
 
Figure 3.19: Ex-vivo aorta sections controls. Rat aortic rings were incubated for 2 days in 
fresh control media followed by calcification media (3.0 mM Pi) for 7 days. The rings were 
subsequently incubated with either Fluorescein-BP (1 µM, 2 hours) and then fixed with NBF 
(10%, 15 minutes) or fixed with NBF (10%, 15 minutes), permeabilised in KOH (1%, 1 hour) 
and then incubated with Alizarin S (0.00005% Alizarin S in 1% KOH, 24 hours). Brightfield 
(A, B, C, D), Fluorescence (I, J, K, L), Alizarin S (E, F, G, H). Merged images (M, N, O, P) 
recorded using both Alizarin S and Fluorescein-BP channels. Data shown are representative 
of at least 3 independent experiments yielding comparable results. Scale bars = 250 µm. 
Next, a more detailed analysis of the calcification in the aortic rings as well as their location 
was conducted using 5 µm sections (Figure 3.20). Calcified aortic rings, which were derived 
from eight week old male Fischer rats, were fixed and cryosectioned on day 7. The sections 
were then incubated with Fluorescein-BP (55) followed by Alizarin S. Fluorescent imaging 
confirmed differences in calcification between the control and 3 mM Pi specimens.  




Figure 3.20: Determination of calcification in rat aortic ring sections. Rat aortic rings were 
incubated for 2 days in fresh control media followed by calcification media 3.0 mM Pi) for 7 
days and fixed with NBF (10%, 15 minutes). Rings were cryosectioned into 5μm sections. 
Sections were incubated with Fluorescein-BP (1 µM, 2 hours), permeabilised in KOH (1%, 1 
hour), incubated with Alizarin S (0.00005% Alizarin S in 1% KOH, 24 hours), followed by 
DAPI (500 nM, 5 minutes). Brightfield (A, B), Fluorescence (E, F), Alizarin S (C, D). Merged 
images (G, H) recorded using Alizarin S, Fluorescein-BP and DAPI channels. Images shown 
are representative of at least 3 independent experiments yielding comparable results. Scale 
bar = 250 µm. 
It is clear from the sections in Figure 3.20 that the calcification is present in the medial layer 
of the aorta. The Fluorescein-BP (55) probe appears to have a stronger signal in comparison 
to the Alizarin S as well as being more defined. This also allows the location of the 
calcification to be determined; which in this rat model occurs as in the medial layer of the 
aorta. To confirm the location of calcification within the ring sections, α-smooth muscle actin 
(SMA) immunofluorescence (IF) staining was performed. α-SMA is a stain for smooth muscle 
cells restricted to the vascular system.73,74 The calcified aortic ring sections were stained with 
both α-SMA and DAPI and when the two images were compared, Figure 3.21 A and B, is 
evident that the Fluorescein-BP is localised in areas which have a large concentration of α-
SMA.  




Figure 3.21: IF of calcified aortic rings with α-SMA (A) and Fluorescein-BP (B). Rings 
were incubated for 2 days in fresh control media followed by calcification media 3 mM Pi for 
7 days and fixed with NBF (10%, 15 minutes). Rings were cryosectioned into 5 μm sections. 
α-SMA IF (A): Sections were incubated with α-SMA (1:100, 24 hours) followed by Alexa 
Fluor® 496 (1:250, 1 hour). Sections were washed and then stained with DAPI (500 nM, 5 
minutes). Fluorescein-BP fluorescence (B): Sections were incubated with Fluorescein-BP (1 
µM, 2 hours) followed by DAPI (500 nM, 5 minutes). Data shown are representative of at least 
3 independent experiments yielding comparable results. Scale bars = 100 µm. 
 ApoE-/- mice  
As mentioned in section 3.3.3 another method for studying disease progression is to use 
models obtained from genetically modified mice. ApoE-/- mice which were obtained from a 
collaboration with Dr P. Hadoke (University of Edinburgh); mice were fed a high fat diet until 
22 weeks of age whereupon they were culled, and the aortae dissected. Dr Junxi Wu from the 
Hadoke group performed the von Kossa staining and the OPT imaging. 
Serial sections of AopE-/- mice were stained with both von Kossa and Fluorescein-BP (55) 
(Figure 3.22). Von Kossa staining showed calcification in sections 50, 60 and 70 with no sign 
of calcification in sections 30, 40 and 80. When fluorescence imaging was carried out on the 
subsequent sections (31, 41, 51, 61, 71 and 81) a similar staining pattern was observed in 
sections 51, 61 and 71 while sections 41 and 81 showed additional staining, <50 µm, at much 
lower levels which were not detected when stained with von Kossa.  




Figure 3.22: Von Kossa (A-C and G-I) and fluorescence (D-F and J-L) imaging of aortic 
sections of a 22 week old ApoE-/- mice fed a high fat diet. Sequential sections were stained 
with either von Kossa (silver nitrate, 20 minutes; 5% sodium thiosulfate, 5 minutes; 0.1% 
neutral red 2 minutes) or Fluorescein-BP (1 µM, 2 hours) and DAPI (500 nM, 5 minutes). 
Scale bars = 0.1 cm for von Kossa and 100 µm for fluorescence. Von Kossa staining and 
images were performed by Dr Junxi Wu. 
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It appears that the von Kossa stain although able to detect macrocalcific lesions, is not likely 
to detect smaller micro-calcification deposits. On the other hand, the Fluorescein-BP (55) 
probe is more sensitive, as also shown in the previous experiments, and was able to detect both 
macro-calcification and micro-calcification.  
A second study conducted with ApoE-/- mice involved optical projection tomography (OPT) 
of whole aorta. OPT is a technique that images biological samples in 3D and provides similar 
information to standard confocal microscopy techniques without the need for taking physical 
sections from the sample. The specimen is rotated and optical images are captured.75,76 
Different excitation wavelengths can be chosen when using fluorescent probes but anatomical 
information can also be obtained by imaging the tissue autofluorescence. The ApoE-/- aorta 
were incubated with Fluorescein-BP (55) and then embedded in low melting point agarose for 
OPT imaging. Tissue was excited at both 475 nm and 425 nm to visualise probe localization 
and tissue autofluorescence, specifically elastin, respectively (Figure 3.23). Sections of the 
whole aorta were also obtained from the OPT imaging where signal from the Fluorescein-BP 
(55) (Figure 3.23 A) and the tissue autofluorescence (Figure 3.23 B) were merged.  
 
Figure 3.23: OPT of whole ApoE-/- mice aorta. Aortae was incubated with Fluorescein-BP 
(55) (1 µM, 24 hours) followed by embedding in low melting agarose, dehydrated (100% 
EtOH, 3 times) and cleared (BABB, 48 hours). Green arrows indicate intraplaque 
calcification while blue arrow indicates tissue autofluorescence. (A) and (B) show whole aorta 
imaging at 475 nm (Fluorescein-BP) and 425 nm (autofluorescence) respectively; (C-D) 
cross-section of aorta at a number of different sites. 
In this instance, sections provide information of the localization of the macro-calcification, 
≥50 µm, (Figure 3.23 D) with other areas presenting macro-calcification as well as micro-
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calcification deposits (Figure 3.23 E) and other locations in the aortae that only show smaller 
micro-calcification deposits (Figure 3.23 F) which would have perhaps not been identified by 
conventional Alizarin S and von Kossa staining.  
 Conclusion 
Fluorescein-BP (55) gives a dramatically enhanced signal output over more conservative 
imaging methods such as Alizarin S and von Kossa stains for the detection of calcium 
phosphate in a range of in vitro studies. It has been shown to be non-toxic and low µM 
concentrations has been used in both condition-specific and temporal studies of calcification 
in cell-based models of CVD and bone disease. In contrast to the calcium leaching assay which 
is not suitable for high-throughput applications, Fluorescein-BP (55) can be applied to 
experiment carried out in a 96-384 well plate which would allow for high-throughput multi-
well analysis of calcification. When applied to ex vivo WT aortic sections and ApoE-/- sections, 
Fluorescein-BP (55) shows binding to intraplaque calcification. In ApoE-/- tissue, two different 
scales of calcium-based deposits are visible which suggest that the Fluorescein-BP (55) probe 
can detect both macro- and micro-calcification. When compared with von Kossa staining of 
comparable sections, the latter is unable to detect the microcalcification suggesting that 
Fluorescein-BP (55) can be used as a method for the detection of calcification in animal models 
and has the potential to translate into human models. Furthermore, the employment of this 
probe may enable the elucidation of key mechanisms underpinning these pathological 
processes involved in CVD. 
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Chapter 4- Human Tissue and Potential 
Biomarkers for Plaque Vulnerability 
 Carotid and coronary plaques 
Atherosclerotic cardiovascular disease accounts for the vast majority of deaths worldwide. 
Despite decades of investment in delivering effective medical therapy, the prevalence of 
atherosclerotic cardiovascular disease continues to increase. Carotid plaques are found in 
vessels in the neck that supply oxygen to the brain while coronary plaques are located on 
vessels on the surface of the heart that supply blood to the heart. 
Even though they have different characteristics (Table 4.1); carotid plaques have a thicker 
fibrous cap, higher chance of plaque haemorrhage, lower erosion rate and higher percentage 
of calcified nodules, recent evidence suggests that the pathophysiology is broadly similar in 
the two vascular beds with similar risk factors and stages of plaque development.1–5 Indeed, a 
strong connection between the extent of coronary atherosclerosis and the progression of 
carotid atherosclerosis, as well the stabilizing effect that calcium deposits have on both carotid 
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Table 4.1: Differences between coronary and carotid artery disease. 
 
 Rodent vs human models 
Animal models, especially rodents have been used to investigate the pathology of 
cardiovascular diseases, however, studying atherosclerosis using rodent models has several 
limitations. One of the most prominent restrictions is in contrast to human plaques, rodents 
plaques do not rupture and therefore do not reflect plaque instability very well.  Another 
difference between human and rodent models is that differently from human, rodents receive 
a high cholesterol diet increasing their level of cholesterol in the serum, this is not normally 
seen in patients with atherosclerotic plaques.12–18 Other differences arise in the immune system 
and gene expression where T cells and monocyte markers are fairly different between the two 
species.13,14,19 Another major limitation is the location of the plaque within the species, in 
rodent models plaques occur mainly in the carotid artery and are not normally seen in the 
coronary arteries.12,15,20 Due to these key differences between rodent and human models, it is 
crucial that human plaque tissue is analysed and assessed in order to understand disease 
progression, pathogenesis and prevention, in parallel to animal studies.  
 
 
 Coronary artery disease Carotid artery disease 




Age of formation <40 years Men >40 years 
Women post-menopause 
Shear stress Complex effect on arteries 
because of anatomical 
differences i.e. curvature, flow  
Mainly in the carotid 
bifurcation area 
Symptomatic  
mechanism of the 
disease 
Acute thrombosis Acute thrombosis, stroke 
Severe angiographic 
stenosis 
Results in myocardial infarction Frequently results in stroke 




Fibrotic, stable Ulcerated, lipid rich, unstable 
Thrombus Main cause of occlusion Rare cause of occlusion, 
usually small intramural 
thrombi 
Plaque ulceration Thrombus related, acute event Chronic, small microemboli on 
the surface, rarely acute event 
Calcification In 5-10% In 50-60% 
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 Early detection of calcification, PET and Fluorescein-BP 
Calcification is a key feature of coronary atherosclerotic plaques and, in particular, the burden 
of calcification correlates with the future risk of cardiovascular events. Large population 
studies, such as the MESA study,8 have highlighted an inverse correlation with coronary artery 
calcium density with low density calcium conferring the highest risk of cardiovascular events.9  
As such, there is increasing interest in identifying markers of early micro-calcification that 
may better improve risk stratification and downstream management of patients with 
cardiovascular disease.10 Early coronary calcification can be detected with positron emission 
tomography using the radiotracer Na18F.11 However PET has limited spatial resolution and 
cannot be used in conjunction with existing invasive imaging techniques. Developing 
alternatives techniques to identify micro-calcification with improved spatial resolution and 
potential translation in to the cardiac catheterisation laboratory is an important research goal 
with the potential to improve cardiovascular risk prediction. 
A fluorescent dye, Fluorescein-BP (55), has been developed to detect HAP. Both probe 
components, alendronate (26) and Fluorescein (54) are FDA approved and this therefore 
makes the Fluorescein-BP (55) probe particularly attractive for human translation as a method 
for the detection of vascular calcification. 
Fluorescence spectroscopy can provide higher spatial resolution than PET and therefore is able 
to afford better anatomical information on the plaque and its stability. Moreover the 
fluorescent signal can potential be detected with modern invasive coronary catheters. Building 
on cell and ex vivo mouse models (Chapter 3) which have provided exciting and promising 
results, the translation of the Fluorescein-BP probe(55) to detect HAP in human vascular tissue 
is essential. 
 Selectivity of Na18F PET tracer 
In Chapter 2, the ability of Fluorescein-BP (55) to bind to specific calcium compounds was 
determined. Fluorescein-BP (55) exhibited high specificity towards HAP in comparison to 
other calcium compounds (CaOx, CaPi and CaPyr) analysed as well as greater selectivity in 
comparison to the Alizarin S stain. The selectivity of the Na18F tracer for HAP, CaPi, CaOx 
and CaPyr was quantified and compared with the discrimination of Fluorescein-BP. Calcium 
minerals (HAP, CaOx, CaPi and CaPyr) were incubated in Na18F for 20 minutes after which 
unbound tracer was removed by a series of centrifugation steps and the solid particles were 
subsequently imaged using PET/CT. Similarly to Fluorescein-BP (55), Na18F shows no 
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selectivity towards CaOx and CaPyr, however it was found to bind to both HAP and CaPi 
nonetheless showing stronger affinity for HAP (Figure 4.1). These results show the benefit of 
imaging with a probe such as Fluorescein-BP (55) due to its high affinity for HAP in 
comparison to other minerals which compares favourably with current methods of staining 
(Alizarin S and von Kossa) and imaging (PET). 
 
Figure 4.1: Selectivity of 18F-NaF PET tracer towards calcium minerals. Calcium minerals 
were incubated with 18F-NaF for 20 minutes after which un-bound tracer was removed and 
the solid particles were analysed by PET/CT. Data shown is from at least 3 repeats and shown 
as the mean ± S.E.M. * p< 0.05, ** p< 0.01, *** p< 0.001 compared to HAP.  
  PET/CT and Fluorescein-BP imaging of ex vivo coronary plaques 
We next compared Fluorescein-BP (55) binding to the detection of vascular calcification on 
computed tomography and Na18F PET in 8 samples of human coronary tissues (7 affected by 
calcific atherosclerotic disease and 1 control tissue which was free of atherosclerosis). All 
tissue samples were initially assessed using PET/CT scans followed by sectioning of the tissue 
as required to allow appropriate fluorescence images to be obtained. A representative sample 
is shown in Figure 4.2. PET/CT imaging showed both areas of macro-calcification, as detected 
by CT (Figure 4.2 B), and areas of micro-calcification, as detected by Na18F PET (Figure 4.2 
C). Samples from both areas were sectioned and stained (Figure 4.2 D-K). The images show 
that Fluorescein-BP probe (55) was able to bind to both macro- and micro-calcification and 
co-localizes with Alizarin S staining (Figure 4.2 E and I).  




Figure 4.2: Imaging of calcified coronary tissue. (A) Volume rendered image; (B) CT image; 
(C) PET image, with Na18F tracer, of vascular tissue. Yellow and purple boxes indicate the 
areas selected for tissue sectioning where brightfield and fluorescence images of calcification 
were taken. (D, E, F, G) Brightfield and fluorescence (Alizarin S, Fluorescein-BP, DAPI) 
images of tissue in area in the yellow box presenting area of high CT activity. (H, I, J, K) 
Brightfield and Fluorescence (Alizarin S, Fluorescein-BP, DAPI) images of tissue in area in 
the purple box presenting area of high PET activity. Sections were incubated with Fluorescein-
BP (1 μM, 2 hours), Alizarin S (2%, 10 minutes) and DAPI (500 nM, 5 minutes) and 
subsequently imaged. Scale bars = 0.2 cm for brightfield and 100 µm for fluorescence. 
The control tissue sample (Figure 4.3), where there was no evidence of atheroma, displaced 
neither increased PET/CT activity (Figure 4.3 B) signal nor fluorescence staining (Figure 4.3 
C-F). 




Figure 4.3: Imaging of coronary tissue without atheromatous plaque. (A) Volume rendered 
image; (B) PET image, with Na18F tracer, of vascular tissue. Orange box indicates the area 
selected for tissue sectioning where Brightfield and Fluorescence images of calcification were 
taken. (C, D, E, F). Sections were incubated with Fluorescein-BP (1 μM, 2 hours), Alizarin S 
(2%, 10 minutes) and DAPI (500 nM, 5 minutes) and subsequently imaged. Scale bars = 0.2 
cm for brightfield and 100 µm for fluorescence. 
 Fluorescein-BP imaging of ex vivo carotid plaques 
Fluorescein-BP (55) imaging studies were repeated with ex vivo carotid plaque tissues from 
patients that were admitted for a carotid endarterectomy following a recent stroke or transient 
ischaemic attack. The samples were embedded, sectioned and stained using both Alizarin S 
and Fluorescein-BP (55). A representative sample was selected and stained using both Alizarin 
S (Figure 4.4 A and C) and Fluorescein-BP (55) (Figure 4.4 B and D). These results once 
more show the ability of Fluorescein-BP (55) to stain areas of plaque calcification that co-
localised with the Alizarin S stain. Indeed Fluorescein-BP staining was observed in both areas 
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of macro- (Figure 4.4 A and B), and micro-calcification (Figure 4.4 C and D) confirming the 
observations in the rodent models reported in Chapter 3 and in the coronary samples.  
 
Figure 4.4: Determination of calcification in human carotid tissue. (A, C) Alizarin S staining 
of carotid tissue. Green boxes indicate the areas where Fluorescence images of calcification 
were taken. (B, D) Fluorescence (Fluorescein-BP, DAPI) images of tissue. Sections were 
incubated with Fluorescein-BP (1 μM, 2 hours) and DAPI (500 nM, 5 minutes) and 
subsequently imaged. Scale bars = 0.2 cm for brightfield and 100 µm for fluorescence. 
The coronary and carotid samples provide sections with both macro and micro calcification, 
in stable and unstable plaques, all of which can be detected using Fluorescein-BP (55) showing 
the reproducibility of the probe on different types of calcified samples. Another advantage of 
the Fluorescein-BP (55) probe is the lack of background staining which could lead to false 
positives. By contrast the control sample which was free from atheromatous plaque and 
calcification did not demonstrate any staining while areas with micro and macro deposits 
fluoresced. Although this might be the case when using Alizarin S on sections that are highly 
calcified, when staining sections with micro-calcification, often the stain appears very weak 
and not visible under the microscope. 
 Comparison of PET and Alizarin S with the upregulation of 
osteogenic markers 
Recently, Osteopontin (OPG) and Osteoprotegerin (OPN) have been reported to detect early 
stage calcification in blood plasma. OPN and OPG (Figure 4.5) are two of the many bone 
regulatory proteins that have been shown to be present in atherosclerotic plaques in vitro and 
seem to be expressed by vascular cells in vivo.21–23 
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OPG is a cytokine of the tumour necrosis factor receptor and acts as an inhibitor of the 
RANKL-RANK interaction.22,24,25 By doing so it prevents the proliferation and differentiation 
of osteoclast and leads to bone resorption.22,24,26–28 OPG deletion results in a significant 
increase in aortic medial calcification which suggests the protective role of OPG against 
atherosclerotic calcification.25,27,29 Recent studies showed that plasma levels of OPG were 
increasingly high in patients with acute coronary syndrome in comparison to those with stable 
angina or normal arteries; as a result, OPG may be a marker of onset atherosclerosis and plaque 
stability.22,24,26,27  
 
Figure 4.5: Role of OPG and OPN on VSMCs.  
OPN is a multifunctional glycoprotein which is implicated in a range of acute and chronic 
inflammatory processes and has been shown to act as an inhibitor of calcification.25,26,30,31 
Recent studies have suggested that OPN antagonizes the macrophage mediated pathologic 
mineralization process by inhibiting osteoclast formation and increasing the expression of 
macrophage-derived inflammatory molecules.31 Recent studies have shown that the OPN 
protein is upregulated in atherosclerotic plaques and is higher in patients with cardiovascular 
disease than in the ones without, especially in lesions with active calcification where it 
increases with increase of disease severity.24,26,31  
Both OPG and OPN have been shown to have the potential to be used as early stage detection 
of unstable plaques, however, no reports are available in the literature showing the correlation 
between these biomarkers and Na18F PET activity. Here, tissues that exhibit Na18F PET 
activity as well as no activity (Figure 4.6), were analysed for OPG and OPN and linked to 
Alizarin S images. Na18F/CT analysis was categorised into tissue with Na18F signal 
present/absent and/or increased CT attenuation (>1000 CT units) present/absent. Examples of 
the range of Na18F activity are shown in Figure 4.6 where samples display no Na18F/CT 
activity PET-CT- (Figure 4.6 A), high PET activity with little or no CT signal PET+CT- 
(Figure 4.6 B, C – two different samples) and a sample with high CT signal and Na18F signal 
PET+CT+ (Figure 4.6 D).  




Figure 4.6: PET/CT images of coronary tissue. Negative control sample not displaying any 
type of calcification PET-CT- (A), 2 calcified samples displaying high level of Na18F PET 
tracer uptake PET+CT- (B, C) and positive control sample displaying high CT signal 
PET+CT+ (D). 
While the intensity of Na18F activity did not correlate with fluorescence signal obtained from 
the Fluorescein-BP (55) probe, macroscopic calcium deposits had a higher fluorescent signal 
(Figure 4.2 F and Figure 4.4 B) in comparison with microscopic deposits (Figure 4.2 J and 
Figure 4.4 D). OPG and OPN were only present in areas of with Na18F signal. 
All tissue samples were initially assessed using PET/CT scans (Figure 4.6) followed by 
sectioning of the tissue as required to allow appropriate sections to be taken and subsequently 
analysed by immunohistochemistry (IHC). IHC revealed that, uncalcified tissue (Figure 4.7 
A, E, I), PET-CT-, does not stain for Alizarin S, which was expected, and neither OPG and 
OPN staining was visible. When looking at a PET+CT+ sample (Figure 4.6 D and Figure 4.7 
D, H, L), Alizarin S staining was present around the arterial wall indicating the presence of 
calcification, however, when OPG and OPN staining was carried out no staining was visible. 
This supports previous findings on the lack of OPG and OPN expression in the blood of 
patients with normal arteries or stable angina.24,30 However, when analysing two PET+CT- 
samples (Figure 4.6 B and C and Figure 4.7 B, C, F, G, J, K) these show higher levels of OPG 
and OPN in comparison to the controls confirming that these two proteins are highly expressed 
in unstable coronary arteries. On closer inspection, OPG and OPN localized in different 
locations within the PET active samples. While OPN signal was found in regions of high Na18F 
activity, OPG expression was evident in the peripheral margin surrounding the micro-
calcification. 




Figure 4.7: Alizarin S staining, OPG and OPN immunohistochemistry of coronary tissue. 
(A, E, I) control sample PET-CT-, non-calcified; (B, F, J) PET active sample 1, showing 
active/unstable calcification; (C, G, K) 2 PET+CT- samples, showing active/unstable 
calcification; (D, H, L) PET+CT+, showing inactive/stable calcification. (A, B, C, D) Alizarin 
S staining of coronary tissue. (E, F, G, H) OPG IHC, (I, J, K, L) OPN IHC. IHC analysis 
performed with Vectastain ABC kit (mouse IgG) where all antibodies were anti-human mouse 
clones (I:100 dilution). All IHC were counterstained with H&E. Scale bars = 0.2 cm. IGG 
controls shown in Appendix 3. 
 Comparison of Alizarin S with the upregulation of osteogenic 
markers 
OPG and OPN IHC on carotid specimens was carried out to determine whether the staining 
pattern was similar to that observed in coronary tissue. In these samples Alizarin S and OPN 
appear to co localize in most areas (Figure 4.8 A, B, E, F) while OPG staining is focussed in 
the surrounding areas (Figure 4.8 A, B, E, F), suggesting that OPG might play a protective 
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role in vascular calcification. This theory is supported by animal studies whereby a positive 
association between OPG levels in serum and clinical cardiovascular disease severity has been 
demonstrated.29,32 
 
Figure 4.8: Alizarin S staining, OPG and OPN immunohistochemistry of carotid tissues. 
(A, B) Alizarin S staining of carotid tissue. (C, D) OPG IHC, (E, F) OPN IHC. IHC analysis 
performed with Vectastain ABC kit (mouse IgG) where all antibodies were anti-human mouse 
clones (1:100 dilution). All IHC were counterstained with H&E. Scale bars = 0.2 cm. IGG 
controls shown in Appendix 3. 
 Comparison of Fluorescein-BP, OPG and OPN on coronary plaques 
From data shown in Figure 4.2 and Figure 4.4 it is evident that Fluorescein-BP (55) can be 
used to detect both macro- and micro-calcification without discriminating between the disease 
activity. In fact, in contrast to the Na18F PET signal, the Fluorescein-BP probe (55) shows a 
stronger signal when binding to samples with macro-calcification in comparison to micro-
calcification. However, this does not imply that the probe is not able to detect submicron 
calcification deposits as when analysing these samples a fluorescent signal is obvious. On the 
other hand, from data shown in Figure 4.7 and Figure 4.8 it is apparent that OPG and OPN are 
biomarkers for active disease and localize in areas with high Na18F PET signal. These sets of 
data raise an important clinical question; does Fluorescein-BP (55) co-localize in the same 
regions as OPG and OPN staining? To answer this question, tissue sequential sections that 
were previously analysed for Fluorescein-BP (55) staining, were treated for OPG and OPN 
IHC and were examined side by side (Figure 4.9). It is apparent that, Fluorescein-BP (55) 
OPG and OPN co-localize in the same area. OPG shows a very faint stain around the 
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calcification nodule while Fluorescein-BP (55) and OPN staining around the same nodule as 
well as staining some smaller deposits.  
 
Figure 4.9: Fluorescein-BP staining, OPG and OPN immunohistochemistry of carotid 
tissues. (A) Fluorescein-BP (55) staining of carotid tissue: sections are incubated with 
Fluorescein-BP (1 μM, 2 hours) and DAPI (500 nM, 5 minutes) and subsequently imaged. (B) 
OPG IHC, (C) OPN IHC. IHC analysis performed with Vectastain ABC kit (mouse IgG) where 
all antibodies were anti-human mouse clones (1:100 dilution). All IHC were counterstained 
with H&E. Scale bars = 100 µm for fluorescence, 0.2 cm for brightfield.  
These results are indicative that Fluorescein-BP (55) can be used to detect areas of active 
calcification to the same extent as OPG and OPN, but in contrast to the IHC, Fluorescein-BP 
(55) can also be used to detect areas of calcification which do not show any activity and are 
stable. 
 Conclusion 
Building and extending upon results from Chapter 3, here, it was demonstrated that 
Fluorescein-BP (55) is a highly sensitive and specific marker of hydroxyapatite in vascular 
coronary and carotid human tissue. Fluorescein-BP (55) has been compared to one of the 
current gold standard techniques for identifying calcification, Alizarin S, and has been shown 
to co-localize in the same areas. When applied to tissue presenting both macro- and micro-
calcification, Fluorescein-BP (55) shows binding to both types of vascular calcification which 
is not otherwise possible using one stand-alone technique, eg. PET/CT.  
Vascular calcification in atherosclerotic plaques contains high concentrations of crystalline 
HAP.33 Within the arterial walls, extracellular vesicles containing hydroxyapatite are released 
from lipid-rich macrophages and apoptotic smooth muscle cells which increase the plaque 
structural stress and corresponding risk of fibroatheromatous cap fracture.34 The inflammatory 
environment driving the production of HAP deposition is associated with a tendency to 
destabilise plaques and results in clinical cardiovascular events.35,36 Recent clinical trials have 
focused attention on the vital role that early calcification plays in carotid, aortic aneurysmal 
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and coronary artery disease and hence there is a clinical imperative to better understand the 
mechanisms governing early calcification in the vascular wall.35–37 The ability to differentiate 
calcium derivatives in regions of calcification, specifically by detecting hydroxyapatite, will 
facilitate the division of unstable and stable cardiovascular phenotypes in future clinical trials.  
Moreover, OPG and OPN could also be used as biomarkers for unstable cardiovascular 
phenotypes as they have been shown to be present in increasing concentrations in tissue 
showing micro-calcification in comparison to sections which are atherosclerotic free or have 
stable macro-calcification which do not stain for either protein. However, limited data is 
available showing: 1) the relationship between OPG and calcification; as well as 2) the 
relationship between PET-active vascular tissue, OPG and OPN. These studies are only the 
beginning of understanding the mechanism behind the role of OPG in protecting and inhibiting 
vascular calcification suggesting that more data is required before any valid explanation could 
be presented. 
Comparing Fluorescein-BP (55) with OPG and OPN IHCs reveals that all three can be used 
to detect areas of active calcification to the same degree; however in contrast to the IHC, 
Fluorescein-BP (55) also detects stable calcific lesions. This notably aids the field of 
cardiovascular research as up to now, a range of imaging tools are required to visualise both 
macro- and micro-calcification, however, the application of Fluorescein-BP (55) allows for 
only one technique to be used, which can elucidate calcific structures and differentiate between 
the different sizes of the calcification. This could allow for a more accurate definition of the 
cut-off point for macro and micro-calcification compared to that provided by both PET and 
CT.  
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Chapter 5- Chemical Composition of 
Vascular Calcification Deposits 
 Raman spectroscopy 
Spectroscopy is the study the interactions of radiation with matter and is a field that 
encompasses a wide range of techniques. Raman spectroscopy is based on the interaction of 
light and matter and was initially observed by C.V. Raman in 1928.1–3 Raman and Krishnan 
hypothesized that an energy transfer, similar to the one that takes place during X-ray 
spectroscopy, should take place when electromagnetic radiation is scattered by atoms or 
molecules.3–5 
When a photon of light interacts with a molecule, it allows the molecule to transit to a virtual 
energy state, and although this transition is short lived, this increase in energy means that the 
molecule is at a higher energy state (Figure 5.1).2 The molecule can then relax back in two 
manners:  
- to the initial ground state in a single step by releasing the same amount of energy as 
that of the incoming photon. This process is called Rayleigh (or elastic) scattering.2–
4,6 When this occurs, no energy is transferred to the molecule and therefore the process 
does not yield any information. 
- to a different ground state when the molecule releases a different quantum of energy 
to that of the incident photon. This process is called Raman (inelastic) scattering and 
can be divided into two further processes; Stokes and anti-Stokes scattering.4,6,7 Stokes 
scattering occurs when energy is transferred to the molecule from the incident photon 
while anti-Stokes scattering occurs when the molecule loses some energy to the 
scattered photon which is then greater than the energy of the incident photon.1,3,4,6,7 




Figure 5.1: Diagram of energetic transitions involved in Raman scattering. Rayleigh 
scattering is elastic; the incident photon is of the same energy as the scattered photon. Raman 
scattering is inelastic; in Stokes scattering, the incident photon is of greater energy than the 
scattered photon, while in anti-Stokes scattering, the scattered photon is of greater energy of 
the incident photon. 
Stokes scattering is most commonly observed, however the signal is inherently weak with only 
1 in 107 photons undergoing Raman scattering.1,7–9 To obtain Raman scattering, a laser is used 
to provide coherent, monochromatic light for molecule excitation. A diffractive spectrometer 
based on a reflective grating is then used to disperse the light onto highly sensitive detectors 
which will eventually generate a spectrum.1,10 A simplified schematic of a microscope for 
Raman spectroscopy is shown below (Figure 5.2). 
 
Figure 5.2: Overview of Raman microscope system for Spontaneous Raman Spectroscopy. 
Figure reproduced with permission.8 
For a molecule to be able to produce Raman scattering it requires a change in the polarizability 
of its bonds during a vibration. Raman inactive or forbidden molecular vibrations will not 
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generate Raman scattering.11 A typical Raman spectrum is a plot of intensity of the scattered 
light (in AU) relative to the frequency of the scattered light (in wavenumbers). Specific bonds 
will vibrate at unique wavenumbers and therefore each molecule will have a characteristic 
spectroscopic fingerprint.9,12 Raman can be applied to a wide range of samples; from solids, to 
cells and tissues; very little preparation is required and spectra are easily obtained within 
seconds.  
 
 Raman spectroscopy of biological samples  
Raman spectroscopy has become increasingly popular in recent years as a tool to characterize 
and analyse cells and tissues, as well as a diagnostic tool for diseases both in vitro and in 
vivo.1,8,12–15 This is due to it being label-free, safe and non-invasive. It relies on the inherent 
scattering nature of all biomolecules and can be used to detect specific extra- and intracellular 
structures such as proteins, lipids and nucleic acids with submicron spatial resolution in both 
living and fixed systems, allowing for characterization and comparison of biologically 
interesting samples without alteration (Figure 5.3).5,12,16–18 
 
Figure 5.3 Raman spectra of SKBR3 cells by Raman microscopy. Spontaneous Raman 
spectrum of SKBR3 cell pellet measured using 785 nm excitation. Key bands are indicted. 
Figure reproduced with permission.15 
Current analytical techniques most frequently used to assess the morphology of samples 
involve disrupting the very process under investigation, for example immunohistochemistry 
and immunofluorescence. There is a need for a non-destructive, non-invasive technique that 
is capable of analysing samples at a biomolecular level.1,19–21 Raman spectroscopy has been 
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established in the recent years as a powerful laboratory technique, and recently in vivo clinical 
trials indicate its potential for biomolecular characterisation and diagnsis.22–24 It could prove 
particularly crucial in diagnosing disease early in the pathogenesis as it can be used to detect 
chemical alterations before morphological changes appear. 
 
 Raman spectroscopy of mineralized vascular tissue 
CaPi rich solid mineral species associated with vascular calcification have been commonly 
compared to those found during the development of bone and tooth, leading to a number of 
hypotheses as to potential precursors.12,25 The most commonly proposed precursors to bone 
HAP are ACP, brushite, octacalcium phosphate (OCP), β-tricalcium phosphate (βTCP) and 
whitlockite, a magnesium substituted βTCP (WTK) (Table 5.1). These species all have a 
distinct Raman signal, and are yet to be fully be characterized in cardiovascular systems.25 
  
Table 5.1: Inorganic CaPi-rich phases and their corresponding Raman signals. 
Inorganic CaPi-
rich phases 
Formula Raman Signal 
V1 PO43- (cm-1) 
Ref. 
ACP CaxHy(PO4)z.nH2O 
n=3-4.5; 15-20% H2O 
955 26 
HAP Ca5(PO4)3(OH) 960-963 5,12,21,25,27 
OCP Ca8(HPO4)2(PO4)4.5H2O 957 26 
βTCP β-Ca3(PO4)2 970 21,26 
WTK Ca9(MgFe)(PO4)6PO4H 973 5 
 
Raman spectroscopy has previously been used for the characterization of the atherosclerotic 
plaque.18,20,21,27,28 Latterman et al. imaged the cross section of atherosclerotic plaques from 
rabbits with high-cholesterol diet-induced disease and provided detailed characterization of 
the lipidic component of the tissue.18,20,27,28 Other groups have developed fibre-optic 
techniques using miniaturized Raman probes to aid the diagnosis of atherosclerosis in 
vivo.18,21,29 Recently, calcification has also gained a lot of attention and both vascular and valve 
calcification have been studied extensively, not only using Raman, but with other imaging 
techniques.5,18,27,30,31 Raman spectroscopy has been used for its powerful ability to analyse the 
inorganic mineral structures in biological tissue by having a high sensitivity to changes in the 
crystallinity and atom substitution of biological apatite. Building on previous work, in this 
chapter, calcified vascular cell monolayers, ex vivo rat aortic tissue and human vascular tissue 
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will be analysed. This allows for information, which is complementary to the results provided 
by fluorescence, to be obtained.  In particular it allows for the assessment of the crystallinity 
of the calcium species, in order to shed further light on the calcification process. Additionally, 
a comparison of Raman spectroscopy with PET/CT images will be carried out to improve 
understanding of the binding of the Na18F PET tracer to the calcified plaques. 
 
 Raman on Calcium species 
Spontaneous Raman spectroscopy is able to distinguish peaks that are at 1 cm-1 apart allowing 
for an accurate characterisation of more subtle spectral features such as minor changes in the 
shape or position of a peak thus allowing analysis of phenomena such as crystallinity and 
polymorphism. In order to determine the chemical composition of cardiovascular calcification, 
the Raman fingerprint of known calcium phosphate species was analysed. Literature reports 
the presence of five potential calcium minerals in vascular tissue; with HAP being the only 
mineral present in cellular models and ACP, OCP, βTCP and WTK present in vascular tissue 
and valves.25,26,32 Raman spectra of synthetic, non-biogenic, commercial minerals were 
obtained on the InVia Renishaw microscope using a 785 nm laser, and are reported below 
(Figure 5.4). This allowed for a direct comparison between the minerals as well as aiding in 
the subsequent determination of the mineral phase present in both cell and human models.  
 
When analysing mixtures of different minerals, such as ACP and HAP, two distinct peaks are 
visible (Figure 5.4), looking closely at the mixture of 3:7 ACP:HAP, one major peak with a 
side peak were visible suggesting that the two compounds could be distinguished when 
analysed together. Using Origin, peak fitting of the spectrum was performed and clearly 
showed the distinct two peaks at 955 and 960 cm-1, it was also possible to analyse the area 
under the two fitted peaks which in this instance accounted for 25% ACP and 75% HAP which 
is only slightly different from the experimental mixture produced, indicating that this 
technique can be used to analyse mixture and can fairly accurately report the ratios of 
compounds present in the solid mix.  




Figure 5.4: Phosphate (v1) Raman signal of different calcium species (A) and spectra of 
ACP:HAP mixtures (B). Values and spectra obtained using an InVia Renishaw microscope 
with a 785 nm laser. Red dashed line indicative of ACP, red dotted line indicative of HAP. 
 Raman analysis on calcified cell pellet 
Calcification can occur in a wide range of tissues, spanning from soft tissues to vascular 
tissues.33–35 In the field of vascular biology, calcification can occur at different locations, and 
therefore different cell models are required to study the specific molecular biology and 
pathways behind the disease.36,37 
 
An example of a cell phenotype present in vascular tissues is the primary vascular smooth 
muscle cell (VSMC) which is one of the cellular components of the normal blood vessel wall. 
VSMCs provide structural integrity and regulate the diameter of the vessel by contracting and 
relaxing in response to vasoactive stimuli. In contrast to skeletal and muscle cells, VSMCs are 
not terminally differentiated and can change their phenotype in response to environmental 
change to become calcifying osteoblastic cells, thereby facilitating the production of 
extracellular matrix components.36–39 VSMCs are the principal cell type that are involved in 
vascular calcification and are primarily used to study calcification in conditions such as 
atherosclerosis and chronic kidney disease (CKD).36,38,40 
Calcified rat VSMC cell pellets were analysed by Raman spectroscopy (Figure 5.5). Cells 
were cultured for 7 days under two different conditions: control and calcifying media (1.4 mM 
Ca and 2.4 mM Pi). The cell monolayer was then treated with trypsin to allow the cells to be 
collected in the form of a pellet for Raman analysis. 




Figure 5.5: Spontaneous Raman spectra of VSMC cell pellets. Calcified and control VSMCs 
cell pellet. Raman spectroscopy of cell monolayers obtained using Renishaw InVia, 785 nm 
laser, 30 s, 100%. Spectra are offset for clarity and normalized to the phenylalanine peak 
(1003 cm-1). Spectra are a representative of at least three repeats. Red dashed line indicative 
of 960 cm-1 HAP value. 
Spectra obtained from Raman analysis of the cell pellet showed the most common cellular 
peaks; phenylalanine, amide bonds and lipid (Table 5.2). However, when the cell monolayer 
was cultured in calcium and phosphate enriched media, which should induce calcification, no 
peak corresponding to calcium mineralisation was observed amongst the other signals. 
 
Table 5.2: Raman shift of common cell features 
  
The lack of calcium mineral deposited in the cell pellet is due to the collection process 
employed. When cells undergo treatment with trypsin and pelleted, the extracellular matrix 
disintegrates and releases the calcification crystals which have been deposited on the 
Peak position (cm-1) Major Assignments 
855 C-C stretch 
875 C-C stretch 





1247-1270 Protein amide III band 
1595-1720 Amide I (C=O stretching mode of proteins/ C=C of lipids) 
2880 CH2, lipids 
2940 CH3, proteins 
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extracellular matrix, resulting in an absence of a peak corresponding to the calcium mineral. 
This was confirmed by incubating the cells with Fluorescein-BP (55), which as reported in 
Figure 2.16 shows selectivity towards HAP and binds to calcium mineral deposits when 
incubated with cells as seen in Chapter 3. After incubation with Fluorescein-BP (55) the cell 
monolayers were washed to remove any unbound probe and subsequently underwent treatment 
with trypsin, pelleted and fluorescence analysis was performed on the supernatant. The 
supernatant should contain all the extracellular matrix content and therefore also the bound 
Fluorescein-BP (55) would consequently provide a strong fluorescence signal. Figure 5.6 
illustrates this as it shows that the supernatant of the calcified cell monolayers has a 
fluorescence signal of 75 AU which is comparable to the intensity of the same concentration 
of Fluorescein-BP (55) in media alone without cells. In contrast, the supernatant of the control 
does not present any fluorescence signal as unbound probe was removed in the washing step. 
This proves that, when the cell monolayer undergoes trypsinisation and pelleting, the calcium 
mineral, which has been deposited on the ECM, is removed from the cell bulk (pellet) and is 
present in the supernatant instead (Figure 5.6). It is apparent that the fluorescence intensity of 
the supernatant of the calcified cell monolayer and of the media alone are not equivalent; this 
could be due to small amounts of Fluorescein-BP (55) entering the cells and binding to calcium 
minerals present in the matrix vesicles.  
 
Figure 5.6: Fluorescence signal of the supernatant of pelleted VSMCs incubated with 
Fluorescein-BP (55). VSMCs are grown to confluence and then transferred to either control 
media or calcification media (2.4 mM Ca and 1.4 mM Pi) for 7 days, changing media on 
alternate days. Once calcified, cells were incubated with Fluorescein-BP (1 μM, 2 hours) and 
then centrifuged. Pellet and supernatant were separated and the supernatant was analysed 
using a Fluoromax-3. Data shows is an average of three independent results and are shown 
as the mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001. 
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 Raman analysis of calcified cell monolayer 
Another way of obtaining Raman spectra of calcified primary cells or cell lines is to analyse 
the cell monolayer directly. This can be done by seeding and calcifying the cells on Raman-
inactive substrates such as CaF2 slides. In comparison to glass or plastic, CaF2 slides do not 
produce any Raman signal and therefore do not mask the Raman spectrum of the cell 
monolayer. Rat VSMCs were seeded on CaF2 slides that had previously been autoclaved, and 
the cells were incubated with either control media or calcification media, (2.4 mM Ca and 1.4 
mM Pi), for 7 days. On day 7, the monolayer was fixed and subsequently analysed by Raman 
spectroscopy. In contrast to the cell pellet, the calcified rat VSMC monolayer grown on CaF2 
slides shows the appearance of a peak at 960 cm-1 which is absent in the control (Figure 5.7), 
corresponding to HAP. 
 
 
Figure 5.7: Spontaneous Raman spectra of rat VSMC monolayer grown on CaF2 Raman 
slides. Cells were seeded and then incubated with either control media or calcifying media 
(2.4 mM Ca and 1.4 mM Pi). Cells were incubated with media for 7 days changing media on 
alternate day. Raman spectroscopy of cell monolayer obtained using Renishaw InVia, 785 nm 
laser, 30 s, 100%. Spectra are offset for clarity and normalized to the phenylalanine peak 
(1003 cm-1). Spectra are a representative of at least three repeats. Red dashed line indicative 
of 960 cm-1 peak (HAP). 
Previously, in section 5.2.2, VSMCs were discussed as an example of cell phenotype present 
in vascular tissue. Another important cell phenotype used to study vascular calcification is the 
primary valve interstitial cell (VICS); these cells are the most prevalent cells in the heart valve 
and are thought to be responsible for maintaining the structural integrity of the valve.41,42 In 
contrast to the VSMCs, VICS are used to study conditions such as aortic valve stenosis, due 
to calcification of the valve leaflets. Together with atherosclerosis, aortic valve stenosis is one 
of the most common causes of cardiovascular disease.43,44 Aside from primary cells, cell lines 
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can also be used to study vascular calcification. In general, cell lines offer a reliable, 
convenient and economical system in which to investigate vascular calcification in vitro.39,45 
An example of this is the MOVAS-1 cell line which exhibits a smooth muscle cell phenotype, 
and has been previously employed to investigate the VSMC cell cycle.45 
 
Primary rat VSMCs, primary rat VICS and MOVAS-1 cells were cultured, calcified and 
analysed by Raman spectroscopy. The HAP peak, at 960 cm-1, was present in all phenotypes. 
The cell monolayers were cultured under different calcification conditions (2.7 mM Ca and 
2.4 mM Pi; 2.4 mM Ca and 1.4 mM Pi), and overall these studies showed that with increasing 
concentrations of calcification media, there was an increase in the intensity of the 960 cm-1 
peak. ACP or OCP were not observed in any of the cell monolayers, suggesting that within 
the 7 days incubation period, the calcium phosphate deposited by the cell has been converted 
to HAP.  
 
Figure 5.8: Static Raman spectra of different vascular cell monolayers. MOVAS-1 (A), 
primary rat VICs (B), primary rat VSMCS (C) were grown on CaF2 slides and incubated with 
either control or calcifying media (2.4 mM Ca and 1.4 mM Pi or 2.7 mM Ca and 2.4 mM Pi) 
for 7 days with media change on alternating days. On day 7, cells were fixed with 10% NBF 
(15 minutes) and then imaged using Renishaw InVia, laser 785 nm, 30 s, 100% laser power. 
Images are representative of at least three repeats. Spectra are offset for clarity and 
normalized to the phenylalanine peak (1003 cm-1). (D) Table reporting the peak intensity for 
HAP at both concentration for MOVAS-1, rat VICS and rat VSMCs. 
Both MOVAS-1 and rat VSMCs show a 4-fold increase in the intensity of the HAP peak 
between the two calcification conditions (2.4 mM Ca and 1.4 mM Pi or 2.7 mM Ca and 2.4 
mM Pi) (Figure 5.8), while the rat VICS seem to calcify just as efficiently when using either 
Chapter 5 – Anatomical information of vascular calcification 
120 
 
set of conditions (Figure 5.8).  Upon closer inspection, it is apparent that MOVAS-1 and rat 
VSMCS are more prone to calcification, when using 2.7 mM Ca and 2.4 mM Pi as indicated 
by a higher intensity HAP peak, in comparison to the rat VICS. This might be due to the fact 
that VSMCs (primary and cell line) are more predisposed to a change in phenotype and 
therefore allow for accelerated migration, proliferation and production of extracellular matrix 
components. 
The MOVAS-1 cell line was selected due to its convenient and economical nature to address 
whether the HAP peak was observed in the same area as the Alizarin S staining. As mentioned 
in chapter 3, Alizarin S is one of the most commonly used techniques to stain calcium.46 This 
experiment showed that the calcium staining by Alizarin S co-localised with calcium imaging 
by Raman; with Raman spectroscopy being able to elucidate the type of calcium present as 
HAP (Figure 5.9). 
 
Figure 5.9: Full spontaneous Raman spectrum for MOVAS-1 (A) and Alizarin S staining 
(B, C). Cells grown on CaF2 slides and incubated with either control (A, C) or calcifying 
media (2.4 mM Ca and 1.4 mM Pi) (A, B) for 7 days with changing media on alternate days. 
On day 7, cells were fixed with 10% NBF (15 minutes) and then imaged using Renishaw InVia, 
laser 785 nm, 30 s, 100% laser power. Following Raman imaging, the monolayer was then 
incubated with 2% Alizarin S (5 minutes), washed three times with water and then imaged. 
Black circles are indicative of the area imaged by Raman spectroscopy. Images are 
representative of at least three repeats. Spectra are offset for clarity and normalized to the 
phenylalanine peak (1003 cm-1). 
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 Raman analysis on calcified aortic rings 
As mentioned in Chapter 3, cell cultures are of limited use in the study of calcification as they 
lack the architecture and matrix of normal vessels.47 Cultured aortae can provide 
complementary information that bridges the gap between traditional cell culture and animal 
models.47,48 Rat aortae were cultured in 3 mM Pi enriched media and then analysed by Raman 
spectroscopy. A range of methods were explored in order to obtain a clean and noise free 
Raman spectrum (Figure 5.10).  
 
Figure 5.10: Flowchart showing the methods explored for rat aorta culture and analysis.  
Aortae from wild type rats were dissected and either embedded in agarose or not. The aortae 
were embedded in low melting agarose. Once solidified, the embedded sections were sectioned 
using a compressotome (from which 10 µm sections were obtained) or cut into 1-2 mm rings. 
The agarose embedded rings and sections were then cultured in 3 mM Pi enriched media for 7 
days. Once calcified, the sections were fixed, followed by removal of agarose upon gentle 
heating.  In a second experiment, the non embedded aorta were cut into 1-2 mm rings and then 
calcified in 3 mM Pi enriched media after which they were either analysed as rings or cryo-
sectioned in optimal cutting temperature (OCT) medium and analysed as sections. 




When analysed by Raman spectroscopy, both embedded and non-embedded aortic rings and 
OCT samples gave a higher background signal in comparison to the agarose sections and 
therefore the latter were selected for further analysis. Gentle heating allowed for the majority 
of the agarose to be dissolved and washed off, however, a small amount was present when the 
aortae were analysed. Nonetheless, the remains of agarose had no impact on the HAP peak, 
which, as for the peak observed in cell models was visualised at 960 cm-1 (Figure 5.11 A). The 
peak at 960 cm-1 only appears in the calcified sample and is not present in the control; within 
the calcified sample the signal is obtained in the medial layer of the aorta which is consistent 
with the fluorescence signal obtained from the Fluorescein-BP (55) in Chapter 3. The peak 
found in the calcified samples co-localizes with the Alizarin S stain (Figure 5.11 B-C) carried 
out on the rings and correspondingly there was no staining present in the control sample 
(Figure 5.11 C). Once again, the Raman signal for HAP was mainly present in the medial layer 
of the aorta (Figure 5.11 B). 
 
Figure 5.11: Raman and Alizarin on aortic ring sections. (A) Raman spectra of calcified and 
control aortic ring sections. Raman spectroscopy of cell monolayer obtained using Renishaw 
InVia, 785 nm laser, 30 s, 100%. Spectra are offset for clarity and normalized to the 
phenylalanine peak (1003 cm-1). Red dashed line indicative of the 960 cm-1 peak (HAP). (B) 
Alizarin of aortic ring calcified at 3 mM Pi for 7 days (C) Alizarin S of aortic ring cultured in 
control media for 7 days. Black circles indicate areas where the Raman spectra were taken. 
Spectra and images are representative of at least three repeats. Scale bars = 0.1 cm. 
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 Raman on calcified human samples analysis and comparison to 
PET/CT   
Rodent models offer the possibility of investigating the pathology of cardiovascular disease 
however, as mentioned in Chapter 4, they have several limitations. For this reason, the ability 
to analyse and assess human tissues is key in understanding disease progression and 
prevention. Human tissue samples were obtained from a collaboration with a PhD student, 
Alastair Moss, MD, in Marc Dweck’s group (UoE). Samples which had been collected during 
autopsy from victims of sudden death (Appendix 2), were imaged by PET/CT using Na18F 
PET tracer and divided into three categories (Table 5.3). The tissue was subsequently 
processed and embedded in paraffin wax prior to Raman analysis.  
 
Table 5.3: Study patient population. Tissue samples are divided into three groups: No 
PET/CT activity, CT active and PET active. 
Number of 
samples 
No PET/CT activity CT activity PET activity 
1 4 3 
 
PET/CT imaging using Na18F has been reported as a novel tool for vascular disease 
diagnosis.49,50 Na18F can be used to identify areas of micro-calcification that are associated 
with an unstable plaque phenotype, and which are beyond the resolution of CT. Indeed, Na18F 
PET is currently being explored as a method for detecting high risk coronary plaques and 
improving cardiovascular risk prediction (clinicaltrials.gov NCT02278211).49–51 
Embedding samples in paraffin wax comes with its disadvantages as paraffin’s Raman 
spectrum has peaks in the regions of amide I, III and in other areas in the low wavenumber 
regions which overlap with signals obtained from tissue samples. Recent literature reported 
that, when paraffin embedded, tissues require at least 30 minutes in xylene and ethanol to 
completely remove the paraffin.52 However, there is a fine balance between removal of 
paraffin and deterioration of tissue structure, as xylene can interfere with the lipid peaks.52 The 
report mentioned that there are computational methods such as independent component 
analysis (ICA), partial least square (PLS) and independent component partial least square (IC-
PLS) that would allow the removal of paraffin peaks. However, for the purpose of this study, 
and the interest in the spectral window around 940-1010 cm-1 which displays no paraffin 
bands, no computational tools were required. 
The vascular tissue obtained was embedded, sectioned and subsequently placed on CaF2 slides. 
Once dried, the slides were placed in xylene for 15 minutes followed by dehydration in ethanol. 
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As soon as they were dehydrated the sections were ready for imaging and did not require 
additional processing. Sections from tissue presenting no calcium or fluoride signal (control, 
Figure 5.12 A, D), high calcium signal (CT active, Figure 5.12 C, F) as well as high fluoride 
signal (PET active, Figure 5.12 B-E) were selected in order to address whether there were any 
differences in the apatite crystallinity and/or any molecular substitution in the structure. 
 
 
Figure 5.12 PET/CT activity of the different tissue classes. (A-C) volume rendered image of 
the tissue. (D-F) close up of the tissue. (A, D) tissue which shows no PET/CT activity, (B,E) 
tissue that presents PET activity and (C,F) tissue that shows CT activity only. Blue box 
indicative of which tissue was selected in image C. 
Spectra from tissues with high calcium signal, and little to no fluoride signal, displayed 
macroscopic HAP (Figure 5.13 D).  Around the plaque and plaque rupture area, however they 
also displayed the presence of another apatite species, WTK (Figure 5.13 C). WTK has been 
analysed by Raman spectroscopy and has been reported to be present in vascular tissue by You 
et al.5 in early 2018. Analysis of 4 samples presenting high CT activity showed areas of WTK 
surrounding the larger HAP macrocalcification. When peak fitting, on Origin, what appeared 
to be the WTK spectrum obtained from the highly calcified tissue which did not display any 
fluoride signal, it was apparent that there were two overlapping peaks which belong to HAP 
and WTK (Figure 5.13 F). When analysing the area under the curves, there appears to be a 
30:70 ratio between HAP and WTK. 
Spectra from tissue reporting high fluoride signal on the other hand, showed no WTK (Figure 
5.13 B) but microscopic HAP deposits. The Raman analysis was followed by Alizarin S 
staining which showed that this commonly used stain was unable to discriminate between the 
two calcium species (as reported in Chapter 2). 
 




Figure 5.13 Raman spectroscopy (A-F) and Alizarin S staining (G-I) analysis of control, 
PET active and CT active vascular tissue. Tissue was embedded in paraffin wax and sectioned 
into 5 µm sections and placed on CaF2 slides. Sections were dehydrated using xylene and 
ethanol washes and then imaged using Renishaw InVia, laser 785 nm, 60 s, 100% laser power. 
Following Raman imaging, the monolayer was incubated with 2% Alizarin S (5 minutes), 
washed three times with water and then imaged. Arrows are indicative of the location imaged 
by Raman spectroscopy, black areas where no HAP or HAP was found while purple arrow 
indicates area where WTK was found. (A) and (G) represent Raman spectrum and Alizarin S 
image of control sample, (B) and (H) represent PET active sample while (C, D) and (I) 
represent CT active sample.  (E) Represents overlaid WTK and HAP spectra obtained from 
CT active sample (C, D), while (F) shows the peak fitted analysis of the WTK experimental 
spectrum showing the presence of both HAP and WTK. Red dotted line are indicative of the 
970 cm-1 peak (WTK), red dashed line representative of the 960 cm-1 peak (HAP). Scale bars 
= 0.2 cm. 




However, one of the three PET active samples, in contrast to the other two, exhibited small 
amounts of WTK around areas where larger calcification deposits were visible (spectrum not 
shown). This sample belonged to a patient who had diabetes mellitus which would explain the 
presence of high levels of magnesium in the body and therefore the substituted apatites. 
The presence of WTK has been reported previously in patients with uraemia and end-stage 
renal disease, where nanocrystals analysis showed the presence of both HAP and WTK.53,54 In 
patients presenting with uraemia, WTK had been described as a preliminary stage in soft tissue 
calcification prior to HAP deposition, however, the number of studies investigating WTK is 
subordinate to those reporting HAP and ACP in uremic vascular calcification,53,55 while in 
end-stage renal disease studies, WTK has been described in advanced conditions.54 
Surprisingly, before 2010, WTK had rarely been reported to be a component of vascular 
calcification. 
 
The WTK studies resulted in the development of novel models to address the role of 
magnesium in cell studies. In some cell-based models, magnesium is shown to have a 
protective role in living organisms.56 Other literature also illustrates how magnesium 
significantly reduces calcification both in bovine as well as human primary VSMCs, in 
addition to downregulating known pro-calcification markers and upregulating anti-
calcification markers towards restoring more physiological conditions.56,57 Louvet et al. were 
one of the first groups to show the inhibitory effect that magnesium has on hydroxyapatite 
formation and precipitation. Their in vitro work showed that magnesium was able to stabilize 
amorphous calcium phosphate and inhibit the formation of HAP by forming WTK.32,56,57  
 
Louvet’s analysis elucidates the potential role of WTK around areas of macrocalcification in 
the analysed CT active samples. However, when WTK and HAP (Figure 5.14) and CaPi, 
CaOx, CaPyr (Chapter 4, Figure 4.2) were analysed by PET/CT, no fluoride uptake was 
observed for both CaOx and CaPyr, but no difference was observed between the uptake by 
WTK, CaPi and HAP, indicating that Na18F uptake is not specific to HAP and therefore cannot 
give any anatomical information on the morphology of the crystals in the vascular tissue. On 
the other hand, Raman spectroscopy is able to distinguish between the species and is therefore 
able to provide additional information that PET lacks. 




Figure 5.14: HAP and WTK incubation with Na18F. HAP and WTK were incubated with 
Na18F for 20 minutes and then scanned using PET/CT scanner. Data shown is an average of 
three independent results and are shown as the mean ± S.E.M.  
 Conclusion 
Raman spectroscopy has been a useful tool in the study of vascular calcification to address the 
specific nature of the mineral phase for both in vitro and ex vivo models. In cell models, 
calcium and phosphate enriched media promotes the deposition of hydroxyapatite. It is 
surprising that no other species is detectable, especially ACP, a precursor of HAP. But this 
could be due to the immediate conversion, during fixation, of any ACP to HAP as the latter is 
more thermodynamically stable.53,58 Interestingly, the level of calcification is different for 
different primary cells. This could be due to the VSMCs being more prone to a change in 
phenotype, and therefore extracellular matrix component production, however, in order to 
validate this, additional studies employing immunofluorescence targeting cytoskeleton 
markers are required. These studies would help elucidate whether VSMCs are more prone to 
phenotypical change when compared to VICs. In ex vivo human tissue models, HAP was not 
the only mineral observed. WTK co-existed with HAP in tissue samples which showed high 
CT activity but not in tissue with high PET activity. However, due to the limited number of 
samples no definite conclusion can be made as to whether WTK was present due to a tolerance 
mechanism of the cells to inhibit HAP production, or whether it was caused by the disease or 
diet. Additional studies, with a larger sample population, and more detailed medical charts on 
the tissue provenance are required to address the active role of WTK in vascular calcification 
caused by atherosclerosis. 
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Chapter 6- Conclusion and Future Work 
In chapter 1 we discussed the importance of detecting vulnerable atherosclerotic plaques and 
how the limitations of the current imaging modalities available to study CVD is lacking in 
valuable patient diagnosis and positive outcomes. The only available technique that has shown 
to somewhat detect vulnerable plaques is PET with the use of Na18F bone marker. However, 
the understanding of the mode of action this probe and why it binds to vulnerable plaques and 
not stable ones is yet to be understood. 
We dealt with this problem, in chapter 2, by synthesising a range of fluorescent probes to study 
the PET tracer as well as to look directly at the vulnerable plaques, mainly the HAP protective 
layer. Three fluoride specific optical probes were synthesised, two based on the cyanoacrylate 
motif and one based on rhodamine.  Their selectivity towards anions, specifically, fluoride was 
tested and only the rhodamine-based probe showed selectivity. However, unfortunately the 
concentration required to activate the rhodamine-based probe was too high in comparison to 
the MBq amount of Na18F which is used in humans.  
The other way of assessing vulnerable plaques is by using fluorescent probes conjugated to 
HAP selective molecules.  A number of fluorophores were explored (Cy5.5, Cy7 and 
fluorescein) and were either reacted with alendronate, an FDA approved BPs, or a HAP-
selective peptide.  Selectivity tests to address whether the probes were selective to HAP and 
would not interact with any other calcium minerals were performed and showed that only the 
alendronate conjugated fluorophore was selective for HAP while the HAP selective peptide, 
although conjugated to a different fluorophore, would interact with all species equally. Ideally, 
both alendronate and HAP selective peptide should have been coupled to the same fluorophore 
to be certain that the alendronate was more selective.  Their binding was also compared to 
Alizarin S, the gold standard stain for HAP, which showed that the alendronate conjugate was 
more selective than Alizarin S as the latter interacted in a similar fashion to the HAP selective 
peptide indicating the significant opportunity that the alendronate probe could provide in the 
detection of HAP. 
Fluorescein-BP (55) was then used in cell and ex vivo studies. Toxicity studies and localization 
studies were carried out first and showed that at the concentration used the probe does not 
cause cell apoptosis. Confocal imaging of the MOVAS-1 cell monolayer confirmed what had 
previously been reported, the probe was localizing between cells in the extracellular matrix 
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where the HAP crystals were depositing. Comparative studies with the calcium leaching assay 
as well as Alizarin S stain showed that in both condition-specific and temporal studies of CVD, 
the Fluorescein-BP is less time consuming and more sensitive than both assays which could 
allow the probe to be used for high-throughput multi-well analysis of calcification. 
Fluorescein-BP was also able to detect calcification in MC3T3 cells showing the versatility of 
the probe and the potential to use to study other diseases that involve HAP deposition.  
Fluorescein-BP was also used on ex vivo WT aortic sections as well as ApoE-/- mouse sections 
and in both instances shows to bind to intraplaque calcification. ApoE-/- are genetically 
modified mice that have been fed on a high fat diet and therefore should present symptoms 
and plaque morphology similar to the ones found in humans. Upon closer inspection of the 
intraplaque calcification, two different types of deposits were visible. Larger 
macrocalcification and smaller microcalcification were both detected using Fluorescein-BP 
while Von Kossa was only able to detect the larger deposits suggesting that this probe can be 
used as a tool to study early detection of calcification. 
Animal models have provided a good tool to investigate the pathology of CVD however, there 
are key limitations when studying the disease using rodents. For this reason, in chapter 4 
calcified coronary and carotid human tissue were also assessed. Coronary and carotid tissue, 
calcified and control samples, were sectioned and stained with Fluorescein-BP and Alizarin S. 
With these samples, we demonstrated that Fluorescein-BP is a highly sensitive and specific 
biomarker for HAP in human tissue and when compared to Alizarin S  co-localizes in the same 
area. When compared to the current techniques used in the clinic to detect calcification, PET 
and CT, Fluorescein-BP is able to detect both type of stable and unstable calcification which 
neither PET nor CT can do, suggesting that the probe could have a potential application in the 
clinic to detect early stage vulnerable calcification. Biomarkers that only detect early stage 
calcification could also have a role in early diagnosis of CVD. In chapter 4, OPG and OPN as 
two potential markers were assessed on both carotid and coronary vascular tissue and both are 
present in high concentrations in vulnerable tissue while go undetected in control or stable 
vascular tissue. 
In the last chapter, chapter 5, we looked at using Raman spectroscopy to detect calcification 
in vascular tissue. Throughout the thesis the biggest focus has been on the detection of HAP 
which has a strong characteristic Raman peak at 960 cm-1. Studies to address whether this peak 
was present in calcified cell models, ex vivo sections and human sections were carried out 
showing that, in both cells and ex vivo sections, the characteristic peak at 960 cm-1 is present 
and its intensity increases with increasing degree of calcification. However, when assessing 
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human tissue, a different peak at 973 cm-1,WTK, appears in areas that are stained with Alizarin 
S. This peak nevertheless, only appears in tissue samples that have stable phenotype and not 
present in vulnerable plaques. Various assumptions have been made on the role of WTK in 
cell and tissue models but additional studies are required to determine its actual role in vascular 
tissue. 
In this thesis we discussed the development of a highly fluorescent probe for the detection of 
HAP in vitro and with the potential of in vivo applications. The probe has shown to be more 
selective than the current techniques which are used in the lab and the clinic with Alizarin S 
stain and Von Kossa binding to any calcium or any phosphate respectively and with Na18F 
PET/CT not being able to distinguish between WTK and HAP. The probe has shown to have 
great sensitivity in vitro and ex vivo mouse and human vascular tissue. The probe is synthesised 
with two low cost reagents which have been approved by the FDA, making the translatability 
of this probe from the bench to humans easier. Future in vivo studies in mouse and humans are 
required and might be enabled by intravascular administration of the Fluorescein-BP probe 
using catheters fitted with a confocal endomicroscope probe. This would negate the need for 
use of costly NIR dye, such as Osteosense, as endomicroscope probes do not require the 













Chapter 7– Material and Methods 
135 
 
Chapter 7- Materials and Methods 
 Synthesis 
7.1.1 General Information 
All non-aqueous reactions were carried out under an atmosphere of dry nitrogen using oven-
dried glassware that was cooled under a dry nitrogen atmosphere.  Unless otherwise noted, 
starting materials and reagents were obtained from commercial suppliers and were used 
without further purification.  Toluene, THF, MeCN, MeOH and DCM were dried and purified 
by passage through activated alumina columns using a Glass Contour Solvent Purification 
System.  Saturated aqueous solutions of inorganic salts are represented as (volume, sat. aq.). 
On resin chemistry was performed on functionalised 1% DVB crossed-linked chloromethyl 
polysterene with a loading capacity of 1.75 mmol g-1 and performed using SPE tubes, draining 
to a vacuum box and agitation on a Stuart B2 tube spinner at 20 rpm.  
For peptide synthesis, all amino acids and resins were purchased from either Novasyn (Merck) 
or Sigma-Aldrich. All amino acids were N-Fmoc protected and side chains were protected 
with Boc (Lys); OtBu (Ser); Pbf (Arg). All peptides were synthesised on Rink Amide AM PS 
resin with a loading capacity of 0.69 mmol g-1. Synthesis of peptides was performed manually 
using SPE tubes, draining to a vacuum box and agitation on a Stuart B2 tube spinner at 20 
rpm, while monitoring of coupling steps was performed using tandem chloranil and TNBS 
testing 
1H and 13C NMR spectra were obtained on Bruker instruments at the stated frequency using 
TMS as a reference and residual solvent as an internal standard.  Infra-red spectra were 
recorded neat on a Shimadzu IRAffinity-1.  Electrospray (ESI) mass spectra were obtained on 
a Bruker micrOTOF II instrument. ESI-MS was performed in positive ion as well as negative 
ion mode on a liquid chromatography-ion trap mass spectrometer. Mass to charge ratios (m/z) 
of all parent (molecular) ions ([M]+/-) and their intensities are reported, followed by (major) 
fragment or adduct ions and their intensities. UV/VIS absorption spectra were measured at 
room temperature with a Shimadzu UV-1800 spectrometer with a 1.0 cm glass cell. The 
scanning speed was set to fast with a sampling interval of 0.1. The scan mode was set to repeats 
with 5 scans for each sample. Fluorescence spectra were measured using a Horiba Fluoromax-
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3 spectrometer, scanning the necessary range by 0.50 nm increments, 0.50 seconds integration 
time and each spectrum reported as an average of 5 scans. 
Melting points were determined on a Gallenkamp Electrothermal Melting Point apparatus and 
are uncorrected. Flash chromatography was carried out using Merck Kieselgel 60 (Merck 
9385) under positive pressure unless stated otherwise.  Eluent compositions are quoted as v/v 
ratios.   Preparative reverse phase HPLC was conducted on a Waters® 600 (225 μL) system 
using a 486 tuneable absorbance detector recording at 210 nm equipped with a Phenomenex® 
Luna C18(2), 5 μm, 250 × 21.2 mm column using H2O (0.1% TFA) and acetonitrile (0.1% 
TFA) as eluent at a flow rate of 18 mL min-1. 
Raman imaging was carried out using an InVia Renishaw Microscope with a 785 nm laser 
excitation source which was used to excite the sample through a 50, N.A. 0.75 objective. The 
total data acquisition was performed during 30 s for spectra with a 50% laser power using the 
WiRE software. All the spectra acquired were background subtracted using a background 
correction algorithm present on WiRE software. 
7.1.2 Fluoride sensor 
2-cyano-3-(6-hydroxy-2-naphthalenyl)-]-2-[2-(2-methoxyethoxy)ethoxy]ethyl ester (3)  
 
A solution of 6-hydroxy-2-naphthaldehyde (6) (100 mg, 0.50 mmol, 1 eq) in THF (6 mL) was 
added to a mixture of 2-(2-(2-methoxyethoxy)ethoxy)-ethyl 2-cyanoacetate (7) (130 mg, 0.50 
mmol, 1 eq) and DMAP (10.0 mg, 0.10 mmol, 0.2 eq). The reaction was stirred at 60 °C for 
24 h. When the reaction was complete (checked by TLC), it was cooled to rt and then 
concentrated in vacuo. Purification by column chromatography (50% EtOAc in hexane) gave 
the title compound 3 as yellow solid (160 mg, 72%) 
 
Rf (EtOAc:hexane, 1:1) = 0.36; mp 135-137 ºC, lit1 137-138 ºC; IR (solid, cm-1):  3304 (O-
H), 2218 (C≡N), 1697 (C=O), 1622 (C=C), 1589 (C=C), 1110 (C-O-C); 1H NMR (500 MHz, 
CDCl3) δ 8.07 (1H, s, CHCCN), 8.02 (1H, s, ArH), 7.98 (1H, dd, J = 8.8, 1.8 Hz, ArH), 7.79 
(1H, d, J = 8.6 Hz, ArH), 7.69 (1H, d, J = 8.8 Hz, ArH), 7.19 – 7.16 (1H, m, ArH), 7.16 (1H, 
s, ArH), 4.48–4.46 (2H, m, COOCH2), 3.89–3.86 (2H, m, COOCH2CH2), 3.81–3.78 (2H, m, 
CH2), 3.74 (2H, dd, J = 5.8, 2.8 Hz, CH2), 3.69–3.66 (2H, m, CH2), 3.55 – 3.53 (2H, m, CH2), 
3.32 (3H, s, OCH3); 13C NMR (126 MHz, CDCl3) δ 162.89 (CN), 156.99 (C=O), 154.83 
(=CH), 137.27 (Ar C), 134.42 (Ar CH), 131.71 (Ar CH), 127.90 (Ar C), 127.40 (Ar CH), 
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126.61 (Ar C), 126.05 (Ar CH), 119.49 (Ar CH), 115.90 (Ar C), 109.88 (Ar CH), 100.14 (C), 
71.89 (CH2), 70.81 (CH2), 70.66 (CH2), 70.59 (CH2) 68.86 (CH2), 65.61 (CH2), 59.00 (CH3); 
m/z (ESI+, H2O:MeOH): 386 ([M+H]+, 95%), 266 (100), 222 (90). 1H and 13C spectroscopic 






AlCl3 (1 g, 7.5 mmol, 3 eq)  was added to a solution of 6-methoxy-2-naphthaldehyde (8) (500 
mg, 2.6 mmol, 1 eq) in chlorobenzene (15 mL) and the reaction mixture was heated under 
reflux at 130 °C for 4 hours. The reaction was followed by TLC and when completed, the 
solution was cooled to rt.  The mixture was added to HCl (20 ml; 5 N aq.) and was extracted 
with chloroform (20 mL). The organic layer was then concentrated under reduced pressure. 
Purification by column chromatography (15% EtOAc in hexane) gave the phenol 6 as a yellow 
oil (0.10 g, 20%).  
 
Rf (EtOAc:hexane, 15:85) = 0.25; 1H NMR (500 MHz, CDCl3) δ 10.06 (1H, s, CHO), 8.23 
(1H, s, ArH), 7.89 (1H, bd, J=8.9, 0.7 Hz, ArH), 7.88 (1H, dd, J=8.6, 1.6 Hz, ArH), 7.73 (1H, 
d, J=8.6 Hz, ArH), 7.17 (1H, dd, J=8.9, 2.5 Hz ArH), 7.16 (1H, d, J=2.5 Hz, ArH); 13C NMR 
(126 MHz, CDCl3) δ 191.98 (CHO), 156.24 (Ar C), 138.20 (Ar C), 134.50 (Ar CH), 132.45 
(Ar C), 131.78 (Ar CH), 128.96 (Ar C), 127.44 (Ar CH), 123.74 (Ar CH), 118.96 (Ar CH), 
109.99 (Ar CH);  m/z (ESI+, H2O:MeOH): 173 ([M+H]+, 80%), 102 (100%). 1H and 13C 
spectroscopic data in good agreement with literature.2 
 
2-(2-(2-methoxyethoxy)ethoxy)-ethyl 2-cyanoacetate (7) 
 
Triethylene glycol monomethyl ether (10) (500 mg, 3.00 mmol, 1 eq) and DMAP (2 mg, 0.02 
mmol, 0.06 mol% eq) were added to DCM (10 mL). The solution was added dropwise to a 
solution of cyanoacetic acid (9) (310 mg, 3.65 mmol, 1.2 eq) which was previously dissolved 
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in DCM (5 ml) and the mixture stirred at 0 °C for 10 minutes. To this solution DCC (755 mg, 
3.60 mmol, 1.2 eq) was added and the reaction mixture was stirred at 0 °C for 6 hours. The 
reaction mixture was allowed to warm to rt and diluted with DCM (30 mL). DCU was then 
removed by filtration. The solution was dried (MgSO4) and concentrated under reduced 
pressure. Purification by column chromatography (100% Et2O) gave the cyanoacetate 7 white 
solid (0.36 g, 86%). 
 
Rf (Et2O, 100%) = 0.47; mp 150 ºC; IR (solid, cm-1) 1745 (C=O), 1257 (C-O); 1H NMR (500 
MHz, CDCl3) δ 4.38-4.35 (2H, m, COOCH2), 3.75-3.73 (2H, m, COOCH2CH2O), 3.68-3.63 
(6H, m, 3  CH2O), 3.57-3.53 (2H, m, CH2O), 3.50 (2H, s, CH2CN), 3.38 (3H, s, OCH3); 13C 
NMR (126 MHz, CDCl3) δ 163.01 (C=O), 112.91 (CN), 71.95 (CH2), 70.70 (CH2), 70.62 
(CH2), 70.61 (CH2), 68.52 (CH2), 65.82 (CH2), 59.04 (CH3), 24.69 (CH2); m/z (ESI+, 
H2O:MeOH): 485 ([2M+Na]+, 100%), 254 ([M+Na]+, 65), 1H and 13C spectroscopic data in 
good agreement with literature.3 
 
2-cyano-3-(6-tert-butyldimethylsilyloxy-2-naphthalenyl)-]-2-[2-(2-methoxyethoxy)
ethoxy]ethyl ester (4) 
 
2-Cyano-3-(6-hydroxy-2-naphthalenyl)-]-2-[2-(2-methoxyethoxy)ethoxy]ethyl ester (3) 
(0.070 g, 0.20 mmol, 1 eq), TBDMS-Cl (0.075 g, 0.50 mmol, 1.1 eq) and imidazole (0.050 g, 
0.70 mmol, 4 eq) were stirred in DMF (5 mL) at rt for 1 hour. The reaction mixture was then 
diluted with ether (15 mL) and subsequently washed with water (3  15 mL). Purification by 
column chromatography (50% EtOAc in hexane) gave the silyl derivative 4 as a yellow oil 
(0.090 g, 44%). 
 
Rf (EtOAc:hexane, 1:1) = 0.4; IR (neat, cm-1): 2218 (C≡N), 1728 (C=O), 1622 (C=C), 1583 
(C=C), 1571 (C=C); 1H NMR (500 MHz, CDCl3) δ 8.36 (1H, s, CHCCN), 8.32 (1H, brs, 
ArH), 8.14 (1H, dd, J = 8.7, 1.7 Hz, ArH), 7.84 (1H, d, J = 8.8 Hz, ArH), 7.76 (1H, d, J = 8.7 
Hz, ArH), 7.21 (1H, d, J = 2.2 Hz, ArH), 7.15 (1H, dd, J = 8.8, 2.2 Hz, ArH), 4.50–4.46 (2H, 
m, COOCH2), 3.87–3.82 (2H, m, CH2), 3.76–3.72 (2H, m, CH2), 3.69–3.66 (4H, m, 2 × CH2), 
3.57–3.54 (2H, m, CH2), 3.38–3.36 (3H, m, OCH3), 1.03 (9H, s, SiC(CH3)2C(CH3)3), 0.30–
0.26 (6H, m, SiC(CH3)2C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 163.00 (CN), 156.81 (C=O), 
155.41 (=CH), 137.29 (Ar C), 134.40 (Ar CH), 131.29 (Ar CH), 128.41 (Ar C), 127.85 (Ar 
CH), 126.95 (Ar C), 125.83 (Ar CH), 123.47 (Ar CH), 115.92 (Ar C), 115.04 (Ar CH), 100.91 
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(C), 71.97 (CH2), 70.85 (CH2), 70.66 (CH2), 70.22 (CH2), 68.80 (CH2), 65.63 (CH2), 59.04 
(CH3), 25.65 (3  CH3), 18.14 (C),  -3.92 (2  CH3); m/z (ESI+, H2O:MeOH): 522 ([M+Na]+, 




Imidazole bearing Rhodamine 6G (5) 
 
Rhodamine 6G (0.5 g, 1.12 mmol, 1 eq) was dissolved in MeOH (10 mL).  To this solution, 
hydrazine hydrate (0.625 ml, 0.02 mol, 20 eq) was added dropwise. The mixture was heated 
under reflux until the red colour disappeared. The solution was cooled to room temperature, 
poured into distilled water (100 mL) and left stirring overnight. A white solid formed which 
was removed by filtration and dried in vacuo to give Rhodamine 6G hydrazine. Without 
further purification the next step was carried out.  Rhodamine 6G hydrazine (0.4 g, 0.94 mmol, 
1 eq) and 2-formyl imidazole (0.4 g, 0.94 mmol, 1 eq) were added to ethanol (10 mL). The 
mixture was heated under refluxed overnight in the presence of catalytic amount of acetic acid. 
The reaction mixture was cooled to room temperature which resulted in the precipitation of a 
colourless solid. Further purification was carried out by column chromatography (10% EtOAc 
in DCM) to obtain the imidazole bearing rhodamine 5 as a colourless solid. (0.39 g, 78 %) 
Rf (EtOAc:DCM, 1:9) = 0.85; mp 340 ºC; IR (solid, cm-1) 1707 (C=O), 1618 (N-H), 1332 (C-
N), 1259 (C-O); 1H NMR (500 MHz, Chloroform-d) δ 11.27 (1H, s, NH), 8.03 – 7.93 (1H, m, 
ArH), 7.81 (1H, s, ArH), 7.46 (2H, m, 2  ArH), 7.09 – 7.01 (2H, m, 2  ArH), 6.98 (1H, s, 
NCH), 6.38 (2H, s , 2  ArH), 6.30 (2H, s, 2  ArH), 3.49 (2H, s, 2  NH), 3.19 (4H, q, J = 
7.2 Hz, 2  NHCH2CH3), 1.86 (6H, s, CH3), 1.30 (6H, t, J = 7.2 Hz, 2  NHCH2CH3); 13C 
NMR (126 MHz, Chloroform-d) δ 166.14 (C=O), 153.34 (C=N), 150.95 (2   Ar C), 147.84 
(2   Ar C), 144.41 (Ar C), 134.85 (Ar CH), 134.09 (Ar CH), 130.20 (Ar CH), 128.33 (Ar 
CH), 127.01 (Ar CH), 126.86 (Ar C), 123.60 (Ar CH), 123.49 (Ar CH), 118.22 (2  Ar C), 
117.67 (Ar CH), 97.28 (2   Ar CH), 78.3 (C), 65.9 (C=N), 38.31 (2  CH2), 16.73 (1  CH3), 
14.76 (2  CH3); m/z (ESI+, H2O:MeOH): 507 ([M+Na]+, 100%). 1H and 13C spectroscopic 
data in good agreement with literature.4 






7.1.3 Cy dye building blocks 
1,1,2,3-tetramethyl-1H-benz[e]indolium (31) 
 
1,1,2-Trimethyl-1H-benz[e]indole (36) (250 mg, 0.42 mmol, 1 eq) was stirred in 1,2-
dichlorobenzene (5 mL). To this, MeI (500 mg, 3.8 mmol, 3.1 eq) was added and the reaction 
was stirred under reflux at 110 °C for 24 h under argon. When complete, the reaction was 
cooled to rt. The solvent was removed under reduced pressure and the resultant solid was 
triturated with ether (20 mL) which was removed by decantation after the mixture was 
centrifuged to give the desired product as a white solid. (0.25 g, 99%)  
 
mp 220-221 °C, lit5 199 °C; IR (solid, cm-1) 1581 (C=C), 1524 (C=C); 1H NMR (500 MHz, 
DMSO-d6) δ 8.33 (1H, dd, J = 8.4, 1.1 Hz, ArH), 8.29 (1H, d, J = 8.9 Hz, ArH), 8.21 (1H, dd, 
J = 8.2, 1.3 Hz, ArH), 8.06 (1H, d, J = 8.9 Hz, ArH), 7.78 (1H, ddd, J = 8.4, 6.9, 1.4 Hz, ArH), 
7.72 (1H, ddd, J = 8.1, 6.9, 1.3 Hz, ArH), 4.05 (3H, s, NCH3), 2.83 (3H, s, NCCH3), 1.72 (6H, 
s, NCC(CH3)2); 13C NMR (126 MHz, DMSO-d6) δ 139.94 (Ar C), 137.02 (Ar C), 133.53 (Ar 
C), 131.02 (Ar CH), 130.23 (Ar CH), 128.87 (Ar CH), 127.63 (Ar CH), 123.88 (Ar CH), 
113.59 (Ar CH), 55.74 (Ar C), 35.47 (CH3), 21.76 (2 × CH3), 14.32 (CH3); m/z (ESI+, 
H2O:MeOH): 224 ([M]+, 100%), 209 (80). 1H and 13C spectroscopic data in good agreement 
with literature.6 
1,1,2-Trimethyl-3-(4-sulfobutyl)- 1H-Benz[e]indolium (32) 
 
1,1,2-Trimethyl-1H-benz[e]indole (36) (1.00 g, 4.80 mmol, 1 eq) was dissolved in 1,2-
dichlorobenzene (20 mL) to give a golden solution. 1,4-Butane sultone (1.86 g, 13.7 mmol, 
Chapter 7– Material and Methods 
141 
 
2.8 eq) was added and the mixture was stirred at 120 °C overnight to give a brown solution. 
Upon cooling a solid separated which was removed by filtration and triturated with ether (20 
mL) which was removed by decantation after the mixture was centrifuged. The product was 
subsequently dried under ambient conditions to give indolium 21 as a grey powder. (1.66 g, 
98%)  
 
mp 242-247 °C, lit7 263 °C; IR (solid, cm-1) 1637 (C=C), 1585 (C=C), 1469 (S=O), 1164 
(S=O), 1161 (C=N); 1H NMR (500 MHz, CDCl3) δ 7.70 (2H, d, J = 8.8 Hz, ArH), 7.65 (1H, 
d, J = 8.6 Hz, ArH), 7.59 (1H, d, J = 8.9 Hz, ArH), 7.31 (1H, m, ArH), 7.23 (1H, m, ArH), 
4.28-4.23 (2H, m, NCH2), 2.52 (3H, s, CH3CN), 2.46-2.36 (2H, m, CH2SO3-), 1.83 (2H, m, 
NCH2CH2), 1.56 (2H, m, NCH2CH2CH2), 1.36 (6H, s, NCCH(CH3)2); 13C NMR (126 MHz, 
DMSO-d6) δ 197.55 (CN), 139.12 (Ar C), 137.40 (Ar C), 133.53 (Ar C), 131.17 (Ar CH), 
130.21 (Ar CH), 128.83 (Ar CH), 127.92 (Ar C), 127.70 (Ar CH), 123.87 (Ar CH), 113.95 
(Ar CH), 55.93 (C), 50.61 (CH2), 48.16 (CH2), 26.70 (CH2), 22.18 (CH2), 22.08 (2 × CH3), 
14.13 (CH3); m/z (ESI+, H2O:MeOH): 368 ([M+Na]+, 80%) 346 ([M+H]+, 100%). 1H and 13C 
spectroscopic data in good agreement with literature.8 
3-(5-Ethoxy-5-oxopentyl)-1,1,2-trimethyl-1H-Benz[e]indolium bromide (34) 
 
1,1,2-Trimethyl-1H-benz[e]indole (36) (1.00 g, 4.80 mmol, 1 eq) was dissolved in MeCN (20 
mL). Ethyl 5-bromovalerate (2.09 g, 10.0 mmol, 2 eq) and KI (85.0 mg, 0.50 mmol, 0.1 eq) 
were added and the reaction was stirred under reflux at 80 °C for 4 days. The solvent was 
removed under reduced pressure and the resultant solid was triturated with ether (20 mL) 
which was removed by decantation after the mixture was centrifuged. The solid was dried 
under ambient conditions to give the blue indolium salt 34 (1.58 g, 82%).  
 
mp 185-190 °C; IR (solid, cm-1)  1722 (C=O), 1635 (C=C), 1580 (C=C), 1163 (C=N); 1H 
NMR (500 MHz, CDCl3) δ 8.32-8.16 (4H, m, ArH), 7.85-7.41 (2H, m, ArH) 4.95 (2H, t,  J = 
7.7 Hz, NCH2), 4.09 (2H, q, J = 7.1 Hz, COOCH2), 3.24 (3H, s, CH3CN), 2.44 (2H, t, J = 6.8 
Hz, CH2CO2Et), 2.14-2.04 (2H, m, NCH2CH2), 1.89 (6H, s, C(CH3)2), 1.86-1.81 (2H, m, 
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CH2CH2CO2Et), 1.22 (3H, t, J = 7.1 Hz, COOCH2CH3); 13C NMR (126 MHz, CDCl3) δ 
195.22 (CN), 172.77 (C=O), 137.13 (Ar C), 133.76 (Ar C), 131.51 (Ar C), 130.14 (Ar CH), 
128.70 (Ar CH), 127.92 (Ar C), 127.70 (Ar CH), 122.79 (Ar CH), 122.34 (Ar CH), 112.35 
(Ar CH), 60.64 (CH2), 55.90 (C), 49.66 (CH2), 33.02 (CH2), 27.32 (CH2), 22.72 (2 × CH3), 
21.88 (CH2), 16.16 (CH3), 14.19 (CH3); m/z (ESI+, H2O:MeOH): 338 ([M]+, 100%), 210 (30). 
Spectroscopic 1H and 13C spectroscopic data in good agreement with literature.8 
3-(4-Carboxybutyl)-1,1,2-trimethyl- 1H-benz[e]indolium (33) 
 
3-(5-Rthoxy-5-oxopentyl)-1,1,2-trimethyl-1H-benz[e]indolium salt (34) (0.98 g, 2.9 mmol, 1 
eq) was suspended in HCl (20 mL; 5 N aq) and heated under reflux at 90 °C overnight to afford 
a yellow solution with a little blue precipitate. The precipitate was removed by filtration and 
the yellow solution was concentrated under vacuum to afford a yellow oil (quant.). 
 
IR (neat, cm-1) 2926 (O-H), 1712 (C=O), 1633 (C=C), 1581 (C=C), 1171 (C=N); 1H NMR 
(500 MHz, MeOD) δ 8.21 – 8.17 (1H, m, ArH), 8.10 (1H, dd, J = 8.9, 2.7 Hz, ArH), 8.02 (1H, 
dd, J = 8.2, 0.5 Hz, ArH), 7.88 (1H, d, J = 8.9 Hz, ArH), 7.67-7.60 (1H, m, ArH), 7.59 – 7.55 
(1H, m, ArH), 4.53 (2H, td, J = 7.8, 1.7 Hz, CH2N), 2.39 – 2.26 (2H, m, CH2COOH), 2.00 – 
1.88 (2H, m, NCH2CH2), 1.71 (6H, bs, NCCH(CH3)2), 1.60-1.56 (2H, m, NCH2CH2CH2); 13C 
NMR (126 MHz, MeOD) δ 198.22 (CN), 175.35 (C=O), 139.98 (Ar C), 138.93 (Ar C), 135.36 
(Ar C), 132.63 (Ar CH), 131.25 (Ar CH), 129.91 (Ar CH), 129.33 (Ar C) 128.92 (Ar CH), 
124.58 (Ar CH), 113.94 (Ar CH), 61.80 (C), 48.91 (CH2), 33.92 (CH2), 28.48 (CH2), 22.99 
(CH2), 22.58 (2 × CH3), 20.65 (CH3); m/z (ESI+, H2O:MeOH): 324 ([M]+, 100%), 210 (10). 










1-(4-Pentynyl)-2,3,3-trimethylbenz[e]indolium iodide (35) 
 
Potassium iodide (1.19 g, 6.9 mmol, 2.2 eq) was suspended in MeCN (2 mL), followed by 5-
chloro-1-pentyne (0.38 g, 3.1 mmol, 1 eq) and stirred at 50 °C. After 10 minutes 2,3,3-
trimethylbenz[e]indole (36) (0.5 g, 2.4 mmol, 1 eq) was added and the reaction stirred for 24 
hours under reflux. The reaction was then cooled to rt, diluted with DCM (15 mL) and washed 
with H2O (3 × 20 mL). The organic layer was dried over magnesium sulfate, filtered and the 
solvent was removed in vacuo. The solid was dissolved in the minimum amount of DCM and 
precipitated using Et2O. The remaining solid was removed by filtration, washed with Et2O and 
dried in vacuo. The indolium salt 35 was obtained as a green solid (0.72 g, 72%). 
 
mp 140-142 °C; IR (solid, cm-1): 3203 (C≡C-H), 2358 (C≡C), 1581 (C=C), 1521 (C=C); 1H 
NMR (500 MHz, CDCl3) δ 8.15 (1H, d, J = 8.9 Hz, ArH), 8.12 (1H, d J = 8.4 Hz, ArH), 8.09 
(1H, d, J = 8.4, ArH), 7.93 (1H, d, J = 8.9 Hz, ArH), 7.77 (1H, dd, J = 8.3, 6.8, ArH), 7.71 
(1H, dd, J = 8.3, 6.8 Hz, ArH), 5.05 (2H, t, J = 7.5 Hz, NCH2CH2), 3.32 (3H, s, NCCH3), 2.55 
(2H, td, J = 6.6, 2.5 Hz, CH2CCH), 2.35 (2H, qn, J = 6.6 Hz, CH2CH2C≡CH), 2.15 (1H, t, J = 
2.5 Hz, CH2CCH), 1.92 (6H, s, NCC(CH3)2); 13C NMR (126 MHz, CDCl3) δ 196.14 (CN), 
138.33 (Ar C), 137.12 (Ar C),  133.80 (Ar C),  131.64 (Ar CH),  130.18 (Ar CH), 128.75 (Ar 
CH), 127.92 (Ar C), 127.76 (Ar CH) , 122.83 (Ar CH), 112.57 (Ar CH), 82.01 (C),  71.22 
(CH), 56.03 (C), 48.99 (CH2), 26.82  (CH2), 22.89 (2  × CH2), 16.82 (CH3), 16.23 (CH2); m/z 












indolium iodide (38) 
 
1,1,2,3-Tetramethyl-1H-benz[e]indolium iodide (31) (120 mg, 0.28 mmol, 1 eq) and 
glutaconaldehyde dianyl hydrochloride salt (37) (70.0 mg, 0.31 mmol, 1.1 eq) were added to 
a round bottom flask containing acetic acid (3 mL) and acetic anhydride (3 mL). The reaction 
mixture was stirred at 120 °C for 2.5 hours. The solvent was removed in vacuo and the 
resulting solid was triturated with EtOAc:H2O (20 mL, 1:1) which was removed by 
decantation after the mixture was centrifuged to give a dark purple solid 38 (52 mg, 40%). 
 
mp 200-202 °C;  IR (solid, cm-1) 1681 (C=O), 1548 (C=C), 1504 (C=C); 1H NMR (500 MHz, 
DMSO-d6) δ 8.33-7.32 (12H, m, 9 × ArH & 3 × =CH), δ 7.28 (1H, d, J = 14.2 Hz, =CH), 7.02-
6.99 (1H, t, J = 7.4 Hz, ArH), 6.90 (1H, d, J = 15.3 Hz, =CH), 6.58 (1H, dd, J = 15.3, 11.1 Hz, 
ArH), 5.27 (1H, dd, J = 14.2, 11.5 Hz, =CH), 4.01 (3H, s, CH3), 2.04 (3H, s, CH3), 1.92 (6H, 
s, 2 × CH3); 13C NMR (126 MHz, DMSO-d6) δ 181.51 (CN), 168.72 (C=O), 154.34 (CH), 
150.59 (CH), 139.98 (Ar C), 139.80 (Ar C), 138.71 (Ar C), 137.61 (Ar C), 133.31 (Ar C), 
131.21 (Ar CH), 130.82 (Ar CH), 130.46 (Ar CH), 129.87 (CH), 129.80 (Ar CH), 129.11 
(CH), 129.04 (Ar CH), 128.76 (Ar CH), 127.25 (Ar CH), 123.51 (Ar CH), 123.42 (Ar CH), 
119.44 (Ar CH), 113.45 (CH), 112.89 (Ar CH), 112.78 (CH), 53.42 (C) 34.43 (CH3), 25.94 (2 
× CH3), 24.49 (CH3); m/z (ESI+, H2O:MeOH): 421 ([M]+, 100%). 1H and 13C spectroscopic 













benz[e]indolium (39)   
 
Glutaconaldehyde dianyl hydrochloride salt (37) (475 mg, 1.65 mmol, 1.1 eq) was added to a 
solution of 1,1,2-trimethyl-3-(4-sulfobutyl)-1H-benz[e]indolium (32) (512 mg, 1.47 mmol, 1 
eq) in acetic acid (4.5 mL) and acetic anhydride (4.5 mL) and was stirred at 120 °C for 3 hours. 
The solvent was removed under reduced pressure and the resultant solid was triturated with 
EtOAc:H2O (20 mL, 1:1) which was removed by decantation after the mixture was centrifuged 
to give the title compound 39 (0.31 g, 40%). 
 
mp 260-263 °C; IR (solid, cm-1) 1685 (C=O), 1544 (C=C), 1492 (SO3-); 1H NMR (500 MHz, 
MeOD) δ 8.37 (1H, d, J = 8.1 Hz, ArH), 8.30–8.23 (2H, m, ArH & =CH), 8.20 (1H, d, J = 8.9 
Hz, ArH), 8.14 (1H, d, J = 8.7 Hz, =CH), 7.95 (1H, d, J = 8.9 Hz, ArH), 7.81–7.76 (1H, m, 
ArH), 7.71–7.61 (4H, m, 3 × ArH &  =CH), 7.48 (1H, dd, J = 14.3, 11.5 Hz, ArH), 7.43–7.37 
(2H, m, ArH & =CH), 7.04 (1H, d, J = 15.1 Hz, =CH), 6.67 (1H, dd, J = 14.3, 11.2 Hz, ArH), 
5.44 (1H, dd, J = 13.7, 11.5 Hz, & =CH), 4.64–4.59 (2H, m, NCH2), 2.92 (2H, t, J = 7.0 Hz, 
CH2SO3-), 2.17 (6H, s, 2 × CH3), 2.06 (3H, s, CH3), 2.05–2.00 (4H, m, CH2CH2CH2CH2SO3-
); 13C NMR (126 MHz, MeOD) δ 181.70 (C=N), 169.99 (C=O), 155.07 (CH), 150.42 (CH), 
138.48 (Ar C), 137.91 (Ar C), 133.61 (Ar C), 131.20 (Ar CH), 130.27 (2 × Ar CH), 129.88 (2 
× CH), 129.43 (Ar CH), 128.38 (Ar CH), 128.36 (Ar CH), 128.02 (Ar CH), 127.39 (Ar C), 
126.75 (Ar CH), 123.74 (Ar C), 122.61 (Ar CH), 119.80 (Ar CH), 113.42 (CH), 112.06 (Ar 
CH), 111.89 (CH), 53.38 (C), 49.81 (CH2), 48.22 (CH2), 45.83 (CH2), 26.63 (CH2), 25.28 (3 
× CH3); m/z (ESI+, H2O:MeOH): 565 ([M+Na]+, 100%), 543 ([M+H]+, 40).  1H and 13C 













3-(4-Carboxybutyl)-1,1,2-trimethyl-1H-benz[e]indolium (33) (5.0 mg, 0.01 mmol, 1.2 eq) was 
added to a solution of 2-[(1E,3E,5E)-6-(acetylphenylamino)-1,3,5-hexatrien-1-yl]-1,1,3-
trimethyl-1H-benz[e]indolium (38) (6.0 mg, 0.01 mmol, 1 eq) in anhydrous pyridine (5 mL) 
and stirred at rt for 24 hours. The reaction mix was triturated with ether and the solid was 
filtered off, washed with ether and dried in vacuo. Column chromatography (0-2 % 
MeOH/DCM) gave compound 42 as a green solid (6.02 mg, 75%). 
 
mp 234-236 °C; IR (solid, cm-1) 3394 (OH), 2922 (CH), 1666 (C=O); 1H NMR (601 MHz, 
MeOD) δ 8.28 (2H, d, J = 8.5 Hz, ArH), 8.09 - 8.04 (5H, m, 3 × ArH & 2 × =CH), 7.92 (1H, 
dd, J = 20.7, 8.6 Hz, =CH), 7.71 - 7.64 (4H, m, 4 ArH), 7.51 - 7.54 (2H, m, =CH), 7.48 - 7.33 
(1H, m, =CH), 6.66 - 6.64 (2H, m, ArH), 6.47 - 6.34 (2H, m, ArH & =CH), 4.29 (2H, t, J = 
7.6, NCH2CH2CH2CH2COOH) 3.76 (3H, s, CH3), 2.32 (2H, t, J = 7.1 Hz, 
NCH2CH2CH2CH2COOH), 2.02 (12H, s, 4 × CH3), 1.95 - 1.90 (2H, m, 
NCH2CH2CH2CH2COOH), 1.84 - 1.79 (2H, m, NCH2CH2CH2CH2COOH); 13C NMR (151 
MHz, MeOD) δ 194.06 (C=O), 178.97 (CN), 173.15 (CN), 149.63 (CH), 140.60 (Ar C), 
140.33 (Ar C), 133.63 (Ar C), 131.91 (2 × Ar C), 131.85 (2 × Ar C), 130.44 (Ar CH), 130.36 
(Ar CH), 129.93 (3 × Ar CH), 129.55 (CH), 128.13 (4 × Ar CH), 127.56 (Ar CH), 126.60 
(CH), 124.73 (Ar CH), 122.18 (Ar CH), 122.15 (Ar CH), 111.02 (CH), 110.98 (Ar C), 110.11 
(CH), 103.56 (CH), 103.21 (Ar CH)  50.81 (C), 48.11 (C), 43.88 (CH2), 36.16 (CH2), 30.73 
(CH3), 26.42 (CH2), 25.90 (4 × CH3), 23.20 (CH2); m/z (ESI+, H2O:MeOH): 595 ([M]+, 
100%). 1H and 13C spectroscopic data in good agreement with literature.10 
 





ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1H-benzo[e]indolinium-3-yl  chloride(43) 
 
1-(4-Pentynyl)-2,3,3-trimethylbenz[e]indolium indole (35) (30 mg, 0.1 mmol, 1.2 eq) was 
added to a solution of 2-[(1E,3E,5E)-6-(acetylphenylamino)-1,3,5-hexatrien-1-yl]-1,1,3-
trimethyl-1H-benz[e]indolium chloride (38)  (38 mg, 0.09 mmol, 1 eq) in anhydrous pyridine 
(5 mL) and stirred at rt for 24 hours. Column chromatography (0-2 % MeOH/DCM) provided 
the title product 43 as a green solid (300 mg, 69%). 
 
mp 207 °C; IR (solid, cm-1) 2929 (C≡C-H), 2113 (C≡C), 1666 (C=C); 1H NMR (500 MHz, 
MeOD) δ 8.25 (2H, t, J = 9.5 Hz, ArH & =CH), 8.09 – 7.94 (5H, m, 3 × ArCH & =CH), 7.68 
– 7.56 (5H, m, 4 ArH & 1 =CH), 7.54 – 7.40 (3H, m, =CH), 6.66 – 6.56 (2H, m, ArH), 6.44 – 
6.32 (2H, m, ArH & =CH), 4.31 (2H, t, J = 6.7 Hz, NCH2), 3.77 (3H, s, NCH3), 2.53 (1H, t, J 
= 2.6 Hz, C≡CH), 2.43 (2H, td, J = 6.7, 2.6 Hz, CH2C≡CH), 2.08 – 2.05 (2H, m, 
CH2CH2C≡CH), 2.01 (12H, s, 4 × CH3); 13C NMR (126 MHz, MeOD) δ 174.52 (CN), 172.30 
(CN), 151.13 (CH), 150.95 (Ar CH), 139.84 (Ar C), 133.63 (Ar C), 133.23 (Ar C), 133.00 (Ar 
C), 132.12 (Ar C), 131.83 (Ar C), 130.30 (Ar CH), 130.26 (Ar CH), 129.72 (Ar CH), 129.70 
(Ar C), 128.09 (Ar C), 127.31 (CH), 127.25 (CH), 125.70 (Ar CH), 125.35 (Ar CH), 124.73 
(CH), 124.41 (CH), 121.93 (Ar CH), 121.85 (Ar CH), 110.47 (2 × Ar CH), 110.32 (2 × Ar 
CH), 103.74 (Ar CH), 102.40 (CH), 82.45 (C), 69.93 (≡CH), 53.40 (C), 42.38  (CH2), 35.54 
(C), 30.43 (CH3), 26.28 (2 × CH3), 26.15 (CH2), 26.07 (2 × CH3), 15.18 (CH2); m/z (ESI+, 













1,2,3,3-Tetramethylbenz[e]indolium iodide (31) (0.51 g, 2.2 mmol, 1 eq) and 
malondialdehyde bis(phenylimine)monohydrocloride (0.73 g, 4.37 mmol, 1.1 eq) in acetic 
acid (5 mL) was heated at reflux under argon. After 30 min the reaction was cooled to rt and 
a solution of 3-(4-carboxybutyl)-1,1,2-trimethyl-1H-benz[e]indolium (33) (0.82 g, 2.41 mmol, 
1.1 eq) in anhydrous pyridine (5 mL) was added and the reaction stirred at rt for 24 hours. The 
reaction mix was precipitated with ether and the solid filtered off, washed with ether and dried 
in vacuo. Column chromatography (0-2 % MeOH/DCM) provided the title compound 33 as a 
red-gold solid (0.65 g, 70%). 
 
abs/em 665/693; Φ 0.68; ε 150,000 M-1cm-1; mp 190 °C; IR (solid, cm-1) 3311 (OH), 2924 
(CH), 1660 (C=O), 1479 (C=C), 1436 (C=C); 1H NMR (500 MHz, DMSO-d6) δ 12.08 (1H, 
s, COOH), 8.50 – 8.37 (2H, m, ArH & =CH), 8.26-8.24 (2H, m, ArH), 8.16 – 7.97 (4H, m, 
ArH), 7.74 (2H, dd, J = 8.9, 4.2 Hz, ArH), 7.69-6.67 (2H, m, ArH  & =CH), 7.53-7.50 (2H, 
m, ArH), 6.61 (1H, t, J = 12.3 Hz, =CH), 6.40 – 6.32 (2H, m, ArH  =CH), 4.24 (2H, t, J = 7.3 
Hz, NCH2CH2CH2CH2COOH), 3.73 (3H, s, NCH3), 2.30 (2H, t, J = 7.2 Hz, 
NCH2CH2CH2CH2COOH), 1.96 (12H, s, 4 × CH3), 1.76 (2H, m, NCH2CH2CH2CH2COOH), 
1.64 (2H, m. NCH2CH2CH2CH2COOH); 13C NMR (126 MHz, DMSO-d6) δ 174.78  (CN), 
174.64 (CO) 173.99 (CN), 158.51 (Ar C), 158.14 (Ar C), 153.35 (CH), 153.32 (Ar CH), 
140.89 (Ar C), 140.24 (Ar C), 133.51 (Ar C), 131.81 (Ar CH), 131.73 (Ar CH), 130.76 (Ar 
CH), 130.67 (Ar CH), 130.41 (Ar CH), 128.20 (CH), 128.09 (Ar CH), 128.00 (Ar CH), 126.00 
(CH), 125.24 (Ar CH), 122.65 (Ar CH), 122.59 (CH), 118.41 (Ar C), 112.09 (Ar CH), 103.66 
(Ar CH), 102.28 (CH), 43.33 (CH2),  33.37 (CH2), 31.67 (CH3),  26.96 (2 × CH3), 26.85 (CH2),  
26.80 (2 × CH3), 21.82 (CH2); m/z (ESI+, H2O:MeOH): 569 ([M]+, 100%).  1H and 13C 
spectroscopic data in good agreement with literature.10  
 






1,2,3,3-Tetramethylbenz[e]indolium iodide (31) (1.42 g, 3.98 mmol, 1 eq) and 
malondialdehyde bis(phenylimine)monohydrocloride (1.13 g, 4.37 mmol, 1.1 eq) in acetic 
acid (5 mL) was heated at reflux under argon. After 30 min the reaction was cooled to rt and 
a solution of 1-pentynyl-2,3,3-trimethylbenz[e]indolium iodide (35) (1.76 g, 4.37 mmol, 1.1 
eq) in anhydrous pyridine (5 mL) was added and the reaction stirred at rt for 24 hours. The 
reaction mix was precipitated with ether and the solid filtered off, washed with ether and dried 
in vacuo. Column chromatography (0-2 % MeOH/DCM) provided compound 47 as a red-gold 
solid (1.78 g, 71%). 
 
abs/em 665/690; Φ 0.70; ε 90,000 M-1cm-1; mp 170 °C; IR (solid, cm-1): 3059 (C≡C-H), 2115 
(C≡C), 1634 (C=C), 1581 (C=C); 1H NMR (500 MHz, DMSO-d6) δ 8.51 – 8.42 (2H, m, ArH 
& & =CH), 8.29 – 8.24 (2H, m, ArH), 8.12 – 8.05 (4H, m, 3 × ArH & =CH), 7.77 (1H, d, J = 
8.9 Hz, ArH), 7.73 (1H, d, J = 8.9 Hz, ArH), 7.72-7.60 (2H, m, ArH & =CH), 7.55 -7.52 (2H, 
m, ArH), 6.61 (1H, t, J = 12.3 Hz, =CH), 6.39 - 6.30 (2H, m, ArH & =CH), 4.27 (2H, t, J = 
7.5 Hz, NCH2), 3.76 (3H, s, NCH3), 2.99 (1H, t, J = 2.6 Hz, CH2C≡CH), 2.38 (2H, td, J = 7.5, 
2.6 Hz, CH2C≡CH), 1.98 (6H, s, 2 × CH3), 1.97 (6H, s, 2 × CH3), 1.97 – 1.92 (2H, m, 
NCH2CH2); 13C NMR (126 MHz, DMSO-d6) δ 175.24 (CN), 173.72 (CN), 153.73 (CH), 
152.98 (Ar CH),  140.83 (Ar C), 140.22 (Ar C), 133.73 (Ar C), 133.33 (Ar C), 131.88 (Ar C), 
131.69 (Ar C), 130.75 (Ar CH), 130.60 (Ar CH), 130.41 (Ar CH), 128.24 (Ar C), 128.19 (CH), 
128.13 (CH),  127.96 (Ar CH), 125.96 (Ar CH), 125.34 (Ar CH), 125.15 (Ar CH), 122.68 
(CH), 122.57 (Ar CH), 118.53 (Ar C), 112.14 (Ar CH), 111.75 (Ar CH), 104.00 (Ar CH), 
102.83 (CH), 84.01 (C), 72.66 (≡CH), 51.28 (C), 51.08 (C), 42.99 (CH2), 31.16 (CH3), 27.31 
(2 × CH3), 27.09 (2 × CH3), 26.65 (CH2), 15.74 (CH2); m/z (ESI+, H2O:MeOH): 535 ([M+]+, 
100%). 1H and 13C spectroscopic data in good agreement with literature.10  
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7.1.5 On resin approach 
(4-hydroxyphenyl)carbamic acid tert-butyl ester PS (50) 
 
N-Boc-4-hydroxyaniline (49) (1.25 g, 6.00 mmol, 30 eq), Cs2CO3 (1.95 g, 6.00 mmol, 30 eq) 
and KI (30.0 mg, 2.0 mmol, 1 eq) were added to acetone (25 mL). To this solution 1% DVB 
crossed linked chloromethyl PS (1.00 g, 1.95 mmol, 10 eq) was added and the mixture was 
stirred at 70 °C for 16 hours. The resin was washed with H2O (4 × 25 mL) followed by DMF 
(4 × 25 mL), DCM (4 × 25 mL) and Et2O (4 × 25 mL). The resin was then dried under reduced 
pressure to give a beige resin. (2.24 g) 
 
IR (solid, cm-1) 1724 (C=O), 1598 (C=C), 1512 (C=C). 
4-aminophenol PS (51) 
 
(4-hydroxyphenyl)carbamic acid tert-butyl ester PS (50) (20.0 mg, 0.03 mmol, eq) is shaken 
at rt with 20% TFA in DCM (0.3 mL) for 2 hours. The resin is then isolated by filtration and 
washed with DCM (2 × 10 mL). The resin is then shaken with 10% TEA in DCM (0.3 mL) 
for 15 minutes, filtered, washed with DCM (4 × 10 mL) and then dried. Keiser and TNBS tests 
carried out showed removal of Boc group took place. (18 mg) 
 











indolium PS (52) 
 
2-[(1E,3E,5E)-6-(acetylphenylamino)-1,3,5-hexatrien-1-yl]-1,1,3-trimethyl-1H-Benz[e]
indolium (31) (50.0 mg, 0.12 mmol, 1 eq) and 4-aminophenol PS 51) (70.0 mg, 0.13 mmol, 
1eq) were shaken in DCM (3 mL) for 2 hours. The resin was then washed with DMF (3 × 10 
mL), DCM (3 × 10 mL) and dried under reduced pressure to give a dark purple resin. (0.11 g) 
 
IR (solid, cm-1) 1631 (C=C), 1600 (C=C). 
4-(2-(1E, 3E, 5E, 7Z)-7-(3-(R)-1,1-dimethyl-1H-benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-
trienyl)-1,1-dimethyl-1H-benzo[e]indolinium-3-yl (42 or 43)  
R= 4- carboxybutyl (33) or 4-pentynyl (34) 
2-[(1E,3E,5E)-6-(acetylphenylamino)-1,3,5-hexatrien-1-yl]-1,1,3-trimethyl-1H-Benz[e]
indolium PS (38) (65.0 mg, 0.12 mmol, 1 eq), 3-(4-carboxybutyl)-1,1,2-trimethyl- 1H-Benz[e]
indolium (33) or 1-(4-pentynyl)-2,3,3-trimethylbenz[e]indolium indole (34) (5.0 mg, 0.01 
mmol, 0.1 eq) or were shaken with pyridine (0.47 mL) and acetic anhydride (0.11 mL) for 3 
hours. The resin was then washed with DMF (3 ×10 mL), DCM (3 × 10 mL) and the filtrate 
was collected. The filtrate was dried under reduced pressure to give a green solid. (61 mg, 64% 
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7.1.6 Fluorescein compounds 
Fluorescein-Alendronate (55) 
 
Sodium alendronate (34 mg, 1 mmol, 5 eq; Alfa Aesar) was dissolved in NaHCO3 (1 mL, sat. 
aq.). Fluorescein (5/6) NHS ester (10 mg, 0.2 mmol, 1 eq; Thermo Fisher) dissolved in DMF 
(0.1 mL) was added to the solution and the reaction mixture was stirred for 2 days at room 
temperature in the dark. The solution was acidified with TFA (10% v/v aq.) and purified by 
RP HPLC [isocratic 80/20 H2O (+0.1% v/v TFA)/MeCN (+0.1% v/v TFA)] to yield the 
fluorescein-BP conjugate as an orange solid (34 mg, 50%). 
 
abs/em 491/515; Φ 0.83; ε 41,400 M-1cm-1; mp 240 °C; IR (solid, cm-1) 1700 (C=O), 1635 
(C=O), 1538 (N-H), 1271 (P=O), 1116 (C-N); 1H NMR (601 MHz, DMSO-d6) δ 10.13 (2H, 
br s, OH isomer 1+2) 8.85 (0.6H, t, J = 5.7 Hz, NH isomer 1), 8.72 (0.4H, t, J = 5.9 Hz, NH 
isomer 2), 8.47 (0.6H, d, J = 1.5 Hz, ArH isomer 1), 8.26 (0.6H, dd, J = 8.0, 1.5 Hz, ArH 
isomer 1), 8.19 (0.4H, dd, J = 8.1, 1.4 Hz, ArH isomer 2), 8.07 (0.4H, d, J = 8.1 Hz, ArH 
isomer 2), 7.70 (0.4H, s, ArH isomer 2), 7.37 (0.6H, d, J = 8.0 Hz, ArH isomer 1), 6.69 (2H, 
dd, J = 5.3, 2.3 Hz, ArH isomer 1+2), 6.63 – 6.53 (4H, m, ArH isomer 1+2) 3.30 (1.2H, q, J 
= 6.5 Hz, NCH2 isomer 1), 3.17 (0.8H, q, J = 6.4 Hz, NCH2 isomer 2), 2.01-1.70 (4H, m, 
CH2CH2 isomer 1+2); 13C NMR (151 MHz, DMSO-d6) δ 168.69 (C=O), 168.55 (C=O), 
164.86 (C=O), 164.67 (C=O), 160.06 (2 × Ar C), 155.02 (Ar C), 153.17 (Ar C), 152.32 (2 × 
Ar C), 152.30 (2 × Ar C), 141.35 (Ar C), 136.96 (Ar C), 135.16 (Ar CH), 129.85 (ArCH), 
129.74 (2 x ArCH), 129.66 (2 x ArCH), 128.55 (Ar C), 126.92 (Ar C), 125.27 (Ar CH), 124.66 
(Ar CH), 123.72 (Ar CH), 122.73 (Ar CH), 113.21 (2 x Ar CH), 113.16 (2 x Ar CH), 109.67 
(2 x Ar C), 109.60 (2 x Ar C), 102.73 (2 × Ar CH), 83.75 (C), 83.72 (C), 72.60 (t, 1JCP = 148 
Hz, C), 41.99 (t, 2JCP = 21 Hz, CH2), 41.65 (t, 2JCP = 21 Hz, CH2), 31.13 (CH2), 24.06 (CH2); 
31P NMR (202 MHz, DMSO-d6) δ 20.21; m/z (ESI+, H2O:MeOH): 630 ([M+Na]+, 10%), 608 










Prepared following the method of Gavin et al..1 5-amino-1-pentanol (34 mg, 1 mmol, 5 eq) 
was dissolved in NaHCO3 (1 mL, sat. aq.). Fluorescein (5/6) NHS ester (10 mg, 0.2 mmol, 1 
eq) dissolved in DMF (0.1 mL) was added to the solution and the reaction mixture was stirred 
for 2 days at room temperature in the dark. The solution was acidified with TFA (10% v/v aq.) 
and purified by RP HPLC [isocratic 80/20 H2O (+0.1% v/v TFA)/MeCN (+0.1% v/v TFA)] to 
yield the fluorescein-OH conjugate as an orange solid (5 mg, 34%).  
 
abs/em 491/517; Φ 0.87; ε 38,400 M-1cm-1; mp 227 °C; IR (solid, cm-1): 3410 (OH), 1624 
(C=O), 1498 (N-H), 1106 (C-N); 1H NMR (601 MHz, DMSO-d6) δ 10.11 (2H, br s, OH 
isomer 1+2), 8.80 (0.6H, t, J = 6.5 Hz, NH isomer 1), 8.66 (0.4H, d, J = 6.5 Hz, NH isomer 
2), 8.46 (0.6H, d, J = 6.6 Hz, ArH isomer 1), 8.25 (0.6H, t, J = 7.5 Hz, ArH isomer 1), 8.17 
(0.4H, t, J = 7.5 Hz, ArH isomer 2), 8.08 (0.4H, t, J = 7.6 Hz, ArH isomer 2), 7.67 (0.4H, d, J 
= 6.5 Hz, ArH isomer 2), 7.37 (0.6H, t, J = 7.6 Hz, ArH isomer 1), 6.70 (2H, br s, ArH isomer 
1+2), 6.63 – 6.52 (4H, m, ArH isomer 1+2), 3.42-3.32 (2H, m, CH2OH isomer 1+2), 3.32 
(1.2H, m, NCH2 isomer 1), 3.19 (0.8H, t, J = 6.8 Hz, NCH2 isomer 2), 1.56 (1.2H, m, CH2 
isomer 1), 1.49-1.21 (4.8H, m, 2 x CH2 isomer 1+2 + CH2 isomer 2); 13C NMR (126 MHz, 
DMSO-d6) δ 168.69 (CO), 168.53 (CO), 164.95 (CO), 164.77 (CO), 160.09 (2 × Ar C), 155.04 
(Ar C), 153.15 (Ar C), 152.31 (2 × Ar C), 141.31 (Ar C), 136.90 (Ar C), 135.15 (Ar CH), 
129.85 (Ar CH), 129.72 (2 × Ar CH), 129.63 (2 × Ar CH), 128.59 (Ar C), 126.92 (Ar C), 
125.32 (Ar CH), 124.68 (Ar CH), 123.68 (Ar CH), 122.67 (Ar CH), 113.23 (2 x Ar CH), 
113.16 (2 x Ar CH), 109.66 (2 x Ar C), 109.59 (2 x Ar C), 102.75 (2 × Ar CH), 102.73 (2 × 
ArCH), 83.78 (C), 61.11 (CH2), 61.03 (CH2), 39.86 (CH2), 32.71 (CH2), 32.68 (CH2), 29.35 
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7.1.7 Azide alendronate synthesis 
Tetraethyl (4-chloro-1-tert-butyldimethylsilyl-1,1-butanediyl)bisphosphonate (61) 
 
Triethyl phosphite (0.29 g, 1.7 mmol, 1 eq) was added dropwise to 4-chlorobutyryl chloride 
(0.25 g, 1.8 mmol, 1 eq) at 0 °C. The resulting mixture was allowed to reach rt after which it 
was stirred at rt for another 15 minutes. DCM (5 mL) was subsequently added followed by 
diethyl phosphite (0.27 g, 1.9 mmol, 1 eq) and DMAP (0.21 g, 1.7 mmol, 1 eq). The reaction 
mixture was then stirred at rt for 2 h after which tert-butyldimethylsilyl chloride (0.29 g, 1.92 
mmol, 1 eq) was added and the mixture was stirred overnight. The reaction mixture was 
washed with HCl (2 × 20 mL; 0.1 M aq), dried over magnesium sulphate and then concentrated 
under reduced pressure. Further purification by column chromatography (5 % EtOAc in 
hexane) to obtain the product as a clear oil (0.21 g, 25%). 
 
IR (neat, cm-1) 1246 (P=O), 1020 (O-Si), 964 (P-OR); 1H NMR (500 MHz, CDCl3) δ 4.19-
4.30 (m, 8H, 4 × OCH2CH3), 3.56 (t, J = 6.0 Hz, 2H, ClCH2CH2CH2), 2.14 – 2.25 (m, 4H, 
ClCH2CH2CH2), 1.37 (t, J = 7.1 Hz, 12H, 4 × OCH2CH3), 0.93 (s, 9H, C(CH3)3), 0.22 (s, 6H, 
2 × CH3);  13C NMR (126 MHz, CDCl3) δ 77.73 (t, 1JPC 156.8 Hz, C), 62.89 (2JCP= 19.4 Hz, 4 
×CH2), 45.56 (CH2), 33.55 (CH2), 27.16 (CH2), 25.85 (3 × CH3), 19.02 (C), 16.47 (4 × CH3), 
-2.54 (2 × CH3); 31P NMR (202 MHz, CDCl3) δ 20.51; m/z (EI+, H2O:MeOH): 439 ([35ClM-
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Tetraethyl (4-azide-1-tert-butyldimethylsilyl-1,1-butanediyl)-bisphosphonate (56) 
 
Sodium azide (0.37 g, 1.0 mmol, 5 eq) was added to tetraethyl-(4-chloro-1-tert-
butyldimethylsilyl-1,1-butanediyl)bisphosphonate (58) (0.57 g, 6.0 mmol, 1 eq) in DMF (10 
mL) and the reaction mixture was stirred at 75 °C for 3 hours. The mixture was then cooled to 
rt and combined with H2O (30 mL) and DCM (30 mL). The layers were separated and the 
organic fraction was further washed with H2O (2 × 50 mL). The solution was dried over 
magnesium sulfate and concentrated in vacuo to give a pale yellow oil (0.47 g, 82 %). 
 
IR (neat, cm-1) 2096 (N3); 1247 (P=O); 1H NMR (500 MHz, CDCl3) δ 4.27 – 4.19 (8H, m, 4 
× OCH2CH3), 3.29 (2H, t, J = 6.5 Hz, N3CH2), 2.19 – 2.08 (2H, m, N3CH2CH2), 2.05 – 1.94 
(2H, m, N3CH2CH2CH2), 1.37 (12H, t, J = 7.0 Hz, 4 × OCH2CH3), 0.93 (9H, s, SiC(CH3)3), 
0.23 (6H, s, Si(CH3)2); 13C NMR (126 MHz, CDCl3) δ 77.21 (t, 1JPC 150.1 Hz, C) 63.01 (d, 
2JCP= 20.6 Hz, 4 ×CH2), 51.90 (CH2), 33.23 (CH2), 25.80 (3 × CH3), 23.74 (d, 3JCP= 5.7 Hz, 
CH2), 19.02 (C), 16.45 (4 × CH3), -2.60 (2 × CH3); m/z (ESI+, H2O:MeOH) 524 ([M+Na]+, 
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7.1.8 Peptide synthesis 
HAP Selective peptide (67) 
Ac-Ser-Val-Ser-Val-Gly-Met-Lys-Pro-Ser-Pro-Arg-Pro-Gly-Gly-Gly-Lys(N3)-Ac 
Produced using Rink Amide AM Resin (500 mg, 0.345 mmol), standard Fmoc SPPS protocols 
described below and RP HPLC ([isocratic 60/40 H2O (+0.1% v/v TFA)/MeCN (+0.1% v/v 
TFA)] to give a colourless solid (180 mg, 51%).  
 
IR (solid, cm-1) 3273 (OH), 2962 (C-H), 2098 (N3), 1624 (C=O), 1527 (CH), 1431 (CH); m/z 
(ESI+, H2O:MeOH) 826 ([M+2Na]2+, 100%), 815 ([M+H+Na]2+, 80, 805 ([M+2H]2+, 40). 
Standard Procedure for Solid Phase peptide synthesis 
Method A – Swelling 
Rink amide AM resin (150 mg, 104 μmol, 690 μmol g-1) was placed in an empty reservoir (6 
mL) and swelled in DCM (5 mL) for 30 minutes, before washing the resin with DMF (3 × 4 
mL) and DCM (3 × 4 mL). 
Method B – Fmoc Deprotection 
A solution of piperidine (20% in DMF, 4 mL) was added to the resin and the mixture was 
agitated for 10 minutes, the solution was drained into a vacuum box and washed with DMF (3 
× 4 mL) and DCM (3 × 4 mL), before repeating the process again. Method C was used to 
check for successful deprotection. 
Method C – Chloranil Test  
To verify a successful coupling or deprotection, a chloranil test was used to check for the 
presence or absence of primary or secondary amines. Chloranil test requires two solutions; 
Solution A acetaldehyde (2% in DMF) and Solution B chloranil (2% in DMF). The test was 
carried out by placing a small number of beads in an Eppendorf tube and adding 5-6 drops of 
each solution. The mixture was then agitated for 5 minutes. If free amines were present the 
beads would turn blue and if no free amines were present no colour change would be observed 
on the beads. 
Method D – Coupling of Amino acids  
The appropriate amino acid (3 eq) was pre-activated by dissolving it with Oxyma (3 eq) in 
DMF (1 mL), the solution was agitated for 3 minutes whereupon DCC (3 eq) was added and 
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the solution was agitated for a further 2 min. The highly activated complex was then added to 
the resin and agitated for 40 minutes. Once the coupling was complete the solution was drained 
and the resin was washed with DMF (3 × 4 mL) and DCM (3 × 4 mL). Method C was then 
used to check for complete coupling. 
Method E – Capping 
Once the final amino acid was successfully coupled, the peptide was acetylated by agitating 
the resin with a solution of Ac2O (20 eq), DIPEA (20 eq) in DMF (1 mL) for 40 minutes. 
Method C was used to check for complete acetylation. 
Method F – Cleavage 
After successfully capping of the peptide, the resin was washed with DMF (3 x 4 mL), DCM 
(5 × 4 mL) and dried under vacuum. Peptide cleavage was carried out by agitating the resin in 
TFA:H2O:EDT:TIS (94:2.5:2.5:1). 
The TFA liquor was collected in a Falcon tube (50 mL) and the resin was washed with more 
of the cocktail liquor (5 × 3 mL) before concentrating the solution under a stream of N2. Cold 
Et2O (20 mL) was then added to the precipitate and the solution was sonicated before being 
centrifuged at 3500 rpm for 2 minutes, the supernatant was decanted, and the process was 
repeated again for up to a maximum of 4 times. The precipitated crude peptide was then 
lyophilized by dissolving it in H2O and MeCN.  
 
Cy5.5-HAP selective peptide (71) 
Cy5.5 (47) (100 mg, 0.96 mmol, 1.2 eq) and HAP selective peptide (67) (130 mg, 0.84 mmol, 
1 eq) were dissolved in DMF (10 mL). To this Cu(MeCN)4BF4 (10 mol %) was added. The 
reaction was left stirring for 24 hours at rt in the dark. The solution was concentrated under 
reduced pressure and purified by RP HPLC [isocratic 65/35 H2O (+0.1% v/v TFA)/MeCN 
(+0.1% v/v TFA)] to yield a blue solid (150 mg, 90%). 
 
abs/em 660/695; Φ 0.73;  ε 110,000 M-1cm-1; IR (solid, cm-1): 3410 (OH), 3000 (NH), 2924 
(CH), 1654 (C=O), 1436 (CH), 1406 (CH); m/z (ESI+, H2O:MeOH) 1075 ([M+2H]2+, 10%), 
715 ([M+3H]3+). 
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7.1.9 Incorporation of probes in calcium minerals 
Fluorescein-BP (42), Cy-Pep (53) and Alizarin S incorporation in calcium minerals 
Aqueous suspension of calcium species (HAP, CaOx, CaPi, CaPyr, Sigma Aldrich and Fisher 
Scientific) (50 mg) were incubated with either Fluorescein-BP (42) (5 µM) or CyPep (53) (5 
µM) or Alizarin S (1%) for 2 hours. Unbound probe was removed after a series of 
centrifugation steps and washing steps which involved: resuspension of the solid in H2O ( 3 × 
15 minutes). Fluorescence analysis of the combined aqueous extracts was performed using 
Synergy HT Multi Mode Microplate reader at 488 nm (Fluorescein-BP), 530 nm (Alizarin S) 
and using Fluoromax-3 at 630 nm (Cy-Pep). 
Na18F incorporation in calcium minerals 
Aqueous suspension of calcium species (HAP, CaOx, CaPi, CaPyr, WTK Sigma Aldrich and 
Fisher Scientific) (50 mg) were incubated with Na18F solution (100kBq/mL) for 20 minutes. 
Unbound probe was removed after a series of centrifugation steps and three washing steps 
which involved: resuspension of the solid in H2O. Calcium solids were scanned using high-
resolution micro-positron emission tomography and non-contrast computed tomography 
[50kVp tube voltage, 300msec exposure time] (Mediso nanoScan PET/CT).  
Fluorescein-BP (55), Cy-Pep (71) and Alizarin S incorporation in calcium mineral 
phantoms 
Calcium species (HAP, CaOx, CaPi, CaPyr (50 mg) were suspended in 2% agarose in H2O (2 
mL) and left to set. Upon hardening, agarose phantoms were incubated with either 
Fluorescein-BP (55) (5 µM) or CyPep (71) (5 µM) or Alizarin S (1%) for 2 hours. Phantoms 
were subsequently washed with H2O (3 × 5 minutes) and then imaged using Zeiss Axiovert 25 









7.2.1 General procedures 
Chemicals used were purchased from Sigma-Aldrich, and tissue culture media and buffers 
were purchased from Thermo Fisher unless otherwise specified. All animals were culled by 
cervical dislocation in accordance with  the Home Office Schedule 1 guidelines in the U.K. 
The dissections took place in a ventilated hood and all tools were sterilised by autoclaving 
prior to dissection. 
7.2.2 Tissue culture 
Wash buffer consisted of Hank's Balanced Salt Solution (HBSS, Life Technologies) 
containing 1% gentamicin (Life Technologies). For cell detachment, TrypLE Express Enzyme 
(Life Technologies), a trypsin replacement, was used. Cell culture media consisted of 
Dulbecco's Modified Eagle Media F-12 (DMEM/F, Life Technologies) or Minimum Essential 
Media (α-MEM, Life Technologies) containing 1% gentamicin and 10% heat inactivated 
foetal bovine serum (FBS, Life Technologies) which was sterilised by passaging through a 
0.22 µm filter. All tissue culture procedures were completed in a ventilated tissue culture hood 
to ensure sterile conditions, at 37°C in 95% air/5% CO2. 
7.2.2.1 Cell types 
Primary mouse VSMC and rat aortic VICs were obtained from either 5 week old male Sprague 
Dawley rats or C57BL6 mice (Charles River Laboratories). The mouse VSMC cell line 
(MOVAS-1) previously described by Afroze,12 was purchased from ATCC, was stored at a 
density of 2.7×106/mL and frozen to -150 ºC until needed.  MOVAS-1 is a cell line isolated 
from aortic smooth muscle tissue which had been immortalized with SV40 large T antigen 
which has been employed previously to investigate the VSMC cell cycle.12–15 MC3T3 cell line, 
was purchased from ATCC and stored at a density of 2.7×106/mL and frozen to -150 ºC until 
needed. The MC3T3 is an osteoblast precursor cell line derived from mouse calvaria and has 
been widely used to study bone biology.16,17 When required, the cells were warmed to 37 ºC 
in a water bath and immediately added to 20 mL of DMEM/F (MOVAS-1) or α-MEM 
(MC3T3) cultured media. The cell suspension was then centrifuged at 670 g for 5 minutes to 
remove any cell debris and DMSO which had been used in the freezing media. The cell pellet 
was then re-suspended in culture media and transferred to a T175 flask to propagate.  
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7.2.2.2 Primary mouse VSMC isolation and culture 
Primary aortic VSMCs were isolated from five week old mice (Charles River Laboratories) as 
previously described.18–20 Mice were euthanized by cervical dislocation the aorta was then 
dissected and the adventitia removed. After washing with HBSS the aorta was cut 
longitudinally to expose the endothelial layer. Eight aortae were pooled together and incubated 
for 10 minutes at 37 °C in 1 mg/mL trypsin to remove any remaining adventitia and 
endothelium. Aortae were washed and incubated overnight at 37 °C in α-MEM culture media. 
Tissues were then washed and then incubated in 100 µL Collagenase type II (425 UI/mL, 
Worthington Biochemical Corporation) for 4 hours at 37 °C. The resulting cell suspension was 
centrifuged at 320 g for 5 minutes. VSMC pellets were resuspended in α-MEM culture media 
and cultured for two passages in T25 tissue culture flasks (Corning) coated with 0.25 μg/cm2 
laminin to promote maintenance of the contractile differentiation state.21 
7.2.2.3 Primary rat VIC isolation and culture 
Primary aortic VICs were isolated from aortic valve leaflets, dissected from the hearts of 5 
weeks old male Sprague Dawley rats (Charles River Laboratories) as previously described.22 
The animal was placed supine, and the abdomen skin, ribcage, fatty tissue and lungs removed  
to expose the heart. The latter was extracted and placed in cold HBSS until all dissections were 
complete. To extract the heart valves, cardiac muscle was trimmed to expose the aorta and the 
aortic root. The artery was then cut open and the valve leaflets were carefully dissected. To 
clean and release the VICs from the leaflets, the following digestions were performed. The 
leaflets were centrifuged at 100 g, for 1 minute to pellet and remove HBSS and then digested 
in 100 µL of Collagenase type II (425 U/mL) for 5 minutes at 37 °C to release valve endothelial 
cells (VECs). Following digestions, the leaflets were subjected to another 30 seconds 
centrifugation at 100 g. The supernatant, which contained the digested VECs, was discarded 
subsequently. A wash with 500 µL of HBSS was applied to rinse off any remaining VECs and 
the leaflets were pelleted with a 30 seconds 100 g centrifugation. The supernatant was 
discarded.  To digest the VICs, the leaflets were incubated with 100 µL of Collagenase II (425 
U/mL) for 2 hours, at 37 °C. At the end of the incubation, VICs were removed from the leaflets 
by forceful pipetting.  The VICs were spun at 670 g for 5 minutes and relocated to a suitable 
sized flask, T75,  and left to propagate. 
7.2.2.4 Cell expansion and calcification 
Cells were cultured until 90-100% confluent, at which point culture media was replaced as 
necessary. For cell expansion, the culture media was initially removed, and the monolayer was 
rinsed with HBSS. For cell detachment, the HBSS was discarded and the monolayer was 
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incubated at 37 °C for 3-5 minutes in the presence of TypLE. The reaction was deactivated by 
adding double the volume of culture media. The cells were then pelleted at 670 g for 5 minutes. 
The supernatant was discarded, and the cells were re-suspended in 1 mL of fresh culture media 
and transferred to a suitable sized flask with pre-warmed culture media. To count the number 
of viable cells, a haemocytometer was used. The cells were then transferred to a new flask and 
left to propagate until 90-100% confluent. 
For calcification experiments, cells were seeded and then were left to propagate at 37 °C, in a 
humidified incubator. 
7.2.2.5 Aortae isolation and culture 
Aortic rings were dissected from eight-week-old Fischer rats. Rats were euthanized by cervical 
dislocation; the aorta was then dissected, and the adventitia removed. After washing with 
HBSS the aortae were cut into ~4 mm thick rings and cultured in α-MEM culture media. 
7.2.2.6 ApoE-/- Mice  
Male atherosclerosis-prone apolipoprotein E-deficient (ApoE-/-) mice were obtained from Dr 
Hadoke.  Mice started a high cholesterol diet (D12336,23–25 Research Diets, Inc. Cholesterol: 
1.25%) at 12-14 weeks old and were kept on the diet for 12 weeks. The mice were subsequently 
culled and aortic arch harvested for further investigations. Tissue was section into 5 µm 
sections. For OPT imaging, ApoE-/- mice were culled at age of 15 months, thoracic aorta were 
carefully dissected and fixed in 10% NBF. 
7.2.2.7 Induction of calcification  
Cells were seeded in culture medium for 2 days and then switched to calcification medium, 
which was prepared by adding; 1 M inorganic phosphate (Pi, mixture of NaH2PO4 and 
Na2HPO4, pH=7.4) and 1M CaCl2 (Ca). Cells were always compared to the control, DMEM/F 
contains 1.05 mM of Ca and 0.95 mM of Pi while α-MEM contains 1.8 mM of Ca and 1.01 
mM Pi. 
For MOVAS-1, cells were grown in DMEM/F culture media to confluence before treatment 
with DMEM/F calcification medium; phosphate alone (3 mM and 5 mM) or phosphate and 
calcium rich (1.4 mM Pi and 2.4 mM Ca or, 2.5 mM Pi and 2.7 mM Ca). Cells were incubated 
for 7 days and the medium was changed every 2-3 days. 
For VICS, cells were grown in DMEM/F culture media to confluence before treatment with 
DMEM/F calcification medium; phosphate and calcium rich (1.4 mM Pi and 2.4 mM Ca or, 
2.5 mM Pi and 2.7 mM Ca). Cells were incubated for 7 days and the medium was changed 
every 2-3 days. 
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For VSMCs, cells were grown in α-MEM culture media  until confluent and switched to α-
MEM calcification medium; phosphate rich (1.8 mM, 2.6 mM and 3 mM). Cells were 
incubated for 7 days and the medium was changed every 2-3 days. 
For MC3T3, cells were grown in α-MEM culture media switched to α-MEM calcification 
medium, which was prepared by adding 2.5 mM β-glycerophosphate (β-GP) and 50 μg/ml 
ascorbic acid (aa). Cells were incubated for 21 days in 95% air/5% CO2 and the medium was 
changed every 2-3 days. 
For aortic rings, rings were cultured in α-MEM culture media. After 1 day, the media was 
changed to α-MEM calcifying media of the following Pi concentrations; 1.8 mM, 2.6 mM, 3 
mM for 7 days with media change on alternative days.  
7.2.3 Imaging of cell and tissue cultures 
7.2.3.1 Tissue processing and embedding 
Tissue was either embedded in wax or in OCT. For OCT,26 sectioned into 5 µm thick slices 
and placed on slides. For waxed samples, NBF fixed tissues were slowly dehydrated, following 
a technique previously described,20 using a series of alcohol incubations as follows: PBS (2 × 
5 minutes), followed by EtOH (70%, 1 h), EtOH (4 × 95% for 1 hour), EtOH (100%, 1 hour), 
EtOH:xylene (50:50 1 hour), xylene (2 × 1 hour) and transferred into wax embedding cassettes 
in paraffin wax at 60 °C for 4 hour. The wax blocks were embedded in plastic moulds and 
trimmed using an Ernst Leitz AG microtome to expose sample surface. The paraffin wax-
embedded samples were then cooled on ice for 30 minutes and sectioned at 4 µm thickness. 
They were then floated in a 40 °C water bath for 1 minute before carefully transferring onto 
electrostatically charged slides. The slides were dried overnight at 37 °C. 
7.2.3.2 Staining with Fluorescein-BP 
Culture media was removed, and the cell monolayer was subsequently washed with HBSS 
then incubated with appropriate media containing Fluorescein-BP (42) (1 μM) for 2 hours.  
For staining with Fluorescein-BP (42) alone; the media was then discarded, and the cell 
monolayer was washed with HBSS (2 × 2 mL), fixed with 10% NBF for 15 minutes and 
washed with phosphate buffer saline (PBS, 2 × 2 mL) and with H2O (1 × 2 mL).  
For dual imaging with Cell Mask Orange; monolayers were washed with HBSS (2 × 2 mL) 
and fresh HBSS containing Cell Mask Orange (0.5x, Life Technologies) was added for 5 
minutes. Monolayers were washed with HBSS (2 × 2 mL), fixed with 10% neutral-buffered 
formalin (NBF, CellPath) for 15 minutes and subsequently washed with PBS (2 × 2 mL) and 
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H2O. Glass coverslips were mounted onto slides with Prolong Gold Anti-Fade Reagent (Life 
Technologies). 
For dual imaging with DAPI; monolayers were subsequently washed with HBSS (2 × 2 mL). 
Monolayer was incubated with DAPI (300 nM, Life Technologies) for 5 minutes followed by 
washing with HBSS (2 × 2 mL), fixed and mounted as described above. 
For ApoE-/- Mice Sections, WT rats and human sections; sections were de-waxed in xylene 
and incubated with Fluorescein-BP (1 µM) for 2 hours, washed in H2O (2 × 500 µL) followed 
by incubation with 2% Alizarin S (250 µL) for 5 minutes. Sections were washed in H2O (3 × 
500 µL) and subsequently incubated with DAPI (500 nM) for 5 minutes. Sections were washed 
with H2O (1 × 500 µL) and then mounted as described above. 
Fluorescence images were captured using a Leica DMBL-2 upright fluorescent microscope 
and/or Zeiss Confocal LSM 710 and/or Leica DMRB fluorescence microscope. Fluorescence 
intensity detected on Synergy HT Multi Mode Microplate reader at 488 nm. 
7.2.3.3 Alizarin S staining 
For the cell monolayers, cells were fixed with 10% NBF for 15 minutes before washing with 
PBS (2 × 2 mL). The cells were then stained with 2% Alizarin Red (500 µL) for 10 minutes at 
rt, supernatant discarded and the cell monolayer was subsequently washed with H2O (3 × 2 
mL).  
For the aortic rings, after Fluorescein-BP (42) rings were fixed with 10% NBF for 15 minutes 
then permeabilised with 1% KOH for 1 hour followed by overnight staining with 0.00005% 
Alizarin S in 1% potassium hydroxide (KOH). Residual Alizarin S was removed by washing 
H2O (3 × 2 mL).  
For human tissue, sections were de-waxed in xylene and stained with 2% Alizarin red for 5 
minutes, washed with H2O (3 × 500 µL) and dehydrated to visualize calcium deposition.  
7.2.3.4 Von Kossa staining 
For ApoE -/-  and human tissues; sections were de-waxed in xylene and stained with 1% silver 
nitrate (150 µL) under a UV lamp for 20 minutes.27 Sections were rinsed with H2O (3 × 500 
µL) then incubated with 5% sodium thiosulfate (150 µL) for 5 minutes. Subsequently, sections 
were washed with H2O (2 × 500 µL)   and then counterstained with 0.1% neutral red (150 µL) 
for 2 minutes. Sections were dehydrated, with three changes of absolute ethanol and cleared 
with three changes of xylene and mounted using DePex. Images were obtained using a Nikon 
Ni1 Brightfield microscope. 
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7.2.3.5 Immunofluorescence on aortic rings 
5 µm rat aortae sections on slides were incubated with Tris-Buffered Saline and Tween 20 
(TBS/T) for 15 minutes then permeabilised with 0.1% Triton-X in 1x TBS for 30 minutes at 
rt. Sections were washed with TBS/T (3 × 500 µL; 5 minutes per wash) and then incubated 
with blocking buffer (TBS/T and 5% BSA, 200 µl) for 1 hour.  After 1 hour, the blocking 
buffer was removed by washing with TBS/T (3 × 500 µL; 5 minutes per wash), slides were 
then incubated with anti-α-smooth muscle action (α-SMA, 1:100, 200 µL)28 and CD31 (1:100, 
200 µL)26 overnight at 4 °C. Negative control consisted of the same concentration of IgG from 
the same animal species as primary antibody. On day 2, after washing with TBS/T (3 × 500 
µL; 5 minutes per wash), sections were incubated with Alexa Fluor® 496 goat-anti-rabbit 
antibody (1:250, 200 µL, Thermo Fisher) in blocking buffer for 1 hour in the dark. Following 
removal of excess antibody with TBS/T (3 × 500 µL; 5 minutes per wash) sections are then 
incubated with DAPI (300nM) for 5 minutes, washed with TBS/T (1 × 500 µL; 2 minutes per 
wash) and mounted with ProLong Gold Antifade.  Care was taken to remove any air bubbles 
and the slides were left to dry for 24 hours at 4 °C before imaging. Fluorescence signal was 
detected under a Leica DMRB fluorescence microscope. 
7.2.3.6 OPT imaging of ApoE-/- Mice 
The aorta were washed in PBS for 3 hour and then immediately immersed in Fluorescein-BP 
(1 µM) overnight. The aorta were washed in PBS (1 × for 1 hour) and then processed for OPT 
imaging. Aorta were embedded in a 1% solution of low-melting agarose and then dehydrated 
three times in 100% ethanol overnight. Once the aortae were completely dehydrated, ethanol 
was replaced with BABB solution and clear for 2 days. The embedded aortae were then glued 
on a mount and left to dry for 2 hour. Specimens are then scanned using an OPT scanner. 
7.2.3.7 Immunohistochemistry (IHC) of human tissue 
IHC was performed using the Vectastain ABC Kit (mouse IgG) (Vector Labs, Peterborough, 
UK) according to manufacturer’s instructions. Before IHC sections were de-waxed in xylene. 
Immunohistochemical analysis of OPN (1:00 dilution, anti-human mouse clone OPN 
(AKm2A1), Santa Cruz Biotechnology) or OPG (1:00 dilution, anti-human mouse clone OPG 
(E-10), Santa Cruz Biotechnology),29 was conducted after heat-induced epitope retrieval using 
a 10 mM citrate buffer (pH 6) for 1 hour at 70 ºC. Endogenous peroxidase was blocked by 
soaking in 0.3% H2O2 in TBS/T at rt for 30 minutes, followed by non-specific antibody 
blocking with serum for another 30 minutes. Sections were then incubated with the specific 
primary anti-human antibodies overnight at 4 °C. All incubation steps were followed by 
washing in TBS/T. The sections were then washed in TBS/T and then incubated with diluted 
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biotinylated secondary antibody (1:100) for 30 minutes at rt. After washing in TBS/T for 
5 minutes, the sections were then incubated for 30 minutes with ABC reagent (avidin and 
horse radish peroxidase (HPR)). The reaction was developed using premixed 3,3’-
diaminobenzidine (DAB; 0.06% DAB, 0.1% hydrogen peroxide, in PBS) solution (Vector 
Labs) until the desired stain intensity developed (5 minutes).  The sections were rinsed and 
counterstained with haematoxylin and eosin (H&E).27 Dehydration through graded alcohols, 
cleared using xylene in a Leica Autostainer XL and then mounted in DePex. IgG 
Control sections were incubated with mouse IgG (1:100) in place of OPN or OPG or RUNX-
2 antibody. Images were obtained using a Nikon Ni1 Brightfield microscope. 
7.2.3.8 PET/CT analysis human tissue  
Atherosclerotic layers of left main coronary arteries were obtained with ethical approval and 
informed relative authorisation from the next of kin at autopsy from victims of sudden death 
(National Health Service South East Scotland 14/SS/1090). The tissue was immediately frozen 
at -80 °C. Thawed non-decalcified coronary artery specimens were incubated for 20 minutes 
in 18F-sodium fluoride 100kBq/mL solution (10.5MBq 18F-NaF in 99.5mL 0.9% NaCl). 
Samples were washed in 10mLs 0.9% NaCl (2 × 5 minutes) to remove unbound 18F-fluoride. 
Coronary artery specimens were scanned using high-resolution micro-positron emission 
tomography and non-contrast computed tomography [50kVp tube voltage, 300msec exposure 
time] (Mediso nanoScan PET/CT). After whole specimen imaging, the coronary arteries were 
fixed in 10% buffered formaldehyde before being dehydrated, embedded in paraffin wax and 
sectioned (5 μm thickness).30 
7.2.4 Biochemical assays 
7.2.4.1 Calcium leaching assay 
Initially, the culture media was discarded, and the cells were washed with PBS.  The cell 
monolayer was incubated with an appropriate volume of 0.6M HCl and left to leach for 24 
hours at 4 °C. Subsequently, a Calcium Assay Kit (Randox) was used to measure the calcium 
deposition in the cells.  The assay depends on a binding mechanism between O-cresolphthalein 
complexone and calcium ions in an alkaline media. A negative control (0.6 M of HCl) and a 
calcium standard are required to determine the calcium concentration. 5.5 µL of standard, 
negative control and the sample were added to a 96-well plate, in duplicate. 250 µL of 1:1 
ratio of 2-amino-2-methyl-propan-l-ol (R1) and O-cresolphthalein complexone, 8-
Hydoxyquinoline, HCl (R2) were added to each well. The ODs were determined on a Synergy 
HT Multi Mode Microplate reader at 570 nm. Calcium concentration of each sample was 
determined using the following equation: 













Calcium concentration was then standardised using total protein concentration described 
below.  
7.2.4.2 Protein Concentration Assay 
The cellular proteins were denatured using 0.1M NaOH + 0.1% sodium dodecyl sulphate 
(SDS). Protein content of the cell was measured using Bio-Rad DC protein assay. Bovine γ–
globulin protein standards (0.125 - 2 mg/mL) were prepared in the solution: 0.1 M NaOH + 
0.1% SDS. 5 µL of sample or standards were transferred to a 96-well plate, in duplicate. To 
each well, 25 µL of alkaline copper tartrate solution and 200 µL of dilute folin reagent were 
added. The plate was incubated at rt for 20 minutes.  The optical densities (OD) were obtained 
on a Synergy HT Multi Mode Microplate reader at 690 nm. The protein concentration was 
resolved from the standard curve.  
7.2.4.3 Alamar Blue assay  
All wells were washed with HBSS (2 × 2 mL) and then incubated Alamar Blue (10 µL per 100 
µL of media, Life Technologies) for 4 hours. Results were recorded using Synergy HT Multi 
Mode Microplate reader at 570 nm. 
7.2.5 Raman Spectroscopy 
7.2.5.1 Raman on cell pellet 
MOVAS-1 cells were grown, in a T75 flask, in DMEM/F culture media to confluence (day 0) 
and switched to calcification medium or control media. On day 7, MOVAS-1 monolayer was 
washed with PBS (3 × 2 mL) after which the monolayer was incubated with TrypLE Express 
Enzyme (1 mL) for 2 minutes at 37 °C. DMEM/F culture media (10 mL) was added and the 
cells were centrifuged at 100 g, for 5 minutes. The supernatant was removed and the pellet 
was washed with PBS (10 mL). The pellet was resuspended in PBS and subsequently 
centrifuged again. The supernatant was discarded and the pellet kept in PBS (100 µL) until 
imaging. Raman imaging was carried out using a InVia Renishaw Microscope with a 785 nm 
laser excitation source which was used to excite the sample through a 50, N.A. 0.75 objective. 
The total data acquisition was performed during 30 s for spectra with a 50% laser power using 
the WiRE software. All of the spectra acquired were background subtracted using a 
background correction algorithm present on WiRE software. For the purpose of this work, all 
peaks were normalised the phenylalanine which should not be altered in the presence or 
absence of calcification media. 
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7.2.5.2 Raman assessment of cell monolayer 
MOVAS-1, VICS, mouse VSMCs were grown and calcified on CaF2 slides as described under 
the induction of calcification section. On day 7, the monolayers were fixed in 10% NBF for 
15 minutes and then imaged. Raman imaging was carried out in the same manner as mentioned 
under the cell pellet section. 
7.2.5.3 Raman analysis of agarose embedded aortic rings 
Aortic rings were dissected from eight-week-old Fischer rats. Rats were euthanized by cervical 
dislocation; the aorta was then dissected, and the adventitia removed. After washing with 
HBSS the aortae were filled and embedded in 8 % UltraPureTM Low Melting Point Agarose. 
The aortae were then cut into 10 µm sections using a VF-300-07 CompressotomeTM 
(Precisionary) and subsequently cultured in α-MEM. The agarose rings were calcified for 7 
days and then fixed in 10 % NBF for 15 minutes. The agarose was subsequently removed upon 
gentle heating in PBS to allow for Raman imaging. The conditions used for Raman imaging 
were the same as mentioned under the cell pellet section. 
7.2.5.4 Raman on human Sections 
Sections were de-waxed in xylene (15 minutes), EtOH (100%, 15 minutes), EtOH (95%, 15 
minutes), followed by EtOH (70%, 15 minutes). Stored at rt until imaging using the Renishaw 
InVia, 785 nm laser, 60 second, 100% laser power. Spectra obtained were subtracted from 
paraffin spectra using the same parameters mentioned above. 
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Chapter 8- Abbreviations 
#    number 
µM    micro molar 
18F-FDG   fluorodeoxyglucose    
18F-NaF    sodium fluoride 
2D    two dimensional 
3D    three dimensional 
AA    ascorbic acid 
Ac2O    acetic anhydride 
ACP    amorphous calcium phosphate 
ALK    alkaline phosphate 
ApoE-/-    apolipoprotein E knockout mouse 
AU    arbitrary units 
BL    basal lamina 
BMP    bone matrix protein 
Boc    tert-butyloxycarbonyl 
BP     bisphosphonate 
Ca    calcium 
CAC    coronary artery calcium scoring 
CaCO3    calcium carbonate 
CaOx    calcium oxalate 
CaPi    calcium phosphate 
CaPyr    calcium phyrophosphate 
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CD31    platelet endothelial cell adhesion molecule-1 
CKD     chronic kidney disease    
CT     computed tomography 
CVD    cardiovascular disease 
Cy     cyanine dye 
DCB     dichlorobenzene 
DCC    N,N’-dicyclohexylcarbodiimide 
DCM     dichloromethane 
DCU    dicyclohexylurea 
DMAP    4-dimethylaminopyridine 
DMF    dimethylformamide  
DTT    1,4-dithiothreitol 
DVB    divinylbenzene 
EC    endothelial cells 
ECM    extracellular matrix 
EDCI    1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ENPP1    ectonucleotide pyrophosphatase/phosphodiesterase 1 
Et2O     diethyl ether 
FAM     Fluorescein 
FC    foam cells 
FDA    Food and Drug Administration 
f-HAP    fluorinated hydroxyapatite 
G    glycine 
GFP    green fluorescent protein 
h     hour 
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HAP     hydroxyapatite 
HCl    hydrochloric acid 
ICA    independent component analysis 
IF    immunofluorescence 
IGG    immunoglobulin G 
IHC    immunohistochemistry 
IR    infrared 
IVUS    intravascular ultrasonography  
K    lysine 
Ki    inhibitory constant 
KI    potassium iodide 
LDLR-/-    low density lipoprotein receptor deficient mouse 
LOD    limit of detection 
M    methionine 
M    molar 
Mac    macrophages 
MC3T3    mouse calvaria osteoblast precursor cell line 
Me    methyl 
MeCN     acetonitrile 
MeI    methyl iodide 
MeOH    methanol 
MESA    multi-ethnic study of atherosclerosis 
MGP     Matrix Gla Protein 
MLp    modified lipoproteins  
mM    millimolar 
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MMP    Matrix Metalloproteinases 
Mon    blood monocytes 
MOVAS-1   mouse vascular smooth muscle cells 
MRI    magnetic resonance imaging 
MW     microwave 
N     normal  
n    number of replicates 
NaN3    sodium azide 
NBF    neutral buffer formalin 
NHS    n-hydroxysuccinimide 
NIR    near infrared 
NIRF    near-infrared fluorescence  
NIRS    near-infrared spectroscopy  
ºC     degrees Celsius  
OCP    octacalcium phosphate 
OCT     optimal cutting temperature 
OCT    optical coherence tomography  
OPG     Osteoprotegerin  
OPN    Osteopontin 
OPT    optical projection tomography 
P    proline 
P    P-value 
P2-Et    phosphazene base 
PET    positron emission tomography  
Pi    phosphate 
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PLS    partial least squares 
pM    pico molar 
PS     polystyrene 
R    arginine 
S    serine 
S.E.M.    standard error mean 
Sat.    saturated 
SPPS    solid phase peptide synthesis 
Sulfo     sulfonated 
TBAF    tetrabutylamminium fluoride 
TBDMS-Cl   tert-butyldimethylsilyl chloride 
TFA    trifluoroacetic acid  
THF    tetrahydrofuran 
UV    ultraviolet 
V    valine 
VECs    vascular endothelial cells 
VICs    vascular interstitial cells 
VIS    visible 
VSMCs    vascular smooth muscle cells     
WT    wild type 
WTK    whitlockite 
α-SMA    alpha-smooth muscle actin 
β-GP    β-glycerolphosphate 
β-TCP    beta-tricalcium phosphate  
ε    extinction coefficient 
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λabs    absorption wavelength 
λEm     emission wavelength 
λEx     excitation wavelength 
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1.1 Chapter 1 
Figure 1.3 and 1.6 
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 Patient information 
Appendix 2.1 Coronary tissue samples 
Ethics code: National Health Service South East Scotland 14/SS/1090 
Patient information: 
Patient Date of post mortem Age Gender Cause of death (1,2) 
1 23/08/2016 46 M Ischaemic heart disease  
2 16/11/2016 49 M Ischaemic heart disease (1) 
Coronary artery atherosclerosis (2) 
3 18/01/2017 49 F Complications of alcohol toxicity 
4 28/02/2017 71 F Ischaemic and hypertensive heart 
disease (1) 
Diabetes mellitus (2) 
5 11/05/2017 50 M Haemopericardium (1) 
Dissection of thoracic aorta (2) 
6 24/05/2017 67 M n/a 
7 07/06/2017 48 M n/a 
8 27/09/2016 57 M Ischaemic heart disease 
 
 
Appendix 2.2: Carotid tissue samples 
Ethics code: Lothian NRS Bioresources 15/ES/0094 
Patient information: 
Patient Date of Surgery Age Gender PMH 
1 23/6/17 74 M Myocardial infarction, pleural plaques, 
COPD, severe left ventricular systolic 
dysfunction, aortic stenosis 
2 17/10/17 54 M COPD, smoking 
3 20/10/17 
 












 IGG control 
 
Appendix 3 Figure 1: IGG control of coronary (A, B, C, D) and carotid (E, F) arteries. IHC 
analysis performed with Vectastain ABC kit (mouse IgG) where all antibodies were anti-










 Staining solutions 
 
Wiegert’s Iron Haematoxylin  
Haematoxylin (1 gr) was dissolved in 95% alcohol (100 mL). 29% Ferric Chloride in H2O (4 
mL) was dissolved in distilled H2O (95 mL) containing HCl (conc., 1 mL). The haematoxylin 
solution was combined to the Ferric Chloride solution in a 1:1 ratio. 
1% Acetic H2O 
Acetic acid (glacial, 1 mL) was dissolved in distilled H2O (99 mL). 
2% Alizarin Red 
Alizarin Red (2.00 g) was dissolved in distilled H2O (100 mL). The pH was adjusted to 4.1-
4.3. 
1% Silver nitrate solution 
Silver nitrate (1.00 g) was dissolved in distilled H2O (100 mL). 
5% Sodium thiosulfate solution 
Sodium thiosulfate (5.00 g) was dissolved in distilled H2O (100 mL). 
0.1% Nuclear fast red solution 
Aluminium sulfate (5.00 g) was dissolved in distilled H2O (100 mL). The solution was 
stirred and subsequently nuclear fast red (0.10 g) is added. 
2% Acidic H2O 
HCl (conc., 1 mL) was added to 70% ethanol (99 mL). 
